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 Abstract 
Guillain-Barre syndrome (GBS) is an acute inflammatory neuropathy that is frequently 
triggered by an infectious illness. It is thought to be autoimmune in origin, but differs from other 
autoimmune diseases in being of male predominance and not showing a HLA-association.  
Chronic inflammatory demyelinating polyradiculoneuropathy is a chronic inflammatory 
neuropathy, which shares some pathological features with GBS.  
We investigated the clinical features of GBS in an Australian cohort of subjects by performing a 
retrospective chart review. We obtained subjects from several public hospitals and private 
neurologists in Queensland and New South Wales. 
We found 335 patients, for 228 of whom electrophysiological data was available. Of these acute 
inflammatory demyelinating polyradiculoneuropathy (AIDP) with 168 cases was the most common 
form, whilst axonal and focal forms were rarer. We identified upper respiratory tract infections, 
occurring predominantly in winter months, as the most frequently named triggering factor for GBS. 
The illness severity in our cohort was similar to that in earlier Australian studies.  
Also, we identified a cohort of 78 subjects fulfilling diagnostic criteria for CIDP from similar 
sources. 
We investigated a possible underlying genetic susceptibility to develop GBS or CIDP by 
contacting members of this cohort and collecting their DNA. We embarked on both a candidate 
gene approach to investigate the killer immunoglobulin-like receptors (KIRs) and their HLA 
ligands, as well as performing a genome-wide association study (GWAS) of the subjects with GBS 
as a hypothesis-free method. 
For the KIR/HLA system, whilst no significant differences were detected in the frequency of 
KIR genes, HLA-C2 and HLA-B Bw4-T were more frequent in subjects with GBS than controls 
(p<0.001). The inhibitory pairs of KIR-2DL2/HLA-C2 and KIR-3DL1/HLA-B Bw4-T were more 
frequent in GBS than controls (p<0.005). Whilst there were some differences between CIDP 
subjects and controls, interestingly, there were no difference between subjects with GBS and CIDP. 
This could point to similarities of pathogenesis between these two inflammatory neuropathies. 
A GWAS was performed on a largely identical cohort of 190 subjects with GBS. Whilst this 
cohort is relatively small for a modern GWAS and no genome-wide significant results were 
expected, we were able to identify a number of regions of interest based on clusters of SNPs in 
linkage disequilibrium of increased significance. These included rs10519519 on Chromosome 2, 
which is associated with MYT1L, a transcription factor in neuronal development; rs7663689 on 
Chromosome 4, which is in the promotor region of IL15; rs11151180 on Chromosome 18 which is 
in a gene-free region; rs17095496 on Chromosome 14, which amongst other genes is associated 
with DACT1, which encodes a regulator of cell division involved in the NF-κB pathway; and 
rs2302524 on chromosome 19, associated among other genes with NFKBIB, which encodes an 
inhibitor of the NF-κB pathway. Relative negatives included the HLA region, as indeed were all 
other candidate genes previously studied in GBS. 
Taken together, these findings could indicate a role of the innate immune system, particularly 
natural killer, cells in the pathogenesis of GBS. Downstream mechanisms, including dysregulation 
of the adaptive immune system also seem important. Finally, the finding of genes of neuronal 
development in GBS GWAS could indicate a role for target organ susceptibility in GBS. 
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Chapter 1  Guillain-Barré Syndrome  –  Overview of 
pathogenesis 
1.1. Introduction 
Guillain-Barre Syndrome (GBS) was first described at the beginning of the 20th century 
by three French neurologists Georges Guillain, Jean-Alexandre Barré, and André Strohl, who 
reported two soldiers with acute areflexic paralysis, followed by recovery. They reported the 
combination of increased protein concentration with a normal cell count in the cerebrospinal 
fluid (CSF) - albuminocytological dissociation, which separated the condition from 
poliomyelitis. Despite the fact that Landry de Thezillat had already reported similar cases in 
1859, the combination of these clinical and laboratory features became known as Guillain-
Barré syndrome (GBS) (Guillain 1916, van Doorn, Ruts et al. 2008).  
Today, Guillain-Barré Syndrome (GBS) is defined as an acute or subacute immune 
mediated polyradiculoneuropathy. The cardinal clinical features of GBS are progressive, 
usually symmetric, flaccid muscle weakness accompanied by absent or depressed deep 
tendon reflexes and ascending sensory changes. The course is usually monophasic, with 
clinical recovery following the rapid initial deterioration.  
The annual incidence in Australia is estimated at about 1 per 100,000 (Storey, Cook et al. 
1989), which is in keeping with a number of world-wide studies (Hughes and Rees 1997, 
Chio, Cocito et al. 2003). The incidence of GBS increases steadily with age from less than 
one per 100 000 in patients younger than 30 years to about four per 100 000 in those older 
than 75 years (Bogliun, Beghi et al. 2004). 
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1.2. Diagnosis 
The diagnosis of GBS relies on the history and physical examination, especially early in 
the disease course, when ancillary testing can be negative. The clinical spectrum of GBS is 
broad, ranging from mild difficulty with walking or pure sensory symptoms to nearly 
complete paralysis, including facial, respiratory, and bulbar muscles.  
Diagnostic criteria have been proposed by the National Institute of Neurological 
Disorders and Stroke (NINDS), and have been widely used both in research and clinical 
practice (Anonymous 1978). These require the presence of progressive muscle weakness in 
more than one limb combined with areflexia or hyporeflexia; maximum severity of the illness 
is reached by 4 weeks at the latest. Supportive features include progression of symptoms for 
up to four weeks, relative symmetry, mild sensory symptoms or signs, cranial nerve 
involvement, recovery starting two to four weeks after progression halts, autonomic 
dysfunction, lack of fever at the onset, elevated protein in CSF with a cell count <10 mm3 and 
electrodiagnostic abnormalities consistent with GBS. 
1.3. Clinical subtypes 
Guillain-Barré Syndrome is a heterogeneous condition, with several variants 
distinguishable by clinical picture, electrophysiological criteria, pathological features and 
serological markers. Based on electrophysiological criteria, several subtypes of GBS have 
been described, however some overlap exists. The most commonly encountered subtypes 
include Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Acute Motor-
Sensory Axonal Neuropathy (AMSAN), Acute Motor Axonal Neuropathy (AMAN) and 
Miller-Fisher Syndrome (MFS). Rarer variants include facial diplegia, acute autonomic 
neuropathy and the pharyngeal-cervical-brachial variant of GBS. 
Neurophysiological testing is most important in subtype classification in the clinical and 
research setting. Neurophysiological criteria for AIDP, AMSAN and AMAN have been 
established (Table 1.1). In AIDP, the presence of patchy demyelination is characterized by 
delayed distal motor latency of the compound muscle action potential (CMAP), decreased 
motor conduction velocity, conduction block and delayed F wave latency. In AMAN, nerve 
conduction studies show decreased CMAP amplitudes, with no evidence of sensory 
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involvement or demyelination. AMSAN is characterized by decreased CMAP amplitudes and 
sensory involvement. In MFS conduction studies of peripheral nerves are usually normal.  
 
 
  
  
  
AIDP 
At least one of the following in each of at least two nerves, or at least two of the following 
in one nerve if all others inexcitable and distal CMAP >10%: 
Motor conduction velocity <90% LLN (85% if distal CMAP <50% LLN) 
Distal motor latency >110% ULN (>120% if distal CMAP <100% LLN) 
Proximal CMAP / distal CMAP ratio <0·5 and distal CMAP >20% LLN 
F-response latency >120% ULN 
 
AMSAN 
None of the features of AIDP except one demyelinating feature allowed in one nerve if 
distal CMAP <10% LLN 
Sensory action potential amplitudes <LLN 
 
AMAN 
None of the features of AIDP except one demyelinating feature allowed in one nerve if 
distal CMAP <10% LLN 
Sensory action potential amplitudes normal 
 
Inexcitable 
Distal CMAP absent in all nerves or present in only one nerve with distal CMAP <10% 
LLN 
  
 
Table 1.1 - Electrophysiological criteria for AIDP, AMSAN and AMAN (Hadden, Cornblath et 
al. 1998, Hughes, Wijdicks et al. 2005). LLN = Lower limit of normal; ULN = upper limit of 
normal 
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1.3.1. Acute inflammatory demyelinating polyradiculoneuropathy  
AIDP is the most common variant of GBS in developed countries, including Europe, 
North America and Australia, with more than 80% of cases suffering from this subtype of 
GBS. 
1.3.1.1. Pathology 
The pathological hallmark of GBS is a multifocal mononuclear cell infiltration 
throughout the peripheral nervous system, with the distribution of inflammation 
corresponding to the clinical deficit (Asbury, Arnason et al. 1969). Pathological alterations 
can be found at all regions of the peripheral nervous system, from the roots to the most distal 
intramuscular motor nerve endings. The lesions are pronounced along the ventral roots, 
proximal spinal nerves, and lower cranial nerves (Kieseier, Kiefer et al. 2004). Macrophages 
and T lymphocytes invade nerve tissue and strip off lamellae of myelin (Prineas 1981). 
Disruption of the blood-nerve barrier, allowing migration of T lymphocytes, could be 
partially due to increased secretion of metalloproteinase MMP9 (Creange, Sharshar et al. 
1999).  
1.3.1.2. Electrophysiology 
Inflammation is thought to start at the level of the nerve roots, where the blood-nerve 
barrier is less well developed. Consistent with this, one of the earliest electrophysiological 
signs is prolonged or absent F waves and absent H reflexes, often with reduced recruitment 
on EMG of affected muscles (Gordon and Wilbourn 2001). Temporal dispersion of CMAP, 
decreased conduction velocity, conduction block and prolonged distal latency follows 
(Albers, Donofrio et al. 1985), combined with spontaneous activity on EMG. As well, 
sensory responses are slowed or absent, often with sparing of the sural nerve (Murray and 
Wade 1980). Axonal degeneration is often seen in subsequent studies, and is associated with 
a worse prognosis (Cornblath, Mellits et al. 1988). 
1.3.2. Acute motor axonal neuropathy  
Acute motor axonal neuropathy (AMAN) is relatively uncommon in developed countries, 
but is the predominant form of GBS in China (McKhann, Cornblath et al. 1991, McKhann, 
Cornblath et al. 1993). It has also been reported to occur in high frequencies in other parts of 
Asia and Mexico. In these regions, AMAN occurs more often in summer and is frequently 
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associated with antecedent Campylobacter jejuni (C. jejuni) infection (Blaser, Olivares et al. 
1991). Affected patients are usually young (15 months to 37 years, median 7 years). Clinical 
signs of AMAN are similar to those of AIDP, however the electrophysiological features are 
those of an axonal neuropathy, without evidence of demyelination, and sparing of sensory 
fibers (McKhann, Cornblath et al. 1991, Vucic, Kiernan et al. 2009).  
In contrast to AIDP, where demyelination is the pathological hallmark, in AMAN 
antibody- mediated attack on the nodes of Ranvier predominates. Particularly, antibodies 
against  Monosialotetrahexosylganglioside 1 (GM1), Monosialotetrahexosylganglioside 1b 
(GM1b), N-acetylgalactosaminyl Disialoganglioside 1a (GalNac-GD1a) and 
Disialoganglioside 1a (GD1a), have been found (Ang, Yuki et al. 1999, Ho, Willison et al. 
1999).  GM1 occurs in high concentration at the node of Ranvier (Corbo, Quattrini et al. 
1993). There is some evidence that this leads to reversible blockage of voltage-gated Na+ 
channels at the node of Ranvier, resulting in conduction block (Weber, Rudel et al. 2000). As 
patients with AMAN usually recover with adequate supportive therapy, the resulting damage 
to the axon appears to be short-lived and may reflect a temporary blockade of conduction, 
although axonal degeneration distally is possible, leading to persistent disability. 
1.3.3. Acute motor and sensory axonal neuropathy 
Acute motor and sensory axonal neuropathy (AMSAN) is the name given to the motor 
axonal form of GBS when there is co-existent sensory involvement. Clinically, patients are 
often severely affected. The pathology is similar to that seen in AMAN with involvement of 
ventral nerve roots and peripheral motor axons targeted as a site of macrophage invasion 
periaxonally; however dorsal nerve roots and sensory fibres are also involved. As in AMAN, 
there appears to be a limited role for demyelination or lymphocytic inflammation (Griffin, Li 
et al. 1996). Immunological studies have shown that patients with AMAN and AMSAN share 
a common profile of anti-GM1, -GD1a, and -GM1b antibodies supporting an antibody-
mediated pathogenesis in both of these conditions (Yuki, Kuwabara et al. 1999). 
1.3.4. Miller Fisher syndrome 
In 1956, the American neurologist Miller Fisher described a syndrome consisting of 
ataxia, areflexia and ophthalmoplegia, now known as Miller Fisher Syndrome (MFS), which 
has proved to be a variant of GBS (Fisher 1956, Mori, Kuwabara et al. 2001). Apart from the 
classical features of the original description, facial weakness, bulbar palsy, dysaesthesia and 
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limb weakness are also seen in some subjects (Mori, Kuwabara et al. 2001). Its incidence has 
been reported as 0.1 per 100000 in one Italian study (Bogliun, Beghi et al. 2004), and about 
5% of GBS cases are estimated to suffer from this variant in developed countries. The 
incidence of MFS appears to be higher in Asia (Lyu, Tang et al. 1997). MFS overlaps with 
AIDP and Bickerstaff Encephalitis (Lo 2007). 
MFS is strongly associated with IgG antibodies against quatrosialoganglioside 1b (GQ1b) 
(Chiba, Kusunoki et al. 1995, Koga, Yuki et al. 1998). The pathophysiology of this condition 
involves the paranode where clusters of GQ1b antigen have been localized using 
immunohistochemical techniques. Unsurprisingly, given the clinical features, cranial nerves 
innervating the extra-ocular muscles appear to be more densely replete with GQ1b antigen 
than other cranial nerves. Ataxia is thought to reflect Anti-GQ1b antibodies targeting 
antigens in the dorsal root ganglia and nerve terminal of the muscle spindle (Liu, Willison et 
al. 2009). 
1.3.5. Overlap syndromes 
The classification of AIDP into AMAN or AMSAN is largely reliant on 
neurophysiological studies, but this has limitations. For example, conduction block, a 
neurophysiological finding typical of demyelination, can be present in axonal disease if 
blocking of the nodes of Ranvier occurs (Uncini, Manzoli et al. 2010). This could lead to the 
misdiagnosis of AMAN as AIDP and may have some impact on the reported prevalence of 
the different forms of GBS in epidemiological studies (Uncini and Kuwabara 2012). Also, 
timing of electrophysiological studies during the illness course might be of importance, with 
axonal features being more prominent later in the disease course, when secondary 
degeneration of axons of demyelinated nerve fibres is not uncommon (Uncini, Manzoli et al. 
2010). 
This relates to the finding that axonal changes are frequently seen in more severe AIDP. 
This picture is referred to as ‘bystander’ damage. According to this hypothesis, axons are 
damaged by the inflammatory process and may become compromised by endoneurial 
oedema, immune attack on axon epitopes situated beneath myelin targets, ischaemia or intra-
axonal accumulation of sodium and calcium due to voltage gated ion channel dysfunction 
(Madrid, Wi et al. 1977, Sobottka, Harrer et al. 2009). 
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1.4. Pathogenesis of GBS 
Based on its pathological features, its response to immunomodulatory therapies and the 
presence of activated lymphocytes and antibodies against neural cell surface antigens, GBS is 
thought to be an immune-mediated disease. However, there are a number of features 
distinguishing GBS from other classical autoimmune diseases, like systemic lupus 
erythematosus or type 1 diabetes mellitus. In contrast to most autoimmune diseases, men are 
about 1.5 times more likely to be affected than are women. Other atypical features include a 
lack of associated autoimmune diseases and no confirmed HLA association. Finally, in 
contrast to autoimmune diseases, GBS is a monophasic disease in most instances, even 
though relapsing disease has been reported (Kuitwaard, van Koningsveld et al. 2009). These 
differences to autoimmune diseases are well recognized, and GBS is often labelled as post-
infectious inflammatory disorder(van Doorn, Ruts et al. 2008). Within this thesis we propose 
the hypothesis that GBS is better thought of as an autoinflammatory disorder, a group of 
disorders characterized by dysfunction of the innate, rather than the adaptive immune system. 
1.4.1. Triggering events 
GBS can rapidly transfer a healthy, fit individual to a highly dependent state requiring 
intensive supportive care. The question as to how and why such a rapidly evolving disease is 
initiated has held the attention of researchers for some time. Of interest in this context is that 
about two thirds of GBS patients report an infection in the weeks preceding their illness, 
however other events have also been recorded (Winer 2001).  
1.4.1.1. Infections 
Gastrointestinal or upper respiratory tract infections are commonly reported. Most 
frequently, evidence of C. jejuni infection or Mycoplasma pneumonia is found. Other 
organisms reported to precede GBS include cytomegaly virus (CMV), Epstein-Barr virus 
(EBV) and other viruses (Hadden, Karch et al. 2001). However, in the majority of cases, no 
specific agent can be identified.  
One Japanese study found that the most frequent antecedent symptoms in GBS and 
related disorders were fever (52%), cough (48%), sore throat (39%), nasal discharge (30%), 
and diarrhea (27%) (Koga, Yuki et al. 2001).  
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1.4.1.2. Vaccinations 
A variety of vaccinations have been reported to trigger GBS.  Administration of vaccines 
prepared from suckling mouse brain or sheep brain led to an acute neuropathy resembling 
GBS in a number of patients (Hemachudha, Griffin et al. 1988). This was thought to be 
caused by cross-reactivity of brain antigens with peripheral nerve antigens. Also, the 
parenteral administration of gangliosides led to a GBS-like picture in some individuals 
(Raschetti, Maggini et al. 1995). This was thought to arise as an immune response to 
ganglioside antigens in peripheral nerve. 
GBS has also been described in context of influenza vaccinations in the US (Schonberger, 
Bregman et al. 1979). During the 2009/10 H1N1 epidemic several cases of GBS were 
reported after H1N1 infection (Chaari, Bahloul et al. 2010) and after vaccinations. A 
preliminary report issued by the Centre for Disease Control and Prevention showed a rate of 
0.8 cases of GBS per 1x106 vaccinations which is in keeping with that seen following other 
seasonal influenza vaccines (Centers for Disease and Prevention 2010).  
There are also case reports of GBS occurring following hepatitis and meningococcal 
vaccines (Blumenthal, Prais et al. 2004, Velentgas, Amato et al. 2012).  
1.4.1.3. Campylobacter jejuni and AMAN 
Epidemiologically, the association of GBS with preceding infections is best established 
for C. jejuni in the AMAN subtype of GBS. This has mainly been established in Asian 
countries. However, it was reported recently that GBS after C. jejuni infections in The 
Netherlands is also strongly, but not exclusively, associated with axonal changes (Drenthen, 
Yuki et al. 2011). Interestingly, the incidence of GBS has declined in New Zealand since the 
rate of C. jejuni infections has decreased (Baker, Kvalsvig et al. 2013).  
C jejuni isolates from patients express lipo-oligosaccharides (LOS) that mimic the 
carbohydrates of gangliosides (Godschalk, Kuijf et al. 2007).  C. jejuni strains that produce 
LOS resembling GM1 and GD1a were found in higher frequencies in patients with GBS than 
in patients with Campylobacter enteritis (Koga, Gilbert et al. 2006).  Also, the LOS structure 
seems to determine ganglioside-antibody specificity and the clinical syndrome that develops 
in the host and ganglioside antibodies often cross-react with C. jejuni strains isolated from the 
same patient. C jejuni isolates from patients with pure motor or axonal GBS frequently 
express a GM1-like and GD1a-like LOS, whereas those isolated from patients with 
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ophthalmoplegia or MFS usually express a GD3-like, GT1a-like, or GD1c-like LOS (Kuijf, 
Godschalk et al. 2007). 
1.4.1.4. Other triggers 
Especially for the demyelinating forms of GBS, a range of other triggers have been 
described. GBS has been associated with trauma, including head injury but not peripheral 
nerve injury, surgical interventions (Shuert and Gamble 1972, Duncan and Kennedy 1987, 
Baldwin, Pierce et al. 1992, Hogan, Briggs et al. 1992),  and even lightning strike 
(Theodorou, Limmroth et al. 2008), but the mechanism by which these events lead to GBS is 
unclear. These all lead to relatively stereotyped patterns of disease (see Chapter 3).  
This indicates that a range of events that lead to activation of the immune system, could 
lead to an immune attack against myelin in a susceptible individual. Interesting in this context 
are the observations made by Kuitwaard et al. on recurrent GBS (Kuitwaard, van 
Koningsveld et al. 2009). In their case series of 32 patients, symptoms and signs of GBS were 
similar for different episodes of GBS, even though symptoms and signs of preceding 
infection (where present) were mostly different.  
1.4.1.5. Relationship between triggering event and GBS 
In summary, a range of triggering events has been described for GBS, which all lead to a 
relatively stereotyped immune response against nerve tissue. All these events appear to have 
in common the enteral, respiratory or parenteral exposure to a pathogen, which is usually 
easily controlled by the host. Some individuals, however, go on to develop a severe acute 
neuropathy. Why this exaggerated, pathological attack on peripheral nerves occurs is unclear, 
and several theories have been proposed.  
1.4.2. Self-tolerance and molecular mimicry  
In order for the immune system to protect the host from pathogens, it has a powerful array 
of effector mechanisms available. These mechanisms must not be used in an attack against 
self-structures; failure of doing so can lead to a range of sometimes severe diseases and is 
encompassed in the term autoimmunity (Matzinger 2002).   
Several mechanisms prevent B and T lymphocytes from attacking self antigens. These 
include firstly the apotosis of autoreactive lymphocytes during development in bone marrow 
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and thymus. Secondly, autoreactive lymphocytes can become inactivated – this is called 
‘anergy’. Finally, there is a complex array of regulatory and suppressive factors and cells, i.e. 
regulatory T cells, that can inhibit T and B cell effector functions. 
Evolutionary pressure will lead to invading pathogens attempting to go unnoticed by 
innate and adaptive components of the immune system by presenting antigens resembling 
host proteins. This phenomenon is also termed ‘crypsis’ - being camouflaged to resemble part 
of the environment.  
The term molecular mimicry was first used by Damian in 1964, even though he dismissed 
the idea (Damian 1964). The hypothesis states that antigens on invading organisms resemble 
host antigens, which leads to dual recognition of host and microbe antigens by T cell 
receptors (TCR) or antibodies. While the main evolutionary aim of the microorganism is 
evasion of immune recognition, the resemblance of microorganism and host antigens could 
lead to an erroneous recognition of auto-antigens and triggering of an immune response 
against host tissues. This has led to the concept that autoimmune disease can be a 
consequence of molecular mimicry. Molecular mimicry due to a range of infectious agents 
has been implicated in the pathogenesis of a range of autoimmune diseases, including 
rheumatic fever, multiple sclerosis, and diabetes mellitus. In GBS, antibodies found are 
predominantly of IgG type, implying T helper cell involvement (Sekiguchi, Uncini et al. 
2012). 
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Figure 1.1 – The concept of molecular mimicry: Relation between infections, antiganglioside 
antibodies, and clinical course of GBS (van Doorn, Ruts et al. 2008) 
Molecular mimicry is an attractive immunopathological mechanism to explain the 
relationship between trigger and immune response in GBS (Ang, Jacobs et al. 2004). 
Indicators of this relationship are: (1) the temporal relationship between infection and GBS 
(Figure 1.1), (2) identification of host T cells and antibodies against gangliosides (Csurhes, 
Sullivan et al. 2005), (3) structural similarities between bacterial LOS and gangliosides 
(Willison and Yuki 2002), and (4) reproduction of a neuritis and in an animal model after 
immunization with gangliosides (Yuki, Yamada et al. 2001, Yuki and Kuwabara 2007). 
However, while immunization with LOS does lead to production of anti-ganglioside 
antibodies in rabbits (Ang, De Klerk et al. 2001), no neurological sequelae have been 
observed in this model. 
These concepts are relatively well established for AMAN, but less so in AIDP. Here, the 
relationship to C. jejuni as trigger is less definite, and no ganglioside antibodies are found in 
the majority of cases.  
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1.4.3. Autoinflammatory diseases and its relevance in GBS 
pathogenesis 
Autoinflammatory diseases (AID) are a group of disorders of the immune system, 
characterized by seemingly unprovoked inflammation. They are predominantly hereditary, 
either inherited in a Mendelian or in a polygenic fashion. Examples include Familial 
Mediterranean fever and other periodic fever syndromes, pyoderma gangrenosum, Behcet’s 
disease and Crohn’s disease (Galeazzi, Gasbarrini et al. 2006). 
 AID are a relatively new group of disorders, and are distinct from classical autoimmune 
diseases. AID and autoimmune diseases share the common feature of an immune attack 
against self and chronic activation of the immune system. However, the specific effector 
mechanisms differ: in AID, the innate immune system causes tissue damage directly, whilst 
in autoimmune diseases the innate system acts via activation of the adaptive immune system. 
In both groups, inflammation can be triggered by preceding infections or vaccinations 
(Efthimiou, Flavell et al. 2008, Touitou and Kone-Paut 2008). Inflammatory markers, like 
CRP and ESR, are always increased in AID, but not necessarily in autoimmune diseases. 
In contrast to autoimmune diseases, AID are not associated with MHC class II haplotypes 
(Theofilopoulos, Gonzalez-Quintial et al. 2010). Rather, AIDs have been linked to a range of 
genetic variations in different loci, including genes related to IL-1β activation (i.e. NLRP3 in 
cryopyrinopathies) (Hoffman, Mueller et al. 2001), and activation of NF-κB (i.e. NOD2 in 
Crohn’s disease) (Hugot, Chamaillard et al. 2001).  
1.4.4. Discussion of hypotheses of GBS pathogenesis 
In summary, different pathogenic models have been proposed to explain GBS 
pathogenesis. The most widely accepted model at present describes GBS as an autoimmune 
disorder, characterized by activated B and T cell mediated responses against peripheral nerve 
proteins triggered by molecular mimicry.  
However, as described in more detail in Chapter 2, GBS lacks both a MHC class II 
association and a link to other autoimmune diseases. Also, whilst auto-antibodies have been 
found in some subforms of GBS (i.e. Anti-GQ1b in MFS), these are usually not found in the 
more common demyelinating variants.  
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In this thesis, we will propose that GBS could be explained by an autoinflammatory, 
rather than autoimmune, process, highlighting the role of the innate immune system in GBS 
pathogenesis.Both autoimmune diseases and AIDs can be quite specific in their target tissue, 
as seen in GBS, or cause more wide-spread inflammation.  
 
1.5. Assessment of severity 
As outlined above, the severity of GBS is highly variable, ranging from barely noticeable 
symptoms and signs to a severe illness necessitating intensive support or even leading to 
death. Dysfunction of respiratory and bulbar muscles or severe autonomic dysfunction 
necessitates intensive care and ventilator support in 10 to 30% of cases (Alshekhlee, Hussain 
et al. 2008).  
A simple, but very reliable, scale for disability in GBS has been developed by Hughes 
(Hughes, Newsom-Davis et al. 1978), and has subsequently been used in a large numbers of 
clinical trials. It consists of a 7 point scale as follows: 
0 = Healthy 
1 = Minor symptoms and signs of neuropathy, able to work and run 
2 = Able to walk without support of a stick, unable to work or run 
3 = Able to walk with a stick or other support 
4 = Confined to chair or bed 
5 = requiring assisted ventilation 
6 = Death 
 
 
 
Immunogenetic studies of Guillain – Barré Syndrome   Page 35 
 
  
 
1.6. Treatment  
One of the features of GBS which strongly supports the concept of GBS being an immune 
mediated disease is its response to immunomodulatory therapy. However, treatment for GBS 
differs markedly from that of other autoimmune diseases. For example, GBS does not 
respond to oral or intravenous corticosteroids, and such therapy might even be harmful 
(Hughes, Newsom-Davis et al. 1978, Hughes, Swan et al. 2010).  
The mainstay of therapy at present is either plasma exchange or intravenous 
immunoglobulins, which have been found to be effective in a number of trials (summarized 
in (Hughes, Wijdicks et al. 2005)). Early initiation of therapy appears important by 
preventing accumulation of damage. Also, spontaneous amelioration of the immune response 
as part of the natural history of the disease could make therapy given late in the disease 
course less effective (Hughes, Swan et al. 2007, Randall 2010).  
1.7. Hypotheses and aims – Part 1 
GBS is a rare, but potentially devastating disease of the peripheral nervous system. Its 
epidemiology differs between geographical regions, with axonal subsets being more frequent 
in the developing world, in contrast to developed countries, where demyelinating forms 
predominate. It is unclear at present whether genetic or environmental factors are responsible 
for this difference. 
Based on epidemiological studies from Europe and North America, as well as older 
Australian studies, we hypothesized that AIDP is still the predominant form of GBS in 
Australia. The first aim of this study was to study a cohort of patients with a confirmed 
diagnosis of GBS, and describe in detail their clinical, para-clinical and electrophysiological 
characteristics. 
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Chapter 2 Immunogenetic factors in Guillain-Barré 
Syndrome  
2.1. Introduction  
The complexity of immune responses is partially determined by variation of the genetic 
background of an individual. After a suitable trigger, there is failure of self-tolerance, and 
self-antigens are attacked by the immune system.  
Whilst a range of infections are often described as environmental triggers for GBS, the 
genetic basis of GBS is unknown. In other autoimmune diseases, such as MS and type 1 
diabetes, where extensive genetic studies have been performed, there are associations of 
disease with many genes that have a small individual risk (Beecham, Patsopoulos et al. 
2013).   
It is likely that genetic variation in immune related genes could contribute to the risk of 
acquiring GBS, similar to more classical autoimmune diseases, or influence severity of 
disease. For autoimmune diseases it is also possible that genetic variation in the target organ 
could contribute to the susceptibility to disease. 
This chapter provides a literature review of the genetics of GBS with particular emphasis 
on genes studied within this thesis. 
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2.2. Evidence for a genetic tendency in GBS 
2.2.1. Familial GBS 
If there were a genetically determined susceptibility to develop GBS, it might be expected 
that disease occurs in families. After an early report of familial GBS (Saunders and Rake 
1965) there have been further reports.  From Holland there is a report of 12 families with 
GBS (Geleijns, Brouwer et al. 2004).  There is a report of a mother and son, both with HLA 
DR2, who both developed GBS (Wilmshurst, Pohl et al. 1999). In another family, 4 siblings 
born to a consanguineous marriage developed GBS (Aquil, Khan et al. 2011).  Also, there is a 
report of GBS in father and son with strikingly similar HLA types (Davidson, O'Sullivan et 
al. 1992). There is also a report of familial GBS from India (Naik, Saroja et al. 2012). Some 
reports could be linked to concurrent infection with C. jejuni (Yuki and Tsujino 1995, 
Tokuhara, Hirokawa et al. 2010), but is not likely for the other reports mentioned above, as 
the onset of GBS occurred many years apart, and frequently in subsequent generations. 
Preceding environmental influence cannot be excluded based on the data presented.  
2.2.2. Interaction of GBS with hereditary neuropathy 
There is a report of axonal GBS in a patient with Charcot Marie Tooth (CMT) disease 
(Odaka, Yuki et al. 2003).   There have been reports of some types of inherited neuropathies 
that are responsive to corticosteroids (Dyck, Swanson et al. 1982).   
2.2.3. Risk in relatives  
Twin studies can be used to evaluate the risk of diseases that can be attributed to genetic 
predisposition, but there are no twin studies in GBS. A Dutch study of familial GBS found 
that siblings of people with GBS have a risk to develop GBS, which is increased by factor 2.6 
compared to the general population (Geleijns, Brouwer et al. 2004). This could possibly be 
due to genetic similarities, but environmental factors cannot be excluded.  
For comparison, in multiple sclerosis, a inflammatory disease of the central nervous 
system with well-established genetic influences, the risk of first degree relatives to develop 
the illness has been reported to be as high as 7.1 (Nielsen, Westergaard et al. 2005).  
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2.2.4. Gender differences 
Another genetically determined risk factor is gender. Males have a significantly higher 
risk for developing GBS than females (Chapter 3), which is an unusual feature in 
autoimmune diseases (McCombe, Greer et al. 2009). Gender is determined by the Y 
chromosome, which carries few genes. Amongst these is the Sry gene, which is responsible 
for the formation of male sexual organs by controlling of gonadal hormone production. A 
second locus is the Yaa gene cluster, which predisposes to autoimmunity in mice after 
translocation of TLR7 from the X chromosome (Subramanian, Tus et al. 2006). Dosage 
effects of X-chromosome genes (e.g. CD40L) are important in many female-predominated 
autoimmune diseases (i.e. SLE). 
2.3. Specific genes associated with GBS  
There have been studies of HLA associations, of genes to do with antigen processing, of 
T cell receptors and Fc receptors, and of immune mediators and cytokines (particularly in the 
promoter regions) which have been associated with many diseases, including autoimmune 
disease (Vandenbroeck 2012).   
Below, we outline studies that have investigated candidate genes to do with GBS. For a 
more exhaustive review on GBS genetics, the reader is referred to Appendix B.  
2.3.1. HLA genes 
The MHC locus on chromosome 6 contains a range of genes related to the immune 
system functions, including genes encoding cell-surface antigen-presenting proteins, the HLA 
molecules. HLA molecules have paramount importance for the specific immune system in 
both health and disease due to their role in antigen presentation to T cells. Also, class I HLA 
molecules are important for the innate immune system, by providing binding sites for Killer 
immunoglobulin-like receptors (see Chapter 2.4). Certain genetic variants have been 
associated with a range of autoimmune diseases, and, indeed, the presence of an HLA 
association is among the criteria used to define an autoimmune disease (Rose and Bona 
1993).  
In GBS, a number of studies in different populations have been conducted over the last 30 
years, without consistent positive results. Early studies using serological methods generally 
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found no HLA association (Latovitzki, Suciu-Foca et al. 1979, Kaslow, Sullivan-Bolyai et al. 
1984, Hafez, Nagaty et al. 1985), although one study in Mexico found that GBS was 
associated with carriage of HLA-DR3 (Gorodezky, Varela et al. 1983). The majority of these 
studies have not found any associations between GBS and carriage of class I or class II HLA 
molecules (Winer, Briggs et al. 1988, Piradov, Dolbin et al. 1995). However, when GBS 
patients have been grouped according to whether they have AIDP or axonal neuropathy, it 
has been found that certain DQB1 molecules are associated with AIDP but not axonal 
neuropathy (Magira, Papaioakim et al. 2003).  A study from Japan found no HLA association 
with GBS but a tendency for increased HLA-DRB1*08:03 in subjects with GBS associated 
with C. jejuni infection (Ma, Nishimura et al. 1998).  A study from Holland found no 
association of HLA class II alleles with GBS (Geleijns, Schreuder et al. 2005). An Australian 
study found no HLA association in GBS, except for a slight negative association of HLA-
DR5 (McCombe, Csurhes et al. 2006). 
In summary, in spite of numerous investigations, no reproducible HLA association has 
been found for GBS. This lack of association of HLA with GBS could partly be due to the 
lack of differentiation between AIDP and AMAN, or insufficient patient numbers. 
Alternatively, the lack of strong HLA class II association with inflammatory neuropathy 
could suggest that class II restricted antigen presentation is not of prime importance in 
susceptibility to GBS. This could be of relevance, especially if components of the innate 
immune system are of more importance in GBS pathogenesis than hitherto acknowledged. 
2.3.2. T cell receptor genes 
There are a number of indications that T cells play an important role in GBS 
pathogenesis. These include the finding of T cell infiltrates in nerve biopsies of patients with 
GBS (Schmidt, Toyka et al. 1996) as well as the presence of cross-reactive IgG1 and IgG3 
antibodies to LOS and gangliosides. Formation of these antibodies typically requires T 
lymphocyte help in their production (Yuki, Handa et al. 1995, Yuki, Ichihashi et al. 1995). T 
cell reactivity to peripheral nerve antigens has been reported in GBS and CIDP (Csurhes, 
Sullivan et al. 2005). 
When T cell receptor genes were studied in GBS, there was no association with GBS 
development, although there was a trend to an influence on the severity of disease (Ma, 
Nishimura et al. 1998). 
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2.3.3. CD1 
CD1 is part of a conserved family of transmembrane glycoproteins, resembling MHC. It 
has been shown to be crucial for capturing and presenting a variety of both microbial and 
self-glycolipids (Porcelli 1995). The human CD1 family consists of five glycosylated 
proteins, CD1A, CD1B, CD1C, CD1D and CD1E, which have limited polymorphisms and 
are all expressed by professional antigen-presenting cells (Porcelli 1995).  
T cells that recognize lipids in association with CD1 molecules can be broadly divided 
into two groups: those that are restricted to CD1A, CD1B and CD1C molecules and have 
similar properties to peptide-specific T cells, and those that are restricted by CD1D, which 
share many of the properties of innate immune cells, labelled invariant natural killer T 
(iNKT) cells (Godfrey and Kronenberg 2004, De Libero and Mori 2005). In fact, lipid 
antigens must be presented by CD1 antigen-presenting molecules to be recognized by T cells 
(Shamshiev, Donda et al. 1999, Shamshiev, Donda et al. 2000). This implies that only lipids 
that can bind to CD1 are immunogenic for T cells (De Libero and Mori 2005).  
CD1A and CD1B have been observed on CD68+ cells and macrophages in the 
endoneurium in nerve biopsies of GBS and CIDP patients (Khalili-Shirazi, Gregson et al. 
1998, Van Rhijn, Van den Berg et al. 2000).  
The second exons of both CD1A and CD1E are allelic, possibly affecting function. These 
alleles have been investigated in GBS, but with conflicting results. An Italian study found 
that subjects with CD1E*01/01 genotype are 2.5 times more likely to develop GBS whereas 
subjects with CD1A*01/02 or CD1E*01/02 have a reduced relative risk (Caporale, Papola et 
al. 2006). This was, however, not confirmed in a larger Dutch study using similar techniques 
(Kuijf, Geleijns et al. 2008), and a subsequent metaanalysis found no difference (Wu, Zhou et 
al. 2012). Interestingly, several reports showed polymorphisms of CD1 as a susceptibility 
factor in multiple sclerosis, a demyelinating disease of the central nervous system 
(Jamshidian, Nikseresht et al. 2010, Caporale, Notturno et al. 2011). 
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2.3.4. IL10 
IL-10 is a cytokine which is secreted by both macrophages and T lymphocytes. It is 
involved in the immune response of both infectious and autoimmune diseases and can have 
both pro-inflammatory and anti-inflammatory effects depending on the milieu.  
One study found that polymorphisms in the promoter region of IL10 were associated with 
disease susceptibility but not disease severity (Myhr, Vagnes et al. 2003).  
2.3.5. TNF alpha 
TNFα is a cytokine produced mainly by macrophages and monocytes. It has an important 
role in early phase of immunity and inflammation by stimulation of the acute phase reaction, 
acting particularly on the innate immune system. Circulating levels of TNFα were found to be 
increased in GBS (Radhakrishnan, Sumi et al. 2003). GBS and MFS has been associated with 
administration of TNFα inhibitors for rheumatological disorders (Shin, Baer et al. 2006).  
A study of polymorphisms of TNFα in 263 subjects with GBS found that these were not 
associated with the disease susceptibility but were associated with disease severity, as 
measured as degree of weakness at the peak of illness and long-term functional outcome 
(Geleijns, Emonts et al. 2007). A study from China showed that TNFα polymorphisms were 
associated with the AMAN and AMSAN forms of GBS (Jiao, Wang et al. 2012). An 
association with GBS was found in a Japanese study (Zhang, Dong et al. 2007). A meta-
analysis of data from 1590 cases of GBS found that polymorphisms of TNFα 308G/A were 
significantly associated with risk of GBS (Wu, Zhou et al. 2012). This makes TNFα the gene 
with the most evidence for a role in GBS pathogenesis. TNFα inhibition (either by genetically 
determined polymorphisms or iatrogenic administration of antagonists) could lead to the 
development of Guillain-Barre syndrome by augmenting the number of activated peripheral 
T cells or by disturbing the intrinsic balance of TNF and its receptors in the local peripheral 
nervous system compartment (Shin, Baer et al. 2006). 
2.3.6. MMP9 
Matrix metalloproteinases can play a role in inflammation, and possibly are involved in 
opening the blood-nerve barrier. MMP9 is expressed in the peripheral nerve in GBS 
(Kieseier, Clements et al. 1998), and is upregulated in peripheral blood (Nyati, Prasad et al. 
2010). A study of polymorphisms of MMP9 in 269 subjects with GBS found that these were 
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not associated with the disease susceptibility but were associated with disease severity, as 
measured as degree of weakness at the peak of illness and long-term functional outcome 
(Geleijns, Emonts et al. 2007). 
 
2.3.7. Fc Receptors 
Fc receptors bind immunoglobulins in immune complexes. Polymorphisms in these 
receptors have been associated with infectious diseases and autoimmunity (Zidan, Sabbah et 
al. 2013). Genotyping of 80 GBS patients and 80 healthy controls from North India found 
that polymorphisms in genes encoding FcγRIIA and FCγRIIIA, but not FcγRIIIB, were 
associated with GBS (Geleijns, Emonts et al. 2007). The FcγRIIIa gene variants were also 
associated with severity of GBS (van Sorge, van der Pol et al. 2005). However, this could not 
be confirmed in a larger metaanalysis (Wu, Zhou et al. 2012). All these receptors bind IgG, 
but differ in their distribution on immune cells, with FCγRIIIA being found predominantly on 
NK cells, whereas FCγRIIA and FCγRIIIB are predominantly found on macrophages and 
neutrophils. 
2.3.8. Lipopolysaccaride receptors 
Several receptors are involved in detection of microbial antigens by the innate immune 
system, including Toll-like receptor 4 (TLR) which binds to lipopolysaccharides (LPS) and 
CD14 (Zanoni and Granucci 2013). The nature of GBS as a post-infectious illness makes an 
involvement of these proteins in pathogenesis seem possible. 
In a Dutch study of 242 GBS subjects polymorphisms of CD14 and TLR4 were not 
associated with GBS (Geleijns, Jacobs et al. 2004). 
2.3.9. Glucocorticoid receptor 
Glucocorticoid receptors (GR) act directly in the nucleus to regulate gene transcription. 
GR also interact with other transcription factors to modulate their ability to regulate 
transcription. In GBS, polymorphisms of the glucocorticoid receptor have not been found to 
be linked to susceptibility, but are related to outcome (Dekker, van den Akker et al. 2009).  
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2.4. Killer immunoglobulin-like receptors 
NK cells use a wide variety of surface receptors to recognize infected and malignantly 
transformed cells and initiate an early immune response. These receptors belong to two 
distinct families, the C-type lectins-like group (CD94:NKG2) which map to chromosome 
12q1.3–13.4, and the immunoglobulin-like super family which consists of the killer 
immunoglobulin-like receptors (KIRs), leukocyte immunoglobulin-like receptors and the 
leukocyte-associated immunoglobulin-like receptors and map to chromosome 19q13.4.3. Of 
those, KIRs constitute the largest family of human NK receptors, with multiple inhibitory and 
activating members which show extensive polymorphism. They are found on both NK cells 
and on subgroups of both CD8+ αβ and γδ T lymphocytes (Snyder, Weyand et al. 2004). 
Interaction of KIR with their Class I HLA ligands can produce both inhibitory and activating 
signals, that regulate NK cell function (Middleton and Gonzelez 2010). 
2.4.1. Genetics of KIR 
KIR receptors are encoded by a gene cluster on chromosome 19q13.4 within the 
leukocyte receptor complex (Kulkarni, Martin et al. 2008). To date, 15 KIR genes and 2 
pseudogenes have been described. There is significant variability in the gene content at the 
KIR locus, which has been attributed to gene duplication and non-allelic homologous 
recombination (Martin, Bashirova et al. 2003, Martin, Kulski et al. 2004).  
The different KIRs are named according to the number of extracellular Ig domains (2D or 
3D) and the length of the cytoplasmic tail (L for long, S for short). Long cytoplasmic tails are 
associated with inhibitory receptors, while short tails are found on activating receptors 
(Dorak 2007). So, while the intracellular parts of activating and inhibitory KIRs differ 
significantly, the extracellular parts of activating KIRs are almost identical in sequence to the 
inhibitory KIRs (Stewart, Laugier-Anfossi et al. 2005). 
Two basic haplotypes have been described, termed haplotype A and B. Haplotype A is 
composed of six inhibitory genes (KIR2DL1, 2DL3, 3DL1, 3DL1, 3DL3, 2DL4) and one 
activating gene (KIR2DS4), together with two pseudogenes (2DP1 and 3DP1) (see Figure 
2.1). Haplotype B is more variable, and consists of a number of both activating and inhibitory 
genes. KIR genes do not undergo somatic rearrangement, but the number of genes on each 
haplotype is variable.  
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Figure 2.1 - Haplotypic variation of 17 KIR genes:  Relative distribution of gene frequencies 
for haplotype A and B (Dorak 2007) 
More than 100 highly homologous KIR variant sequences have been deposited in 
databases (Trowsdale 2001). Consequently, unrelated individuals rarely share identical KIR 
genotypes (Shilling, Guethlein et al. 2002), and ethnic populations differ markedly in the 
distribution of KIR genotype frequencies (Yawata, Yawata et al. 2002). 
2.4.2. KIR ligands  
HLA class I molecules HLA-A, HLA-B and HLA-Cw are ligands for KIRs, allowing NK 
cells to discriminate between normal cells and cells that have lost the expression of MHC 
class I (e.g., tumour cells or virally infected cells). HLA genes are located on chromosome 6, 
and are therefore unlinked to KIR genes on chromosome 19. Thus, inheritance and 
expression of receptor and ligands are independent of each other. Either receptor or ligand 
can be absent in individuals, resulting in a functional null situation (Kulkarni, Martin et al. 
2008).  
The interaction of KIRs with their HLA ligands is complex and not understood in all 
details. It is likely that multiple interactions with numerous different receptors and ligands are 
possible simultaneously and can influence each other.  
HLA-C is recognized by the KIR 2DL1, 2DL2 and 2DL3, and probably by some of their 
activating counterparts. Each HLA-C haplotype belongs to two ligand groups, distinguished 
by a dimorphism at position 80. HLA-C1 has asparagine at this position, whereas HLA-C2 
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contains lysine. To date, the relationship of the inhibitory KIRs 2DL2 and 2DL3 with HLA-
C1 and 2DL1 with HLA-C2 are best understood. It is likely that the activating KIR 2DS2 and 
2DS1, whose extracellular domains are very similar to their inhibitory counterparts, can 
interact with the same HLA molecules.  
 KIR3DL1, and possibly 3DS1, are known to interact with HLA-Bw4. A polymorphism 
at position 80 affects this interaction, with isoleucine containing molecules (HLA-Bw4I) 
displaying a stronger interaction (Carr, Pando et al. 2005).  
Other specific interactions of KIR and HLA molecules are likely, but less well described. 
Specifically, interaction of activating KIR with HLA-C1, –C2 and –Bw4 is likely, even 
though direct binding has not been shown for all (Fauriat, Ivarsson et al. 2010).  
 
Figure 2.2 –HLA-ligand binding specificities for KIR (Kulkarni, Martin et al. 2008) 
2.4.3. Role of KIR in human disease, focusing on autoimmune disease 
KIRs have been implicated in numerous human diseases, e.g. viral infections like HIV 
and hepatitis, malignancies (melanoma, lymphoma), pre-eclampsia, graft-versus-host-disease 
(Venstrom, Gooley et al. 2010) and autoimmune diseases (summarized in (Kulkarni, Martin 
et al. 2008)).  
Specific KIRs have been linked to susceptibility to a variety of other autoimmune 
diseases, including multiple sclerosis (Fusco, Guerini et al. 2010), Crohn’s disease 
(Hollenbach, Ladner et al. 2009), Sjögren’s syndrome, systemic lupus erythematosus (Hou, 
Zhang et al. 2010) and scleroderma (Pellett, Siannis et al. 2007). No studies of KIR in GBS 
or CIDP have been undertaken so far. 
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2.5. Conclusions 
Whilst incompletely studied, there is some evidence to support clustering of GBS in 
families and an increased risk for family members, supporting a role for genetic susceptibility 
in GBS. 
A range of candidate genes have been investigated in GBS; however most of these have 
only been studied in a relatively low number of subjects, and most studies have not been 
replicated.  
Many of the candidate genes studied have been previously linked to other autoimmune 
diseases, where there is considerable evidence for genetic susceptibility. However, as 
mentioned, GBS does differ in a number of aspects from autoimmune diseases. Of interest is 
the lack of an unequivocal Class II HLA association, which is unusual for an autoimmune 
disease.  
Further studies could involve investigation of other, so far untested, candidate genes or a 
whole genome approach with genome-wide association studies. In this thesis, both 
approaches have been pursued independently. 
2.6. Hypotheses and aims – Part 2 
A number of candidate genes have been studied in recent years, but few genes have 
consistently been found to be associated with GBS. That there is genetic susceptibility to 
develop GBS seems likely based on the reports of familial forms of this disease, and the links 
to other inherited neuropathies. 
The second hypothesis of this study was that there are genes that predispose to GBS. To 
test this, the aims were twofold: 
Firstly, to investigate the KIR and HLA ligands associated with GBS and to compare this 
to healthy controls and subjects with CIDP. As outlined above, the KIR-HLA interaction 
provides an interesting topic for research because of its role in the early innate immune 
response to infection. Moreover, because of the complex gene-gene interaction, this gene 
region is not amenable to study using smaller scale genome wide-association studies. It was 
expected that, if KIR/HLA interactions are important in GBS, there would be genetic 
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differences between subjects with GBS and healthy controls. These might or might not be 
seen comparing subjects with CIDP to the GBS cohort. 
The second aim was to use the hypothesis-free approach of a genome-wide association 
study in order to identify regions of interest on the human genome that could contribute to 
susceptibility to GBS.  
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Chapter 3 Clinical features of Guillain-Barré 
Syndrome at seven hospitals on the East Coast of 
Australia 
 
 
Rationale 
Guillain-Barré syndrome has a wide range of clinical presentations, from mild 
presentations to severely affected patients who require long periods of intensive supportive 
therapy. Moreover, GBS is heterogeneous in its electrophysiological properties and 
associated autoimmune markers. 
In the past, AIDP has been thought of as the most common form of GBS in Australia, but 
this has not been systematically studied.  
In order to describe in sufficient detail the patient population studied, the first aim of this 
thesis was an overview of the clinical features of the population. The population described in 
this chapter served as basis for recruitment for the genetic studies outlined in the subsequent 
chapters. 
Using hospital records, we collected and analyzed clinical data from 335 patients 
admitted to seven hospitals along the East Coast of Australia. We found that the predominant 
form of GBS is AIDP. Axonal and focal variants were less frequently encountered. There was 
a male predominance, with a male to female ratio of 1.6 : 1. 
URTIs were the most commonly identified trigger, with other infections, including those 
causing diarrhea being relatively uncommon. Consistent with this was the higher incidence of 
GBS in winter months. However, a wide variety of triggers was identified. 
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Severity of illness was high, with most patients being bedbound or requiring intensive 
support during some part of their illness.  
GBS in Australia seems to have similar characteristics to other countries of the developed 
world. In comparison to studies performed 30 years ago, before the wide-spread use of IVIg 
and plasma exchange for GBS, the illness severity has not significantly decreased, indicating 
a need for more effective therapies for GBS. 
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Chapter 4 Killer-immunoglobulin like receptors and 
their HLA ligands in Guillain-Barré Syndrome 
 
Rationale 
In this thesis two different approaches to the study of genetic susceptibility of GBS were 
used. At first we used a candidate gene approach to study KIRs and their HLA ligands. 
NK cells have a range of receptors on their surface controlling their activation status and 
effector function. Of these, the KIR/HLA system is of paramount interest, not only because 
of its central role in innate immune system activation, but also because of the wide number of 
polymorphisms described, which are intricately linked to their function. Both receptor and 
ligand need to be present for a functional interaction. As such, the KIR/HLA system is not 
amenable to GWAS. 
NK cell function has not been studied in depth in GBS, but there are several links making 
NK cells a potential key factor in GBS pathogenesis. It appears clear that within days after 
the triggering event the immune system becomes dysregulated, with this rapid response 
pointing to dysfunction of the innate immune system, as adaptive responses usually take 
longer to develop. Also, the fact that a range of triggering events can cause a relatively 
stereotyped illness points to involvement of the early immune response, which does not have 
the range of the adaptive immune response.  
We recruited subjects with a confirmed diagnosis of GBS based on Asbury criteria from 
the cohort described in more detail in Chapter 3. Recruitment was incomplete because of the 
retrospective nature of patient identification (patients moved, deceased, refused consent, etc.). 
The control subjects were recruited from staff from the Royal Brisbane and Women’s 
Hospital and UQCCR, students, partners of subjects with GBS and other healthy volunteers. 
We found that KIR receptor gene frequencies were not different between subjects with 
GB and healthy controls (HC). In contrast, HLA-C2 and HLA-B Bw4-T were more frequent 
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in GBS patients than HC. Also, the inhibitory KIR/HLA pairs of KIR-2DL2/HLA-C2 and 
KIR-3DL1/HLA-B Bw4-T were more common in GBS than healthy controls. 
These findings suggest a role for NK cells in the early pathogenesis of GBS. We 
hypothesize that decreased NK cell activity in the context of an infection could lead to 
dysregulation of the adaptive immune system with a subsequent immune attack on myelin. 
Supplementary data for this publication is included on pages 61-66. 
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Supplemental Table 1 – Genefrequency of HLA ligands in subjects with GBS and healthy controls by gender  
 Total  Male  Female 
HLA 
Gene 
GBS 
(n=195) 
N (%) 
Controls 
(n=225) 
N (%) 
P 
OR (95% 
CI) 
GBS 
(n=126) 
N (%) 
Controls 
(n=79) 
N(%) 
P 
OR (95% 
CI) 
GBS 
(n=69) 
N(%) 
Controls 
(n=146) 
N(%) 
P 
OR (95% 
CI) 
HLA-C1 156 (80) 201 (89.3) 0.008 
0.48 (0.36 
– 0.63) 
103 
(81.7) 
68 
(86.1) 
0.42 
0.72 (0.33 
– 1.58) 
53 
(76.8) 
133 
(91.1) 
0.01 
0.32 (0.14 
– 0.72) 
HLA-C2 
130 
(66.6) 
113 (50.2) <0.001 
1.98 (1.61 
– 2.43) 
86 
(68.3) 
41 
(51.9) 
0.02 
1.99 (1.11 
– 3.56) 
44 
(63.7) 
72 
(49.3) 
0.05 
1.80 (1.0 
– 3.26) 
HLA-B 
Bw4-T 
88 
(45.1) 
67 (29.8) 0.0011 
1.93 (1.58 
– 2.38) 
57 
(45.2) 
22 
(27.8) 
0.01 
2.14 
(1.17-
3.91) 
31 
(44.9) 
45 
(30.8) 
0.04 
1.83 (1.02 
– 3.3) 
HLA-B 
Bw4-I 
70 
(35.9) 
61 (27.1) 0.053 
1.50 (1.21 
– 1.86) 
44 
(34.9) 
21 
(26.6) 
0.21 
1.48 (0.8 – 
2.75) 
26 
(37.7) 
40 
(27.4) 
0.13 
1.60 (0.87 
– 2.94) 
HLA-A 
Bw4+ 
69 
(35.4) 
63 (28) 0.104 
1.41 (1.21 
– 1.86) 
44 
(34.9) 
26 
(32.9) 
0.77 
1.09 (0.6 – 
1.98) 
25 
(36.2) 
37 
(25.3) 
0.1 
1.67 (0.9 
– 3.1) 
    
C1/C1 
65 
(33.3) 
110 (48.9) 0.0013 
0.52 (0.42 
– 0.63) 
40 
(31.7) 
38(48.1) 0.03 
0.05 (0.28 
– 0.9) 
25 
(36.2) 
72 (50) 0.08 
0.58 (0.32 
– 1.05) 
C1/C2 
91 
(46.7) 
93 (41.3) 0.272 
1.24 (1.01 
– 1.51) 
63 (50) 
31 
(39.2) 
0.15 
1.55 (0.87 
– 2.74) 
28 
(40.6) 
61 
(42.4) 
0.88 
0.95 (0.53 
– 1.7) 
C2/C2 39 (20) 22 (9.8) 0.003 
2.31 (1.73 
– 3.07) 
23 
(18.3) 
10 
(12.7) 
0.69 
1.29 (0.58 
– 2.87) 
16 
(23.2) 
11 (7.6) 0.002 
3.7 (1.61 
– 8.5) 
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Supplemental Table 2 – Gene frequency of 14 KIR genes and KIR haplotypes of GBS patients and healthy controls by gender.
 Total  Male  Female 
KIR 
gene 
GBS (n 
= 195) 
Controls 
(n=225) 
P 
OR (95% 
CI) 
GBS (n 
= 126) 
Controls 
(n=79) 
P 
OR (95% 
CI) 
GBS (n 
= 69) 
Controls 
(n=146) 
P 
OR (95% 
CI) 
2DL1 182 (93.3) 214 (95.1) 0.43 
0.72 (0.31 – 
1.65) 
118 (93.6) 75 (94.9) 0.7 
0.78 (0.23 – 
2.7) 
64 (92.7) 139 (95.2) 0.46 
0.64 (0.19 – 
2.11) 
2DL2 114 (58.5) 110 (48.9%) 0.05 
1.47 (1.0 – 
2.17) 
79 (62.7) 42 (53.1) 0.17 
1.48 (0.83 – 
2.62) 
35 (50.7) 68 (46.6) 0.57 
1.18 (0.66 – 
2.1) 
2DL3 160 (82.1) 200 (88.9) 0.05 
0.57 (0.33 – 
0.99) 
105 (83.3) 69 (87.3) 0.44 
0.72 (0.32 – 
1.63) 
55 (79.7) 131 (89.7) 0.045 
0.45 (0.2 – 
0.99) 
2DL4 192 (98.5) 224 (99.6) ND  124 (98.4) 78 (98.7) ND  68 (98.6) 146 (100) ND  
2DL5A 67 (34.4) 84 (37.3) 0.52 
0.88 (0.59 – 
1.31) 
48 (38.1) 25 (31.6) 0.34 
1.30 (0.73 – 
2.4) 
19 (27.5) 59 (40.4) 0.07 
0.56 (0.3 – 
1.05) 
2DL5B 47 (24.1) 47 (20.9) 0.43 
1.2 (0.76 – 
1.9) 
33 (26.2) 16 (20.2) 0.33 
1.4 (0.71 – 
2.75) 
14 (20.3) 31 (21.2) 0.87 
0.94 (0.47 – 
1.91) 
2DS1 83 (42.6) 92 (40.9) 0.72 
1.07 (0.72 – 
1.58) 
54 (42.8) 27 (34.2) 0.22 
1.44 (0.8 – 
2.59) 
29 (42.0) 65 (44.5) 0.73 
0.9 (0.5 – 
1.61) 
2DS2 106 (54.4) 111 (49.3) 0.30 
1.22 (0.83 – 
1.8) 
73 (57.9) 44 (55.7) 0.75 
1.1 (0.62 – 
1.93) 
33 (47.8) 67 (45.9) 0.79 
1.08 (0.61 – 
1.91) 
2DS3 59 (30.3) 56 (24.9) 0.22 
1.31 (0.85 – 
2.01) 
42 (33.3) 19 (24.0) 0.15 
1.58 (0.84 – 
2.98) 
17 (24.6) 37 (25.3) 0.91 
0.96 (0.46 – 
1.87) 
2DS4 74 (37.9) 95 (42.2) 0.37 
0.84  (0.57 – 
1.24) 
46 (36.5) 36 (45.5) 0.2 
0.68 (0.39 – 
1.22) 
28 (40.6) 59 (40.4) 0.98 
1.0 (0.56 – 
1.8) 
3DL1 174 (89.2) 212 (94.2) 
0.06
1 
0.51 (0.25 – 
1.04) 
111 (88.1) 76 (96.2) 0.05 
0.29 (0.08 – 
1.04) 
63 (91.3) 136 (93.1) 0.63 
0.77 (0.27 – 
2.21) 
3DL2 195 (100) 223 (99.1) ND  126 (100) 78 (98.7) ND  69 (100) 145 (99.3) ND  
3DL3 194 (99.5) 224 (99.5) ND  125 (99.2) 78 (98.7) ND  69 (100) 146 (100) ND  
3DS1 75 (38.5) 88 (39.1) 0.89 
0.97 (0.66 – 
1.44) 
57 (45.2) 27 (34.2) 0.11 
1.59 (0.89 – 
2.85) 
23 (33.3) 61 (38.4) 0.23 
0.69 (0.38 – 
1.27) 
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Supplemental Table 3 – Genefrequency of KIRs and their specific HLA-Ligands, analysed by gender. Chi-Square test with Bonferonni 
correction for multiple tests; p<0.005 was regarded as significant.  
 Total 
 
Male 
 
Female 
KIR gene / HLA 
ligand gene 
GBS 
n (%) 
HC 
n (%) 
P 
OR (95% 
CI) 
GBS 
n (%) 
HC 
n (%) 
P 
OR (95% 
CI) 
GBS 
n (%) 
HC 
n (%) 
P 
OR (95% 
CI) 
2DL1 + / HLA-C2 + 121 (62.1) 107 (47.6) 
<0.001 
1.98 (1.32 – 
2.93) 
81 (64.3) 40 (50.6) 
0.01 
2.07 (1.13 – 
3.79) 
40 (58.0) 67 (45.9) 
0.06 
1.8 (0.98 – 
2.29) 2DL1 + / HLA-C2 - 61 (31.3) 107 (47.6) 37 (29.3) 35 (44.3) 24 (34.8) 72 (49.3) 
2DS1 + / HLA-C2 + 57 (29.3) 50 (22.2) 
0.052 
1.84 (0.99 – 
3.42) 
37 (29.3) 17 (13.5) 
0.25 
1.74 (0.67 – 
4.51) 
20 (29.0) 35 (24.0) 
0.17 
1.91 (0.75 – 
4.80) 2DS1 + / HLA-C2 - 26 (13.3) 42 (18.7) 15 (18.9) 12 (15.2) 9 (13.0) 30 (20.5) 
2DL2 + / HLA-C1 + 87 (44.6) 101 (44.9) 
0.0016 
0.29 (0.13 – 
0.64) 
62 (49.2) 17 (13.5) 
0.52 
0.64 (0.16 – 
2.46) 
25 (36.2) 62 (42.5) 
<0.001 
0.08 (0.01 – 
0.39) 2DL2 + / HLA-C1 - 27 (13.9) 9 (4) 39 (49.3) 3 (3.8) 10 (14.5) 6 (4) 
2DS2 + / HLA-C1 + 80 (41.0) 102 (45.3) 
0.001 
0.27 (0.12 – 
0.61) 
56 (44.4) 41 (51.9) 
0.02 
0.24 (0.06 – 
0.87) 
24 (34.8) 61 (41.8) 
0.02 
0.26 (0.08 – 
0.8) 2DS2 + / HLA-C1 - 26 (13.3) 9 (4) 17 (13.5) 3 (3.8) 9 (13.0) 6 (4.1) 
2DL3 + / HLA-C1 + 130 (66.7) 179 (79.5) 
0.025 
0.51 (0.28 – 
0.93) 
85 (67.4) 59 (74.7) 
0.44 
0.72 (0.31 – 
1.65) 
45 (65.2) 120 (82.2) 
0.05 
0.41 (0.16 – 
1.04) 2DL3 + / HLA-C1 - 30 (15.4) 21 (9.3) 20 (15.9) 10 (12.7) 10 (14.5) 11 (7.5) 
2DS3 + / HLA-C1 + 49 (25.1) 51 (22.6) 
0.20 
0.48 (0.15 – 
1.51) 
36 (28.5) 17 (21.5) 
0.26 
0.44 (0.1 – 
1.88) 
13 (18.8) 34 (23.3) 
0.11 
0.29 (0.05 – 
1.46) 2DS3 + / HLA-C1 - 10 (5.1) 5 (2.2) 6 (4.7) 2 (2.5) 4 (5.8) 3(2.1) 
3DL1 + / HLA-B Bw4-T + 79 (40.5) 63 (28.0) 
0.0015 
1.97 (1.29 – 
2.99) 
50 (39.6) 21 (26.6) 
0.01 
2.15 (1.15 – 
4.0) 
29 (42.0) 42 (28.7) 
0.04 
1.91 (1.03 – 
3.53) 3DL1 + / HLA-B Bw4-T - 95 (48.7) 149 (66.2) 61 (48.4) 55 (69.6) 34 (49.2) 94 (64.4) 
3DS1 + / HLA-B Bw4-T + 33 (16.9) 28 (12.4) 
0.1 
1.68 (0.89 – 
3.19) 
20 (15.9) 9 (11.4) 
0.87 
1.08 (0.41 – 
2.85) 
13 (18.8) 19 (13.0) 
0.001 
5.75 (1.79 – 
18.4) 3DS1 + / HLA-B Bw4-T - 42 (21.5) 60 (26.7) 37 (29.4) 18 (22.8) 5 (7.24) 42 (28.7) 
3DL1 + / HLA-B Bw4-I + 65 (33.3) 56 (24.9) 
0.021 
1.66 (1.08 – 
2.56) 
40 (31.7) 20 (25.3) 
0.16 
1.57 (0.83 – 
2.99) 
25 (36.2) 36 (24.6) 
0.06 
1.82 (0.97 – 
3.44) 3DL1 + / HLA-B Bw4-I - 109 (55.9) 156 (69.3) 71 (56.3) 56 (70.9) 38 (55.0) 100 (68.5) 
3DS1 + / HLA-B Bw4-I + 33 (16.9) 28 (12.4) 
0.10 
1.68 (0.89 – 
3.19) 
23 (18.3) 8 (9.1) 
0.17 
1.95 (0.74 – 
5.01) 
10 (13.3) 20 (13.7) 
0.12 
2.31 (0.78 – 
6.79) 3DS1 + / HLA-B Bw4-I - 42 (21.5) 60 (26.7) 34 (27.0) 23 (29.1) 8 (10.6) 37 (49.3) 
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 Supplemental Table 4 – Differences in genefrequency of HLA ligands between gender for both GBS subjects and controls  
  GBS  Controls 
HLA 
Gene 
Males 
(n=126) 
Females 
(n=69) 
P Males 
(n=79) 
Females 
(n=146) 
P 
HLA-C1 103 53 0.41 68 133 0.24 
HLA-C2 86 44 0.53 41 72 0.71 
HLA-B 
Bw4-T 
57 31 1 22 45 0.76 
HLA-B 
Bw4-I 
44 26 0.76 21 40 0.89 
HLA-A 
Bw4+ 
44 25 0.88 26 37 0.23 
 
C1/C1 
 
40 25 0.53 
 
38 72 0.89 
C1/C2 63 28 0.23 31 61 0.78 
C2/C2 23 16 0.46 10 11 0.23 
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Supplemental Table 5 – Differences in genefrequency of KIR between gender for both GBS subjects and controls  
  GBS  Controls 
KIR gene Males 
(n = 126) 
Females 
(n=69) 
P  Males  
(n = 79) 
Females  
(n=146) 
P  
2DL1 118 64 0.81 75 139 0.93 
2DL2 79 35 0.1 42 68 0.35 
2DL3 105 55 0.53 69 131 0.59 
2DL4 124 68 ND 78 146 ND 
2DL5A 48 19 0.14 25 59 0.2 
2DL5B 33 14 0.36 16 31 0.86 
2DS1 54 29 0.91 27 65 0.13 
2DS2 73 33 0.18 44 67 0.16 
2DS3 42 17 0.21 19 37 0.83 
2DS4 46 28 0.57 36 59 0.46 
3DL1 111 63 0.49 76 136 0.35 
3DL2 126 69 ND 78 145 ND 
3DL3 125 69 ND 78 146 ND 
3DS1 57 23 0.11 27 61 0.26 
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Supplemental Table 6 – Differences in 
genefrequency of KIRs and their specific HLA-
Ligands between gender. 
 
 
GBS 
 
Controls 
KIR gene / HLA ligand gene Males Females P Males Females P 
2DL1 + / HLA-C2 + 81 40 
0.4 
40 67 
0.47 
2DL1 + / HLA-C2 - 37 24 35 72 
2DS1 + / HLA-C2 + 37 20 
0.84 
17 35 
0.67 
2DS1 + / HLA-C2 - 15 9 12 30 
2DL2 + / HLA-C1 + 62 25 
0.29 
17 25 
0.25 
2DL2 + / HLA-C1 - 39 10 3 10 
2DS2 + / HLA-C1 + 56 24 
0.66 
41 61 
0.69 
2DS2 + / HLA-C1 - 17 9 3 6 
2DL3 + / HLA-C1 + 85 45 
0.89 
59 120 
0.18 
2DL3 + / HLA-C1 - 20 10 10 11 
2DS3 + / HLA-C1 + 36 13 
0.39 
17 34 
0.76 
2DS3 + / HLA-C1 - 6 4 2 3 
3DL1 + / HLA-B Bw4-T + 50 29 
0.9 
21 42 
0.62 
3DL1 + / HLA-B Bw4-T - 61 34 55 94 
3DS1 + / HLA-B Bw4-T + 20 13 
0.57 
9 19 
0.84 
3DS1 + / HLA-B Bw4-T - 37 5 18 42 
3DL1 + / HLA-B Bw4-I + 40 25 
0.63 
20 36 
0.98 
3DL1 + / HLA-B Bw4-I - 71 38 56 100 
3DS1 + / HLA-B Bw4-I + 23 10 
0.26 
8 20 
0.37 
3DS1 + / HLA-B Bw4-I - 34 8 23 37 
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Chapter 5 KIR and their HLA ligands in patients with 
chronic inflammatory demyelinating 
polyradiculoneuropathy 
To compare our findings of KIR and the HLA ligands in GBS with other inflammatory 
neuropathies, we proceeded to investigate the same genetic markers in chronic inflammatory 
demyelinating polyradiculoneuropathy. 
5.1.  Chronic inflammatory demyelinating 
polyradiculoneuropathy  
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired 
disorder of peripheral nerves and nerve roots leading to progressive or relapsing weakness 
and sensory loss over years. While patients with typical signs and symptoms have been 
reported for more than 75 years, the concept of CIDP as a separate entity was introduced in 
1975 (Dyck, Lais et al. 1975). The autoimmune nature of CIDP was previously suggested by 
the response of patients with certain types of neuropathies to treatment with glucocorticoids 
(DeVivo and Engel 1970). Since then multiple therapies, including plasma exchange, 
intravenous immunoglobulins and a range of immunosuppressive drugs have been 
successfully used in CIDP (Koller, Schroeter et al. 2005).  
Whether CIDP is a single disease or a syndrome is still controversial. Many other 
neuropathies have chronicity, demyelination, inflammation on nerve biopsy or other evidence 
of immune mediation in common with CIDP. These include multifocal motor neuropathy 
(MMN), Lewis-Sumner syndrome, anti-MAG neuropathy and POEMS (polyneuropathy, 
organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome. Moreover, a 
range of systemic disorders can be associated with an inflammatory demyelinating 
neuropathy, including Hepatitis B and C, HIV, lymphoma, diabetes mellitus and renal disease 
(Csurhes, Sullivan et al. 2005, Dalakas 2011). However, CIDP can also be triggered by 
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infection. Concurrent central nervous system and peripheral nervous system demyelination is 
sometimes found, meeting diagnostic criteria of both CIDP and MS, and in such cases there 
could be an immune attack on antigens that are common to the peripheral and central nervous 
systems (Sharma, Saadia et al. 2008). Onset of disease is either subacute or chronic, with the 
nadir of disease being reached after 8 weeks, differentiating it from AIDP. The course of 
CIDP is either progressive or relapsing-remitting.  
5.1.1. Diagnostic criteria and electrophysiology 
Numerous diagnostic criteria have been proposed for CIDP since its first description in 
1975 (Van den Bergh and Pieret 2004, Koller, Schroeter et al. 2005, Koski, Baumgarten et al. 
2009, Rajabally, Nicolas et al. 2009). These criteria differ in a number of aspects, but usually 
rely heavily on electrophysiological studies.  
For the purposes of this study, the electrodiagnostic criteria proposed by the American 
Academy of Neurology were used (see Table 5.1). 
5.1.2. Pathology 
Characteristically, segmental demyelination and remyelination with onion bulb formation 
as well as lymphocytic and macrophage infiltration are found (Bouchard, Lacroix et al. 
1999). Nerve enlargements are thought to be due to oedema, onion bulb formation and the 
deposition of acid mucopolysaccharides.  
CD3+ T cells can primarily be localized to perivascular infiltrates in the epineurium and 
perineurium, whereas CD68+ immunoreactive macrophages are localized within the 
endoneurium (Sharma, Saadia et al. 2008). Increased numbers of IFN-γ and IL-5 secreting  
cells in the peripheral blood of patients with CIDP were found in one study (Csurhes, 
Sullivan et al. 2005). Also, increased T cell mediated response against PMP-2251-64 was found 
(Csurhes, Sullivan et al. 2005). Circulating CD4+CD25+ regulatory T cells showed both 
decreased numbers and suppressive function in CIDP (Chi, Wang et al. 2008). Often axonal 
degeneration is superimposed on this demyelinating process, especially with advancing 
disease. Demyelination occurs by active unravelling and degrading of myelin (Prineas 1971).  
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Moreover, antibodies against P0 and P2 were detected in patients with CIDP (Yan, 
Archelos et al. 2001, Inglis, Csurhes et al. 2007). Deposition of immunoglobulin IgM and 
complement or its membrane attack complex on the myelin surface has also been reported, 
At least three of the following four to be fulfilled: 
1. Significant reduction in motor nerve conduction velocity in two or more motor 
nerves: 
a. ,80% of LLN if CMAP >80% of LLN 
b. ,70% of LLN if CMAP <80% of LLN 
 
2. Partial conduction block or abnormal temporal dispersion in one or more motor 
nerves: either peroneal nerve between ankle and below fibular head, median nerve 
between wrist and elbow, or ulnar nerve between wrist and below elbow. 
 
Criteria suggestive of partial conduction block:  
>15% change in duration between proximal and distal sites and >20% drop in 
negative peak (–p) area or peak-to-peak (pp) amplitude between proximal and distal 
sites. 
 
Criteria for abnormal temporal dispersion and possible conduction block:  
>15% change in duration between proximal and distal sites and .20% drop in –p 
area or p-p amplitude between proximal and distal sites 
 
3. Significant prolongation of distal motor latency in two or more motor nerves: 
a. .125% of ULN if CMAP >80% of LLN 
b. .150% of ULN if CMAP <80% of LLN  
 
4. Significant prolongation or absence of F-waves in two or more motor nerves: 
a. .120% of ULN if CMAP >80% of LLN 
b. .150% of ULN if CMAP <80% of LLN 
Table 5.1 - Electrodiagnostic criteria for CIDP as proposed by the American Academy of 
Neurology (1991) 
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arguing for both antibody-mediated and cell-based attack on peripheral nerve (Ben-Smith, 
Gaston et al. 1996, Sanvito, Makowska et al. 2009).  
Studies of NK cells in CIDP are limited in number. Decreased numbers of circulating NK 
were detected in one study (Sanvito, Makowska et al. 2009). 
5.1.3. Immunogenetics 
There are few recent studies of immunogenetics in CIDP. Most previous studies were 
performed at a time when the heterogeneity of CIDP was not fully appreciated and it is 
possible that subjects with other inflammatory demyelinating neuropathies, such as the 
neuropathy associated with anti-MAG antibodies or multifocal motor neuropathy, were 
included. The study of CIDP within families is impacted by the similarities between CIDP 
and inherited neuropathies like Charcot-Marie Tooth disease (CMT). Interestingly, there are a 
number of reports of genetically proven CMT1A with inflammatory changes of nerve biopsy, 
responsive to treatment with corticosteroids (Dyck, Swanson et al. 1982, Vital, Vital et al. 
2003, Ginsberg, Malik et al. 2004). 
Weak HLA associations with HLA-8, CW7, and DR3 were detected in several small 
early studies, but could not be confirmed in others (Adams, Festenstein et al. 1979, Feeney, 
Pollard et al. 1990, van, Schreuder et al. 1991, McCombe, Csurhes et al. 2006). The 
frequency of the M3 allele of α1 anti-trypsin  was found to be increased from 11.5% in 
controls to 29% in CIDP patients (McCombe, Clark et al. 1985).  
Differential gene expression in sural biopsies and skin biopsies in patients with CIDP 
compared with healthy controls showed genes predominantly involved in immunity and 
signal transduction (Renaud, Hays et al. 2005). Consistent with the pathological features, 
these include macrophage genes (Macrophage scavenger receptor 1, Allograft Inflammatory 
factor) and T cell genes (T cell receptor beta locus, class II HLA). Also, Stearoyl CoA 
desaturase, the rate limiting enzyme in the biosynthesis of monounsaturated fatty acid 
(including oleic acid, a major fatty acid in PNS myelin) was upregulated.  
Upregulation of genes involved in inflammatory processes were also detected in skin 
biopsies of patients with CIDP (Lee and Shin). Again, these genes were associated with 
macrophage activation and differentiation. Upregulation of these genes in skin biopsies were 
thought to be indicative of a systemic heightened immune state or an inflammatory reaction 
to myelinated fibres in the skin. 
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Also, genetic differences were found in the V24JQ invariant TCR chain in NKT cells 
originating from peripheral blood and sural nerve biopsies; NKT cells have important roles in 
IL-4 production and regulation of the immune response to a Th2 profile (Illes, Kondo et al. 
2000, Hughes, Allen et al. 2006) and in the response to lipid antigens (Bondarenko, Catapano 
et al. 2013).  
5.1.4.   Comparison of CIDP and GBS 
CIDP shares a number of clinical, pathological and electrophysiological features with 
GBS, whilst differing in others (summarized in Table 5.2). Common features include male 
predominance, and the relatively symmetrical, predominantly motor neuropathy, with 
frequent involvement of other nerve fibres (sensory, autonomic) (McCombe, Pollard et al. 
1987, Hughes, Allen et al. 2006, Dionne, Nicolle et al. 2010). CSF protein is increased in 
both conditions, indicating breakdown of the blood-nerve barrier at a root level with 
subsequent leakage of albumin into the CSF (Kanda 2013). There is a response to immune 
therapy in both illnesses, with a generally favourable prognosis (Kuwabara, Misawa et al. 
2006) 
CIDP differs from GBS in a range of aspects, including length of disease and treatment 
options (see Table 5.2).  By definition, CIDP is a chronic illness with a time-course of more 
than 2 months, in contrast to GBS where the nadir of illness is reached within 4 weeks of 
symptom onset (McCombe, Pollard et al. 1987, Dionne, Nicolle et al. 2010).  Treatment for 
GBS relies on IVIg and plasma exchange combined with supportive care (Hughes, Swan et 
al. 2007). These agents have also been proven effective for CIDP (Hahn, Bolton et al. 1996, 
Mehndiratta and Hughes 2012, Nobile-Orazio, Cocito et al. 2012) . Chronic steroid therapy, 
which is detrimental in GBS, has been shown to be beneficial in CIDP (Dyck, O'Brien et al. 
1982, Nobile-Orazio, Cocito et al. 2012). In CIDP, this is frequently combined with steroid 
sparing agents like azathioprine or methotrexate, but evidence for this is less clear, with only 
case series being available (Dyck, O'Brien et al. 1985, Gladstone, Prestrud et al. 2005).  
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Table 5.2 - Comparison of clinical and paraclinical features of CIDP and GBS 
 GBS CIDP 
Time course  Less than 4 weeks to nadir, followed by 
recover 
More than 8 weeks to nadir, 
relapsing or progressive course 
Gender Male predominant Male predominant (Hughes, Allen et 
al. 2006) 
Clinical picture Symmetric sensory-motor peripheral 
neuropathy 
Bulbar involvement in more than 30% 
(our data)(Dionne, Nicolle et al. 2010) 
Bulbar dysfunction in 6 to 15 % 
(McCombe, Pollard et al. 1987, 
Dionne, Nicolle et al. 2010) 
CSF High protein, normal to mildly elevated 
cell count 
High protein, normal cell count 
Electrophysiology Axonal or demyelinating, often patchy 
polyradiculoneuropathy, sural nerve 
sparing 
Demyelinating, symmetrical 
polyradiculoneuropathy  
Treatment IVIg, Plasma exchange, supportive Steroids, IVIg, Plasma exchange 
immunosuppressive therapy 
 
Confusingly, GBS can have a relapsing course, which can be very difficult to distinguish 
from CIDP (Kuitwaard, van Koningsveld et al. 2009, Olivier, Laribi et al. 2010). Also, during 
the acute episode of GBS, treatment related fluctuations can occasionally be observed (Ruts, 
van Koningsveld et al. 2005, Ruts, Drenthen et al. 2010). Electrophysiological and clinical 
criteria have been proposed to distinguish the two entities (Dionne, Nicolle et al. 2010, Ruts, 
Drenthen et al. 2010) Finally, CIDP can sometimes present with an acute onset, resembling 
GBS with partial recovery; only subsequent fluctuations or deterioration makes a diagnosis of 
CIDP possible.  This form has been called acute onset CIDP (A-CIDP) (Ruts, van 
Koningsveld et al. 2005). 
5.1.5. Natural killer cells in CIDP 
Natural killer cells (NK cells) are lymphocytes that share common progenitor cells with T 
lymphocytes. NK cells  are crucial components of the early innate immune response, due to 
their ability to produce cytokines and chemokines and lyse target cells (Middleton and 
Gonzelez 2010). They also have important roles in the regulation of the subsequent immune 
response against the pathogen.  
In CIDP, NK cells have been found in decreased numbers in blood of patients compared 
with controls (Sanvito, Makowska et al. 2009). Also, IVIg infusions have been found to lead 
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to a substantial decline in the number of peripheral NK cells and a suppression of NK-cell-
mediated cytotoxicity (Bohn, Nederby et al. 2011). In nerve biopsies of patients with CIDP, 
NK cells play a less dominant role, with the histological picture being predominated by T 
lymphocytes and macrophages (Dalakas 2011). 
5.1.6. Aim 
We investigated the possible role of NK cells in the pathogenesis of CIDP using a gene 
based approach. We investigated gene frequencies of KIR and their HLA ligands. We 
compared KIR and HLA ligands to HC and patients with GBS. 
5.2. Methods 
A cohort of patients (n = 78) with a confirmed diagnosis of CIDP was recruited from 
several hospitals in Queensland and from private neurologists. All patients fulfilled standard 
diagnostic criteria for CIDP (Koski, Baumgarten et al. 2009).   
This was compared with a cohort of patients (n = 195) with a confirmed diagnosis of 
GBS from several hospitals on the East Coast of Australia. All subjects fulfilled standard 
diagnostic criteria for GBS (Asbury and Cornblath 1990). As a control group healthy 
volunteers were recruited (n = 225), and matched for ethnicity. 
Ethical approval was obtained; all subjects gave informed consent.  
5.2.1. Laboratory methods 
Highly pure genomic DNA was extracted either from peripheral blood (Nucleospin, 
Machery Nagel, Dueren, Germany) or saliva (Oragene, DNAGenothek, Kanata, Canada).  
For KIR, typing the KIR Genotyping SSP Kit (Invitrogen, Carlsbad, USA) was used. For 
typing specific KIR associated HLA ligands the KIR-HLA Ligand kit (Olerup, Vienna, 
Austria) was used. This kit distinguishes HLA-CwAsparagine80 (HLA-C1) from HLA-
CwLysine80 (HLA-C2) and HLA-BBw4-Threonine80 (HLA-BBw4-T) from HLA-BBw4+ 
Isoleucine80 (HLA-BBw4-I), and tests for presence of HLA-ABw4. These kits do not 
provide complete HLA typing. The kits were used according to the manufacturers’ 
instructions. 
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PCR was performed followed by analysis with gel electrophoresis using a 2% agarose gel 
at 100 volts and photographed using an ultraviolet analyzing system (Biorad). 
5.2.2. Haplotypes and ligands 
HLA-C ligands for KIRs are classified as C1 or C2 KIR ligand groups, based on the 
amino acid at position 80 (Aspargine as C1; Lysine as C2). KIRs interact with specific MHC 
class 1 ligands on the target cell: KIR 2DL1 and KIR 2DS1 interact with HLA-C2, KIR 
2DL2, KIR 2DL3 and KIR 2DS2 have as their ligand the C1 epitope; KIR 3DL1 and KIR 
3DS1 recognize the HLA-Bw4 motif (Jamil and Khakoo). 
Genotypes can be resolved into two broad haplotypes termed A and B based on KIR gene 
content (Middleton and Gonzelez 2010). Group B KIR haplotypes are characterized by 
presence of one or more of the following genes: KIR 2DL2, KIR 2DL5, KIR 2DS1, KIR 
2DS2, KIR 2DS3, KIR 2DS5 and KIR 3DS1. Conversely, group A haplotypes are 
characterized by the absence of all these genes. It is difficult to determine with the methods 
used whether, in the presence of a B haplotype, the other allele is A or B. Therefore, for KIR 
haplotype analysis AA and BX were used, where X can stand for either an A or B haplotype. 
5.2.3. Statistical analysis 
Data analysis was performed using Excel (Microsoft) and GraphPad Prism. Chi Square 
test was used, with p<0.05 regarded as statistically significant. Bonferroni correction was 
used for multiple tests, with adjustment of p divided by the number of tests regarded as 
significant (For KIR genes p<0.003; For HLA ligands p<0.01; for KIR / HLA-ligand 
interactions p<0.005). The association of each polymorphism with the disease was measured 
by Odds Ratio (OR) and its 95% confidence interval (95%CI).  
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5.3. Results 
5.3.1. Frequency of KIR genes 
The frequency of the KIR genes is shown in Table 5.3. For the KIR genes studied no 
statistically significant differences were found both compared with HC and GBS. Also, the 
haplotypes AA and Bx were evenly distributed.  
Table 5.3 - KIR genes in subjects with CIDP, compared with GBS subjects and healthy 
controls. Chi-Square test; Bonferonni correction for multiple tests (ND = not done) 
KIR gene CIDP (n = 78) 
N (%) 
Controls (n = 225) 
N (%) 
P value 
(Fisher) 
GBS (n=195) 
N (%) 
P value 
(Fisher) 
2DL1 74 (94.8) 214 (95.1) 0.95 182 (93.3) 0.78 
2DL2 48 (61.5) 110 (48.9) 0.06 114 (58.5) 0.68 
2DL3 70 (89.7) 200 (88.9) 1 160 (82.1) 0.14 
2DL4 78 (100) 224 (99.6) ND 192 (98.5) ND 
2DL5A 30 (38.5) 84 (37.3) 0.89 67 (34.4) 0.57 
2DL5B 20 (25.6) 47 (20.9) 0.43 47 (24.1) 0.88 
2DS1 35 (44.8) 92 (40.9) 0.59 83 (42.6) 0.78 
2DS2 45 (57.7) 111 (49.3) 0.24 106 (54.4) 0.69 
2DS3 23 (29.4) 56 (24.9) 0.45 59 (30.3) 1 
2DS4 33 (42.3) 95 (42.2) 1 74 (37.9) 0.58 
2DS5 26 (33.3) 80 (34.7) 0.78 63 (32.0) 0.49 
3DL1 74 (94.8) 212 (94.2) 1 174 (89.2) 0.17 
3DL2 78 (100) 223 (99.1) ND 195 (100) ND 
3DL3 78 (100) 224 (99.5) ND 194 (99.5) ND 
3DS1 31 (39.7) 88 (39.1) 1 75 (38.5) 0.89 
 
Haplotype      
AA 20 (25.6) 73 (32.4) 0.31 53 (27.1) 0.88 
BX 58 (74.4) 152 (67.6)  142 (72.9)  
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5.3.2. HLA frequencies in CIDP 
The HLA frequencies are shown in Table 5.4. For the HLA types HLA-B Bw4T and 
Bw4I significant differences were found between CIDP and HC, but not between CIDP and 
GBS. Whilst the frequency of C1 and C2 was similar in all 3 groups, the heterozygous 
situation of C1/C2 was significantly more frequently found in CIDP than HC; no differences 
in the frequency of C1/C2 were detected between CIDP and GBS. 
Table 5.4 - HLA genes in subjects with CIDP, compared with GBS subjects and healthy 
controls Chi-Square test; Bonferonni correction for multiple tests with p<0.01 regarded as 
significant. * p<0.01 
HLA 
Gene 
CIDP 
(n=78) 
N (%) 
Controls 
(n=225) 
N (%) 
P value 
(Fisher) 
OR  
(95% CI) 
GBS 
(n=195) 
N (%) 
P value 
(Fisher) 
OR  
(95% CI) 
HLA-
C1 
67 
(85.9) 
201 (89.3) 0.41 0.72 (0.33 
– 1.56) 
156 (80) 0.30 1.52 (0.73 
- 3.15) 
HLA-
C2 
50 
(64.1) 
113 (50.2) 0.03 1.77 (1.04 
– 3.01) 
130 
(66.6) 
0.78 0.89 (0.52 
– 1.55) 
HLA-B 
Bw4-T 
36 
(46.1) 
67 (29.8) 0.01* 2.02 (1.19 
– 3.43) 
88 (45.1) 0.89 1.04 (0.61 
– 1.766) 
HLA-B 
Bw4-I 
35 
(44.8) 
61 (27.1) 0.0047* 2.18 (1.28 
– 3.74) 
70 (35.9) 0.17 1.45 (0.85 
– 2.48) 
HLA-A 
Bw4+ 
30 
(38.4) 
63 (28) 0.09 1.61 (0.93 
– 2.76) 
69 (35.4) 0.67 1.14 (0.66 
– 1.96) 
 
C1/C1 27 
(34.6) 
110 (48.9) 0.03 0.55 (0.32 
– 0.94) 
65 (33.3) 0.88 1.06 (0.61 
– 1.84) 
C1/C2 42 
(53.8) 
93 (41.3) 0.01* 1.99 (1.16 
– 3.41) 
91 (46.7) 0.1 1.6 (0.93 
– 2.76) 
C2/C2 9 (12.5) 22 (9.8) 0.67 1.2 (0.53 
– 2.74) 
39 (20) 0.11 0.52 (0.24 
– 1.12) 
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5.3.3. Frequency of KIR/ligand carriage  
The comparison of the CIDP and HC subjects carrying different KIR/HLA ligands is 
shown in Table 5.5. The KIR/HLA combinations 3DL1/Bw4T and 3DL1/Bw4I were more 
frequent in CIDP than HC, this was statistically significant for 3DL1/Bw4I even after 
Bonferroni correction.  
No significant differences in KIR/HLA combinations were found between CIDP and 
GBS (see Table 5.6). 
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Table 5.5 – Genefrequency of KIRs and their specific HLA-Ligands CIDP vs. HC. 
Percentages given are for subjects with subjects (n=195) / Controls (n=225). Chi-Square 
test; Bonferonni correction for multiple tests with p<0.005(*) regarded as significant.  
KIR gene / HLA 
ligand gene 
CIDP n (% 
of group) 
HC n (% of 
group) 
P OR (95% 
CI) 
Effect on 
NK cells  
2DL1 + / HLA-C2 + 47 (60.3) 107 (47.6) 
0.06 
1.74  
(1.01 – 3) 
Inhibition 
2DL1 + / HLA-C2 - 27 (34.6) 107 (47.6) 
2DS1 + / HLA-C2 + 23 (29.4) 50 (22.2) 
0.31 
1.61 (0.71 
– 3.62) 
Activation 
2DS1 + / HLA-C2 - 12 (15.4) 42 (18.6) 
  
2DL2 + / HLA-C1 + 43 (55.1) 101 (44.9) 
0.76 
0.77 (0.24 
– 2.42) 
Inhibition 
2DL2 + / HLA-C1 - 5 (6.4) 9 (4) 
2DS2 + / HLA-C1 + 41 (52.6) 102 (45.3) 
1 
0.9 (0.26 – 
3.1) 
Activation 
2DS2 + / HLA-C1 - 4 (5.1) 9 (4) 
  
2DL3 + / HLA-C1 + 60 (76.9) 179 (79.6) 
0.39 
0.7 (0.3 – 
1.58) 
Inhibition 
2DL3 + / HLA-C1 - 10 (12.8) 21 (9.3) 
2DS3 + / HLA-C1 + 20 (25.6) 51 (22.7) 
0.69 
0.65  
(0.14 – 3) 
Activation 
2DS3 + / HLA-C1 - 3 (3.8) 5 (2.2) 
  
3DL1 + / HLA-B 
Bw4-T + 
34 (43.6) 63 (28) 
0.015 
2.01 (1.16 
– 3.46) 
Inhibition 
3DL1 + / HLA-B 
Bw4-T - 
40 (51.3) 149 (66.2) 
3DS1 + / HLA-B 
Bw4-T + 
15 (19.2) 28 (12.4) 
0.12 
2 (0.87 – 
4.63) 
Activation 
3DS1 + / HLA-B 
Bw4-T - 
16 (20.5) 60(26.6) 
  
3DL1 + / HLA-B 
Bw4-I + 
33 (42.3) 56 (24.9) 
0.005* 
2.24 (1.29 
– 3.89) 
Inhibition 
3DL1 + / HLA-B 
Bw4-I - 
41 (52.6) 156 (69.3) 
3DS1 + / HLA-B 
Bw4-I + 
13 (16.7) 24 (10.6) 
0.17 
1.93 (0.82 
– 4.52) 
Activation 
3DS1 + / HLA-B 
Bw4-I - 
18 (23.1) 64 (28.4) 
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Table 5.6  – Genefrequency of KIRs and their specific HLA-Ligands CIDP vs. GBS subjects. 
Percentages given are for subjects with subjects (n=195) / Controls (n=225). Chi-Square 
test; Bonferonni correction for multiple tests with p<0.005 regarded as significant 
KIR gene / HLA ligand 
gene 
CIDP 
N (% of 
group) 
GBS  
N (% of 
group) 
P OR (95% 
CI) 
Effect on 
NK cell 
function 
2DL1 + / HLA-C2 + 47 (60.3) 121 (62.1) 
0.66 
0.88 (0.5 – 
1.54) 
Inhibition 
2DL1 + / HLA-C2 - 27 (34.6) 61 (31.3) 
2DS1 + / HLA-C2 + 23 (29.4) 57 (29.2) 
0.83 
0.87 (0.37 – 
2.02) 
Activation 
2DS1 + / HLA-C2 - 12 (15.4) 26 (13.3) 
  
2DL2 + / HLA-C1 + 43 (55.1) 87 (44.6) 
0.06 
2.67 (0.96 – 
7.4) 
Inhibition 
2DL2 + / HLA-C1 - 5 (6.4) 27 (13.8) 
2DS2 + / HLA-C1 + 41 (52.6) 80 (41.0) 
0.027 
3.33 (1.09 – 
10.2) 
Activation 
2DS2 + / HLA-C1 - 4 (5.1) 26 (13.3) 
  
2DL3 + / HLA-C1 + 60 (76.9) 130 (66.7) 
0.46 
1.39 (0.64 – 
3) 
Inhibition 
2DL3 + / HLA-C1 - 10 (12.8) 30 (15.4) 
2DS3 + / HLA-C1 + 20 (25.6) 49 (25.1) 
1 
1.36 (0.34 – 
5.47) 
Activation 
2DS3 + / HLA-C1 - 3 (3.8) 10 (5.1) 
  
3DL1 + / HLA-B Bw4-T + 34 (43.6) 79 (40.5) 
1 
1.02 (0.59 – 
1.76) 
Inhibition 
3DL1 + / HLA-B Bw4-T - 40 (51.3) 95 (48.7) 
3DS1 + / HLA-B Bw4-T + 15 (19.2) 33 (16.9) 
0.83 
1.19 (0.51 – 
2.76) 
Activation 
3DS1 + / HLA-B Bw4-T - 16 (20.5) 42 (21.5) 
  
3DL1 + / HLA-B Bw4-I + 33 (42.3) 65 (33.3) 
0.32 
1.35 (0.77 – 
2.34) 
Inhibition 
3DL1 + / HLA-B Bw4-I - 41 (52.6) 109 (55.9) 
3DS1 + / HLA-B Bw4-I + 13 (16.7) 31 (15.9) 
1 
1.03 (0.44 – 
2.37) 
Activation 
3DS1 + / HLA-B Bw4-I - 18 (23.1) 44 (22.6) 
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5.4. Discussion 
GBS and CIDP share a number of clinical, pathological and electrophysiological features, 
whilst being distinctly different in others. Whilst both GBS and CIDP are thought to be 
autoimmune, they are different from most other autoimmune disorders by their male 
predominance. The onset of the illness is always subacute in GBS, but can be more variable 
in CIDP. However, CIDP can also initially present as a GBS-like illness, and then only 
becomes evident as CIDP in retrospect when the disease progresses or fluctuates long-term 
(termed Acute-CIDP or A-CIDP) (Ruts, van Koningsveld et al. 2005, Ruts, Drenthen et al. 
2010). Also, there is overlap in the treatments employed, i.e. IVIg and plasma exchange. This 
points to both differences and similarities in pathogenesis in these two disorders. 
In this study the frequency of KIR/HLA gene carriage was assessed in subjects with 
CIDP and compared to both HC and to subjects with GBS. The number of subjects was 
relatively low for a study of this kind, and so the statistical power is limited. However, 
differences in gene frequencies were found between CIDP and HC, but not between CIDP 
and GBS.  
No differences were found between the KIR genes in any of the 3 groups. In contrast, 
HLA were different in several aspects. Whilst in GBS HLA-C2/HLA-B BwT4 was more 
frequent than HC (see Chapter 4), HLA-B Bw4I was more frequent in CIDP than HC, with a 
trend to significance for HLA-B Bw4T. The heterozygous situation HLA-C1/C2 was more 
frequently seen in CIDP than HC. 
However there were some differences in the carriage of combinations of KIR/HLA. 
Interestingly, all differences found in HLA and KIR/HLA frequencies were between CIDP 
and HC or GBS and HC. In contrast, no differences between CIDP and GBS could be 
detected for any of the genes and gene combinations studied. This could possibly indicate 
underlying genetic similarities of CIDP and GBS patients causing the autoimmune attack on 
the peripheral nervous system.  
The similarities in KIR/HLA gene frequencies in GBS and CIDP could indicate 
similarities in the early pathogenesis of these disorders. Indeed, it could be speculated that the 
initial attack against the peripheral nervous system is identical in both disorders, but the 
subsequent immune regulation is more effective in GBS, leading to complete cessation of 
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autoimmunity against myelin (see Appendix A). This does not occur in CIDP. If these were 
correct, one would anticipate similarities in the innate immune system response, but 
differences in genes responsible for immune regulation of the specific immune system. 
The association of certain KIR/HLA ligands with CIDP and GBS could suggest that NK 
cells are involved in the pathogenesis. NK cells are a group of lymphocytes, which are related 
but distinct from T lymphocytes. They were originally described and named due to their 
cytotoxic properties against tumour cells. In recent years our understanding of the role of NK 
cells has expanded, and now encompasses detection and killing of virally infected cells, 
secretion of chemokines and cytokines, antigen presentation and direct cell-cell interactions 
with T cells and dendritic cells (Vivier, Raulet et al. 2011). NK cells are part of the innate 
immune system and are able to respond rapidly to infection without any prior sensitization 
(Rajalingam 2012). NK cell function is regulated by multiple inhibitory and activating 
receptors, of which the functionally most important is the KIR/HLA system. Alternatively, 
the KIR/HLA system is also of relevance in a range of T cell subsets, including CD8 T cells. 
The role of NK cells in the pathogenesis of CIDP has not been studied in depth. One 
study showed decreased numbers of circulating NK cells (Sanvito, Makowska et al. 2009). 
IVIg administration, which is a standard therapy for CIDP (Eftimov, Winer et al. 2009), is 
associated with a decreased number of circulating NK cells and reduced NK-cell-mediated 
cytotoxicity (Bohn, Nederby et al. 2011). In summary, in spite of a relatively small number of 
studied subjects with CIDP, we could detect differences of KIR/HLA ligand combinations 
between CIDP and HC, but not CIDP and GBS. This could indicate a role for NK cells in the 
pathogenesis of both GBS and CIDP and suggests similarities in the early pathogenesis of 
these disorders.  
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Chapter 6 A genome wide association study of Guillain-
Barré Syndrome 
6.1. Introduction 
6.1.1. Overview of recent developments in genetic research 
Around the turn of the century, the first human genome sequence was published, promising a 
new era of understanding of human development and disease (Lander, Linton et al. 2001, Venter, 
Adams et al. 2001). However, the initial DNA sequence of a single individual has raised questions 
rather than providing answers. In recent years, studies have focused on the variability of the human 
genome, particularly focusing on genetic differences in healthy and diseased individuals and 
between different populations. 
In parallel, a collaborative effort on the part of scientists, clinicians, lawyers and the community 
at-large has been initiated to safeguard individuals and direct the usage of genomic data with the 
promise of bettering the health of mankind in what has become the genomic era (Collins, Green et 
al. 2003). 
The studies of the human genome sequence have indicated that the number of human genes is 
lower than previously thought, with recent estimates quoting a number of approximately 22000 
genes (Claverie 2005, Consortium, Bernstein et al. 2012). These protein-coding sequences make up 
1-2% of the genome, and are interspersed by long stretches of non-coding sequences. The role of 
these non-coding parts of the human genome in gene regulation and cell biology is becoming 
increasingly clear (Carninci and Hayashizaki 2007). 
The intense research in genomics has led to a rapid development in techniques available to 
interrogate the genome. Concurrently costs of genomic studies have rapidly decreased. The 
sequencing of the first human genome was an international effort, involving numerous private and 
public institutions around the globe in an 11 year project and a price tag of around US$3 billion 
dollars. In 2008 the “1000 genomes project” was started, with an expected price tag of US$30 – 50 
million dollars. The data was published 3 years later (Abecasis, Altshuler et al. 2010). The “$1000 
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dollar genome”, a catchphrase first devised in 2001 seems to become goal achievable in the not-too-
distant future. 
6.1.2. Genome wide association studies 
In recent years, genome wide association studies (GWAS) have allowed the detection of alleles 
associated with disease phenotypes. The first successful GWAS, which was on age-related macular 
degeneration was published in 2005 (Klein, Zeiss et al. 2005). Since then, substantial progress has 
been made in a number of diseases. For example, massive efforts have been put into multiple 
sclerosis (MS), a demyelinating disease of the central nervous system, where a recent GWAS on 
50000 healthy controls and 26000 MS patients found a total of 110 loci associated with MS 
(Beecham, Patsopoulos et al. 2013).  
A prerequisite for human disease gene mapping is a reasonably high heritable contribution to 
the overall risk for the disease of interest. GWAS are made possible by a dense set of genetic 
markers, known as single nucleotide polymorphisms (SNPs) across the human genome. SNPs are 
sites in the DNA sequence where a single nucleotide varies between members of a species. 
Depending on the site of the mutation, some SNPs can affect the final protein sequence, whereas 
other do not. For homo sapiens, by April 2013 almost 10 million SNPs have been validated across 
the human genome (dbSNP 2013). This equates to roughly one SNP per 350 base pairs throughout 
the human genome.  
GWAS rely on investigations of common genetic variants (SNPs) of different individuals with 
or without a certain trait. GWAS use hundreds of thousands to millions of SNPs distributed 
throughout the genome to determine regions of the genome associated with the trait under 
investigations. To date 1200 GWAS have been published (Pearson and Manolio 2008, Johnson and 
O'Donnell 2009, Genome.gov 2012). GWAS are usually not able to elicit the causative mutation. 
The most widely used nomenclature of SNPs is according to the National Centre of Biotechnology 
Informatics (NCBI) database, which involves a reference number of reported SNPs with the prefix 
“rs”.   
Associations found in a GWAS do not necessarily imply causation. Confounders include 
difference in ethnic ancestry, DNA quality, techniques used at genotyping centres and 
environmental exposures, all of which can affect the same causal pathway. These factors need to be 
corrected for, as much as possible, as part of data cleaning and vigorous quality control (Pearson 
and Manolio 2008). 
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6.1.2.1. Linkage disequilibrium 
SNPs tested during GWAS might or might not be directly responsible for the phenotype studied. 
Most frequently, the SNPs studied in GWAS are in non-coding regions and have an indirect 
association with functional SNPs (Hirschhorn and Daly 2005).   
Genetic association testing is based on linkage disequilibrium (LD) between different SNPs. LD 
measures the degree to which alleles at two loci are associated, using the frequencies of each 
haplotype. Two or more polymorphic loci, e.g. SNPs, are in LD when certain alleles of these loci 
are observed together more often than would be expected by chance in a given population 
(Zondervan and Cardon 2004).  
To calculate LD, the haplotype frequencies for two loci and two alleles is examined (see Table 
6.1). 
Table 6.1 - Definition of haplotype frequencies for two loci with two alleles 
Haplotype Frequency 
A1B1 X11 
A1B2 X12 
A2B1 X21 
A2B2 X22 
 
From this table the frequency of each allele at each locus can be calculated as below (see Table 
6.2). 
Table 6.2 - Definition of allele frequencies based on haplotype frequencies 
Allele Frequency Population nomenclature 
A1 X11 + X12 p1 
A2 X21 + X22 p2 
B1 X11 + X21 q1 
B2 X12 + X22 q2 
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Standard measure of LD is calculated as  
𝐷 = ((𝑥11) × (𝑥22)) − ((𝑥12) × (𝑥21)) 
If two loci are in linkage equilibrium, then, 𝐷 = 0, if they are in linkage disequilibrium, 𝐷 ≠ 0. 
. 
A more frequently used measure of LD is r2, which is defined as 
𝑟2 =
𝐷2
𝑝1 × 𝑝2 × 𝑞1 × 𝑞2
=
(((𝑥11) × (𝑥22)) − ((𝑥12) × (𝑥21)))
2
(𝑥11 + 𝑥12) × (𝑥21 + 𝑥22) × (𝑥11 + 𝑥21) × (𝑥12 + 𝑥22) 
 
The range of r2 is from r2 = 0, signifying complete linkage equilibrium, to r2 = 1, which 
represents complete linkage disequilibrium. There is no defined statistical test that states when two 
loci are in LD, and a wide variety of choices have been used in the literature. Frequently, r2 is 
represented graphically. 
LD is influenced by recombination, genetic drift, population size and, to a lesser extent, 
mutations. 
6.1.2.2. Blocks 
Because of chromosomal segregation during meiosis, LD is dependent on physical co-
occurrence of both SNPs on the same chromosome. The amount of LD between any two SNPs is 
then influenced by recombination, natural selection, mutation, genetic drift, ancestral population 
demographics and mating patterns (Wall and Pritchard 2003, Zondervan and Cardon 2004).  
Patterns of LD are well known for being noisy and unpredictable. Many studies have shown that 
although the background LD is significantly related to genetic distance, small physical distance 
does not guarantee high level of LD (Abecasis, Noguchi et al. 2001, Gabriel, Schaffner et al. 2002). 
For example, pairs of sites that are tens of kilobases apart might be in complete LD, whereas nearby 
pairs of sites from the same region might be in weak LD (Patil, Berno et al. 2001, Wall and 
Pritchard 2003). 
Moreover, the genetic inheritance is not uniform across chromosomes; it rather follows 
formation of blocks, which are in close LD, interspersed by hot spots of separation (Goldstein 
2001). Within these blocks, LD decays only very gradually with distance, or not at all. However, 
within hotspots LD falls away rapidly with distance, leading to increased LD between blocks, up to 
the extreme of only random association between neighbouring blocks. Therefore, a single SNPs 
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within a block could be representative of genetic variation located at some distance, but might be 
unrelated to closely neighbouring SNPs in a different block (see Figure 6.1). 
 
Figure 6.1 - Blocks of LD in the human genome (after (Goldstein 2001)).  
6.1.2.3. Power calculations 
 
Complex or multifactorial diseases are characterized by the interplay of multiple genetic and 
environmental risk factors usually with low effect sizes, which might interact in a complex manner 
(Zondervan and Cardon 2004) (see Figure 6.2). Also, as mentioned above, the SNPs observed in 
GWAS might not be causative, but only in LD with the causative gene. 
Associations between SNPs and causal variants are expected to show low odds ratios, frequently 
below 1.5. In order to obtain a reliable signal, given the very large number of tests performed, 
associations must show a high level of significance to survive correction for multiple testing. This 
therefore requires study of large cohorts of subjects and controls. 
GWAS are limited by complex statistical analysis and power calculations due to the high 
numbers of tests performed whilst testing more than 500,000 SNPs (Dudbridge and Gusnanto 2008, 
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Pe'er, Yelensky et al. 2008). Because of the high numbers of tests performed, using Bonferroni 
correction for multiple tests would give a value for genome-wide significance for a p < 0.05: 
𝑝 <
0.05
500000
= 10−7 
SNPs with a lower p value can be considered for follow-up, but need to be confirmed, usually in 
a replication study. 
 
Figure 6.2 - Statistical power analysis of a case-control study using Quanto (Gauderman 2002) 
As shown in Figure 6.2, especially with smaller effect sizes, large numbers of case-control pairs 
are needed to derive adequate statistical power. In a small study, only effects of high significance 
were detectable, and the risk of a false-positive result is relatively high. This can partially be off-set 
by a relatively large number of control subjects.  
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6.2. Methods 
6.2.1. Study population 
6.2.1.1. Patients 
We obtained DNA of 230 patients with a confirmed diagnosis of GBS. The patient 
characteristics are summarized in Table 6.3. A more detailed overview is provided in previous 
chapters (Chapters 3 and 4). 
Table 6.3 - Patient characteristics 
Patient characteristic  Number 
Gender Male 
Female 
144 
86 
Hughes scale 1 
2 
3 
4 
5 
6 
3 
27 
39 
105 
51 
5 
Subtype AIDP 
AMAN 
AMSAN 
MFS 
Other focal variants 
GBS, unspecified 
104 
11 
3 
21 
7 
84 
 
6.2.1.2. Controls 
Two control groups were used for two independent analyses:  
a) A group of around 3000 samples from healthy Australians collected for the OATS (Lee, 
Mosing et al. 2012) and RAINE (http://www.rainestudy.org.au) studies. These were typed on an 
identical chip with the same methods as for the GBS subjects of this study (OmniExpress, 
Illumina). 
b) Samples from more than 15000 individuals available through the WTCCC consortium in UK, 
obtained from the National Blood Transfusion service and the 1958 British Birth Cohort. These 
Immunogenetic studies of Guillain – Barré Syndrome   Page 90 
 
 
samples were typed using Illumina 660W, leading to only a subset of SNPs being typed both in this 
group and the patient group. 
As the WTCCC cohort is a larger sample than the Australian cohort p values for SNPs of 
interest were expected to be more significant in the WTCCC group, but any SNPs of interest was 
investigated in both groups.  
6.2.2. DNA extraction 
Blood or saliva samples were obtained from the donors. DNA was isolated from full blood 
using the Nucleospin® Blood XL kit (Macherey-Nagel) according to manufacturer instructions. In 
short, 10 mls of blood was treated with proteinase K, followed by cell lysis at 56ºC.  DNA was 
precipitated using 100% Ethanol and separated using a membrane. DNA was eluted with elution 
buffer.  
For saliva, collection was performed using a commercial collection kit, which can be posted to 
patients’ homes (Oragene, DNAGenothek, Kanata, Canada). DNA was extracted using prepIT-L2P, 
according to manufacturer’s instructions.  
DNA concentrations were usually higher than 100 ng/mcl and of acceptable purity as 
determined by spectroscopy using ultraviolet light. Samples were stored at -20ºC. 
6.2.3. Genetic analysis assay 
GWAS was performed at the Laboratory of Prof. Matt Brown, Diamantina Institute, University 
of Queensland. Analysis was performed with the Omni-Express Bead Chip system using HiScan, 
Illumina (San Diego, USA). This chip is able to detect more than 715,000 individual SNPs with a 
call frequency of more than 99%. 
Analysis was performed according to manufacturer’s instructions. In short, 200 ng of original 
DNA was denatured and neutralized. A whole-genome amplification of the denatured DNA was 
performed overnight to increase the amount of the DNA sample. After this, DNA was fragmented 
enzymatically, using end-point fragmentation to avoid over-fragmentation. DNA was then 
precipitated with isopropanol and centrifuged at 4° C to collect fragmented DNA. After 
resuspensation in hybridization buffer, the samples were applied to a Bead Chip and incubated 
overnight to allow binding to the BeadChip. After washing away unhybridized and non-specifically 
hybridized DNA, single-base extensions were marked using fluorophore labels, followed by 
detection using a laser. 
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6.2.4. Quality control and population stratification 
The capability of GWAS to identify true genetic associations depends on the overall quality of 
the data used (Turner, Armstrong et al. 2011). A total of 230 samples were used for primary 
analysis. We excluded related individuals, by excluding samples with >20% of identical genomic 
markers, from further analysis.  
We excluded samples showing a deviation from Hardy-Weinberg equilibrium (HWE) at a 
significance level of <5 * 10-5. Also, samples with a genotyping rate of less than 0.95 and a 
minimum sample completion rate of less than 0.97 were excluded. SNPs with a minor allele 
frequency (MAF) of less than 5% were ignored due to insufficient power.  
The risk of confounding by population stratification increases with sample size. Eigenstrat 
analysis uses principal component analysis to detect and adjust for population stratification on a 
genome-wide scale in large samples (Patterson, Price et al. 2006, Price, Patterson et al. 2006). To 
exclude samples from a different genetic background we excluded all cases with an Eigenvector 
<0.02, leaving 190 samples used for final analysis. The quotient termed lambda was 1.276 pre-
stratification, and reduced to 1.097 after exclusion of these samples. 
6.2.5. Choosing areas of interest 
Because the number of patients studied was relatively low for a GWAS, it was anticipated that 
no genome-wide significant results would be obtained. A Manhattan plot was drawn using 
Haploview (Barrett, Fry et al. 2005). Each chromosome was visually screened for clusters of SNPs 
of increased significance compared to background SNPs. Areas of interest were enlarged, and an 
LD plot obtained. Areas of interest were defined as clusters of SNPs in linkage disequilibrium, with 
at least one SNP reaching genome-wide significance (p<10-5). All genes within a 300kB radius of 
the SNP of highest significance or lying in the same LD block were identified and subsequently 
characterized (candidate genes).  
6.2.6. Relevant negatives 
We performed a comprehensive review for all genetic markers previously studied in both GBS 
and CIDP. SNPs associated with these known genes were investigated for linkage disequilibrium. 
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6.3. Results 
6.3.1. Overview and Manhattan plot 
A total of 633875 SNPs were analyzed on the 190 samples passing quality control. These were 
compared with two cohorts of healthy controls as outlined above (Australian group and WTCCC). 
Likely due to the low number of cases, there were no SNPs meeting criteria for genome-wide 
significance. However, 5 regions of interest could be identified on chromosomes 2, 4, 14, 18 and 
19, which are subsequently described in more detail.  
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Figure 6.3 – Manhattan blot of GBS GWAS using Haploview (Barrett, Fry et al. 2005). Chromosomes are arbitrarily colour-coded. P values of all 
SNPs are coded on the vertical axis as a logarithm of 10. The X axis represents position of the SNP on the human genome.  
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6.3.2. Regions of interest 
For each region of interest the Manhattan plot is shown, in low and high power followed by the 
LD for the region shown in Haploview. The LD plot shows the blocks in the region of interest and 
the location of nearby genes. 
6.3.2.1. Rs10519519 
Rs10519519 is at position 2284303 on chromosome 2, at locus 2p25.3 (see Figure 6.4 and 
Figure 6.5). Neighbouring SNPs of increased significance are listed in Table 6.4. 
rs10519519 is located in an intron of a gene labeled Myelin Transcription Factor 1 - Like 
(MYT1L) (see Figure 6.6). SNPs rs10519519 and rs10495485 were not studied in the WTCCC 
sample. 
 
Figure 6.4 - Manhattan plot of entire Chromosome 2 using Haploview. A marker (red oval) defines 
the region surrounding rs10519519. P values of all SNPs are coded on the vertical axis as a 
logarithm of 10. The X axis represents position of the SNP on the human genome. 
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Figure 6.5 - Manhattan plot Chromosome 2: Zoom of region surrounding rs10519519 (purple 
marker). P values of all SNPs are coded on the vertical axis as a logarithm of 10. The X axis 
represents position of the SNP on the human genome. Neighbouring SNPs in linkage disequilibrium 
are colour-coded according to r2 (see graph). 
 
Table 6.4 - Neighbouring SNPs to rs10519519 of increased significance as compared to the sample 
of HC 
SNP Mutation P Aust P WTCCC OR 
Rs10519519 A/G 2.0E-6 N/A  
Rs10495485 C/T 1.1E-5 N/A  
Rs7598374 A/G 1.37E-4 0.027 1.446 
Rs1421612 G/A 1.55E-4 0.008 1.567 
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Figure 6.6 - LD plot of region 2284303 on Chromosome 2. MYT1L is the only gene found in the neighbourhood of rs10519519 (Haploview) 
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6.3.2.2. rs7663689 
rs7663689 is found at position 142688981 on Chromosome 4, at locus 4q31.21 (Figure 6.7 and 
Figure 6.8). Neighbouring SNPs and their significance levels are listed in Table 6.5. rs7663689 
localizes to the intergenic region between Zinc finger protein 330 (ZNF330) and the IL-15 pre-
protein (IL15) as shown in Figure 6.9. It is part of the promoter region of IL15. 
 
 
Figure 6.7 – Manhattan plot of entire Chromosome 4 using Haploview: The cluster of SNPs of 
increased significance around rs7663689 is marked by the red oval. P values of all SNPs are coded 
on the vertical axis as a logarithm of 10. The X axis represents position of the SNP on the human 
genome. 
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Figure 6.8 - Manhattan plot; Zoom to region surrounding rs7663689.  P values of all SNPs are 
coded on the vertical axis as a logarithm of 10. The X axis represents position of the SNP on the 
human genome. Rs7663689 is marked in purple. Neighbouring SNPs in linkage disequilibrium are 
colour-coded according to r2 (see graph). 
Table 6.5 - Neighbouring SNPs to rs7663689 of increased significance as compared to the 
Australian and WTCCC sample of HC 
SNP Mutation P Aust P WTCCC OR WTCCC 
Rs7663689 T/C 1.7E-4 2.16E-5 1.707 
Rs17701271 A/C 2.28E-4 2.90E-5 1.63 
Rs10519629 C/T 0.005 5.30E-4 1.59 
Rs1519551 G/A 4.04E-4 6.48E-4 0.69 
Rs4254850 T/C 1.55E-4 8.73E-4 1.43 
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Figure 6.9 - LD plot of region 142688981 on Chromosome 4 showing IL15 as the gene most closely linked to rs7663689 (Haploview) 
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6.3.2.3. rs11151180 
Another region of interest could be identified on Chromosome 18 by SNP 1151180 at position 
62845961, locus 18q22.1 (see Figure 6.11). Neighbouring SNPs in linkage disequilibrium are 
summarized in Table 6.6. There were no genes in close vicinity to rs11151180 (see Figure 6.12). 
The closest known in gene is cadherin 7 (CDH7), which starts at 250kB from rs11151180.  
 
 
Figure 6.10 - Manhattan plot of entire Chromosome 18 using Haploview: The cluster of SNPs of 
increased significance around rs11151180 is marked by the red oval. P values of all SNPs are 
coded on the vertical axis as a logarithm of 10. The X axis represents position of the SNP on the 
human genome.  
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Figure 6.11 - Manhattan plot; Zoom to region surrounding rs11151180.  P values of all SNPs are 
coded on the vertical axis as a logarithm of 10. The X axis represents position of the SNP on the 
human genome. Rs11151180 is marked in purple. Neighbouring SNPs in linkage disequilibrium are 
colour-coded according to r2 (see graph). 
Table 6.6 - Neighbouring SNPs to rs11151180 of increased significance as compared to the 
Australian and WTCCC cohort of HC 
SNP Mutation P Aust P WTCCC OR WTCCC 
rs11151180 A/G 0.005 4.46E-5 0.6294 
rS4048109 G/A 0.006 7.153E-5 0.636 
rs1108775 A/G 0.05 1.763E-4 0.6616 
rs1035208 T/C 0.118 2.299E-4 0.6692 
rs1183856 A/G 0.118 2.395E-4 0.0699 
rs11662608 T/G 0.059 3.425E-4 0.6742 
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Figure 6.12 - LD plot rs1115180 region (Haploview); no genes in close neighbourhood to11151180 were found 
Immunogenetic studies of Guillain – Barré Syndrome   Page 103 
 
 
6.3.2.4. rs17095496 
rs17095496 is an intergenic SNP located on Chromosome 14, position 59447241, locus 14q23.1 
(see Figure 6.13 and Figure 6.14). This region had the strongest linkage disequilibrium in our study 
(see Table 6.7), with four SNPs having OR above 2. 
It is located in a large block, which encompasses two proteins, hypothetical protein C14orf135 
and Dehydrogenase/reductase (SDR family) member 7 (DHRS7), and is also associated with 
Disheveled-Binding Antagonist Of Beta-Catenin 1 gene (DACT1) and dishevelled associated 
activator of morphogenesis 1 (DAAM1) (Figure 6.15). 
 
 
Figure 6.13 - Manhattan plot of entire Chromosome 14 using Haploview. The cluster of SNPs of 
increased significance around rs17095496 is marked by the red oval. P values of all SNPs are 
coded on the vertical axis as a logarithm of 10. The X axis represents position of the SNP on the 
human genome. 
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Figure 6.14 - Manhattan plot Chromosome 14, zoom on region surrounding rs17095496 .  P values 
of all SNPs are coded on the vertical axis as a logarithm of 10. The X axis represents position of the 
SNP on the human genome. Rs17095496 is marked in purple. Neighbouring SNPs in linkage 
disequilibrium are colour-coded according to r2 (see graph). 
Table 6.7 - Neighbouring SNPs to rs17095496 of increased significance as compared to an 
Australian cohort and WTCCC cohort of healthy controls 
SNP Mutation P Aust P WTCCC OR WTCCC 
rs17095496 G/A 6.47E-4 3.681E-7 2.125 
rs85425 T/C 5.24E-4 5.569E-7 2.15 
rs17254989 A/G 5.79E-4 6.624E-7 2.106 
rs1427327 T/G 1.69E-4 5.514E-6 2.247 
rs380375 A/G 0.002 1.688E-4 1.899 
rs7155136 A/G 0.048 3.748E-4 1.486 
rs7159883 A/C 0.002 4.27E-4 1.762 
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Figure 6.15 - LD plot of Chromosome 14, region of rs17085496 (Haploview) 
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6.3.2.5. rs2302524 
rs2302524 is found on Chromosome, locus 19q13.2 (see Figure 6.16 and Figure 6.17). The 
SNPs of highest significance are summarized in Table 6.8. This region features a range of genes, 
which names and functions are delineated below (see Figure 6.18). 
Figure 6.16 - Manhattan plot of entire chromosome 19 using Haploview. The cluster of SNPs of 
increased significance around rs2302524 is marked by the red oval. P values of all SNPs are coded 
on the vertical axis as a logarithm of 10. The X axis represents position of the SNP on the human 
genome. 
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Figure 6.17 - Manhattan plot Chromosome 19: Zoom to region surrounding rs2302524 using 
Haploview. P values of all SNPs are coded on the vertical axis as a logarithm of 10. The X axis 
represents position of the SNP on the human genome. 
 
Table 6.8 - Neighboring SNPs to rs2302524 of increased significance as compared to the 
Australian cohorts and WTCCC cohort of healthy controls 
SNP Mutation P Aust P WTCCC OR WTCCC 
rs2302524 C/T 1.9E-4 2.394E-5 1.693 
rs3746003 A/G 0.015 9.24E-5 1.64 
rs3746002 A/G 0.01 1.023E-4 1.635 
rs4251938 C/T 0.003 1.85E-4 1.663 
rs5009916 T/G 0.002 1.84E-4 1.488 
rs4802189 A/C 0.002 2.914E-4 1.558 
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Figure 6.18 - LD plot of region rs2302524 showing several genes closely linked to rs2302524 as detailed in the text (Haploview) 
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6.3.3. Short description of candidate genes 
6.3.3.1. rs10519519 
MYT1L encodes a pan-neural transcription factor associated with neuronal differentiation and is 
expressed in the developing brain (Kim, Armstrong et al. 1997). Moreover, it has been found to be 
of paramount importance in the induction of neurons out of both human and mouse fibroblast 
cultures, together with other growth factors (Vierbuchen, Ostermeier et al. 2010, Ambasudhan, 
Talantova et al. 2011, Pang, Yang et al. 2011, Yoo, Sun et al. 2011). 
6.3.3.2. rs7663689 
Zinc finger protein 330 (ZNF330) is a protein-coding gene. The function of the encoding protein 
is unclear. It has been associated with conduct disorder in a recent GWA study (Dick, Aliev et al. 
2011).  
The IL15 gene encodes a 14-15 kDa glycoprotein, and consists of nine exons and eight introns. 
Four exons (5 to 8) encode for the mature protein (Steel, Waldmann et al. 2012). It is expressed by a 
large number of cells, including monocytes, macrophages, dendritic cells, fibroblasts and nerve 
cells (Grabstein, Eisenman et al. 1994). Two transcript variants are encoded by the same protein, 
but differ in their splicing: The long signal peptide (IL-15-LSP) consists of a 316 bp 5’-untranslated 
region (UTR), 486 bp coding sequence and the C-terminus 400 bp 3’-UTR region. The short signal 
peptide (IL-15-SSP) has a short signal peptide encoded by exons 4A and 5. These isoforms differ in 
their cellular trafficking, but produce the same mature IL-15 protein (Bamford, DeFilippis et al. 
1998).  
6.3.3.3. rs11151180 
CDH7 encodes a membrane protein, which is a calcium dependent cell-cell adhesion 
glycoprotein. It is comprised of five extracellular repeats, a transmembrane region and a 
cytoplasmic tail (Kools, Van Imschoot et al. 2000). It has been related to migration of malignant 
cells (Winklmeier, Contreras-Shannon et al. 2009). 
6.3.3.4. rs17085496 
C14orf135 is a hypothetical protein, alternative name: pecanex-like protein 4, is related to the 
pecanex family in Drosophila. There is no functional information about this protein. Pecanex has 
been linked to neuronal development and sterility in Drosophila (Yamakawa, Yamada et al. 2012). 
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Short-chain dehydrogenases/reductases (SDRs), such as DHRS7, catalyze the 
oxidation/reduction of a wide range of substrates, including retinoids and steroids (Haeseleer and 
Palczewski 2000). It has recently been better characterized and has been found to have an important 
role in metabolism of xenobiotics within the endoplasmic reticulum (Skarydova and Wsol 2012, 
Skarka, Skarydova et al. 2013, Stambergova, Skarydova et al. 2014). It is expressed in retinal tissue, 
and also in B- and T-lymphocytes and liver cells. 
DAAM1 is a formin, a class of actin nucelators, required for centrosome re-orientation during 
cell proliferation and migration (Ang, Zhao et al. 2010, Nishimura, Honda et al. 2012). It localizes 
to the actin-myosin system, evident in the sub-nuclear system during cell division. It has recently 
been found to be overexpressed in acute myeloid leukemia (Bock, Mochmann et al. 2013). 
Dapper homolog 1 (DACT1), a member of DACT family, is an important regulator in the planar 
cell polarity (PCP) pathway (Zhang, Gao et al. 2006). It has been found to be a tumor suppressor 
gene in gastric cancer by inhibition of the NF-κB pathway (Wang, Kang et al. 2012). DACT1 is 
widely expressed throughout the body, including a wide variety of immune cells and neural cell 
types. It has been linked to neuronal development with several rare mutations being linked to neural 
tube defects in humans (Shi, Ding et al. 2012).  
6.3.3.5. rs2302524 
Soluble galactoside-binding lectin 4 and 7 (LGALS4 and LGALS7) are members of the galectin 
family. The galectins are beta-galactoside-binding proteins implicated in modulating cell-cell and 
cell-matrix interactions. Differential and in situ hybridization studies indicate that this lectin is 
specifically expressed in keratinocytes and found mainly in stratified squamous epithelium 
(Barondes, Cooper et al. 1994). Galectin 4 has been found to have decreased expression in 
colorectal cancer (Huflejt, Jordan et al. 1997, Rechreche, Mallo et al. 1997). 
Peroxisomal Enoyl CoA Hydratase 1 (ECH1) encodes a member of the hydratase/isomerase 
superfamily. The gene product shows high sequence similarity to enoyl-coenzyme A (CoA) 
hydratases of several species, particularly within a conserved domain characteristic of these 
proteins. The encoded protein, which contains a C-terminal peroxisomal targeting sequence, 
localizes to the peroxisome (FitzPatrick, Germain-Lee et al. 1995). It has been found to be 
associated with myotonic dystrophy (Rusconi, Mancinelli et al. 2010). 
Heterogeneous Nuclear Ribonucleoprotein L (HNRPL) encodes one of the heterogeneous 
nuclear RNAs (hnRNAs), which include mRNA precursors and mature mRNAs, are associated with 
specific proteins to form heterogeneous ribonucleoprotein (hnRNP) complexes. Heterogeneous 
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nuclear ribonucleoprotein L is among the proteins that are stably associated with hnRNP complexes 
and along with other hnRNP proteins is likely to play a major role in the formation, packaging, 
processing, and function of mRNA. Heterogeneous nuclear ribonucleoprotein L is present in the 
nucleoplasm as part of the HNRP complex (Pinol-Roma, Swanson et al. 1989). 
Sirtuin 2 (SIRT2) encodes a member of the sirtuin family of proteins, homologs to the yeast 
SIR2 protein. Members of the sirtuin family are characterized by a sirtuin core domain and grouped 
into four classes. The functions of human sirtuins have not yet been determined; however, yeast 
sirtuin proteins are known to regulate epigenetic gene silencing and suppress recombination of 
rDNA. Studies suggest that the human sirtuins may function as intracellular regulatory proteins 
with mono-ADP-ribosyltransferase activity. The protein encoded by this gene is included in class I 
of the sirtuin family (Afshar and Murnane 1999, Dryden, Nahhas et al. 2003, Voelter-Mahlknecht, 
Ho et al. 2005). 
NF-κB inhibitor beta (NFKBIB) is a member of the IκB kinase family. The IκB Kinase family 
of proteins binds to NF-κB in holds it inactive in the cytoplasm. Cytokine-induced phosphorylation, 
ubiquitination and degradation of IκB leads to release and translocation of NF-κB into the cell 
nucleus (Mercurio, Zhu et al. 1997). IκB family consist of NKκBI alpha and beta, with close 
structural homology, but have distinct protein-protein interactions (Woronicz, Gao et al. 1997).  
Mitochondrial Seryl-tRNA Synthetase 2 (SARS2) encodes the mitochondrial seryl-tRNA 
synthethase precursor, a member of the class II tRNA synthetase family. The mature enzyme 
catalyzes the ligation of Serine to tRNA(Ser) and participates in the biosynthesis of selenocysteinyl-
tRNA(sec) in mitochondria. The enzyme contains an N-terminal tRNA binding domain and a core 
catalytic domain. It functions in a homodimeric form, which is stabilized by tRNA binding 
(Yokogawa, Shimada et al. 2000). 
Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and help in protein 
synthesis within the mitochondrion (Cavdar Koc, Burkhart et al. 2001). 
F-Box Protein 17 (FBXO17) encodes a member of the F-box protein family which is 
characterized by the F-box motif. The F-box proteins constitute one of the four subunits of the 
ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in 
phosphorylation-dependent ubiquitination (Ilyin, Serandour et al. 2002). 
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6.3.4. Relevant negatives 
A number of genes have been studied in subjects with GBS, some of which have been 
associated with disease susceptibility (Myhr, Vagnes et al. 2003, Geleijns, Emonts et al. 2007, 
Prasad, Nyati et al. 2010, Jiao, Wang et al. 2012). The best evidence is of TNFα polymorphisms, 
which have been described in several studies (Wu, Zhou et al. 2012). For some of these genes, 
namely HLA and CD1, there are conflicting results between studies (Gorodezky, Varela et al. 1983, 
Winer, Briggs et al. 1988, Ma, Nishimura et al. 1998, Magira, Papaioakim et al. 2003, Caporale, 
Papola et al. 2006, Kuijf, Geleijns et al. 2008). Other genes have been studied, but no association 
has been found. Others again are associated with disease severity, but not susceptibility, e.g. MMP9 
(Geleijns, Emonts et al. 2007). Some of these genes have also been studied in CIDP. We undertook 
to investigate SNPs associated with these previously studied genes in our GWAS sample.  
None of the genes studied previously was associated with significant linkage disequilibrium in 
our cohort (see Table 6.9). 
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Table 6.9 - Previously studied genes in GBS and CIDP and p-values of associated SNPs 
Protein Gene Chromosomal 
location 
Link to GBS Link to CIDP SNP  P 
WTCCC 
OR 
WTCCC 
Alpha1 
antitrypsin 
SERPINA
1 
14q32.1 No association (McCombe, 
Clark et al. 1985) 
No association 
(McCombe, Clark 
et al. 1985) 
Rs6647 0.335 1.01 
Apolipoprotein  
E 
APOE 19q13.2 No association (Pritchard, 
Hughes et al. 2003) 
 Rs1031309 0.3291 0.8809 
CD1A 
 
CD1A  Conflicting evidence  
(Caporale, Papola et al. 
2006, Caporale, Uncini et 
al. 2008, Kuijf, Geleijns et 
al. 2008, Uncini, Notturno 
et al. 2011) 
 Rs16840041 0.329 0.7658 
CD1D CD1D  No association (Caporale, 
Papola et al. 2006) 
 Rs859008 0.202 0.8055 
CD1E 
 
 
CD1E  Conflicting evidence 
(Caporale, Papola et al. 
2006, Caporale, Uncini et 
al. 2008, Kuijf, Geleijns et 
al. 2008, Uncini, Notturno 
et al. 2011) 
 Rs1065457 0.885 0.9515 
CD14 
 
 
CD14 5q31.1 No association (Geleijns, 
Jacobs et al. 2004) 
 Rs2563298 0.548 0.9252 
Contactin 2 
(axonal) 
(Transient 
CNTN2 1q32.1  Conflicting 
evidence (Iijima, 
Koike et al. 2011, 
Rs2275697 
 
0.865 1.031 
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axonal 
glycoprotein-1) 
Pang, Chan et al. 
2012) 
 
CD59 
(complement 
regulatory 
molecule) 
CD59 11p13 Anti-CD59 as treatment for 
EAN (Halstead, Zitman et 
al. 2008)  
Case report of 
CD59 deficiency 
(Nevo, Ben-Zeev et 
al. 2013) 
Rs7046 0.3947 0.9109 
Fas (CD95) 
 
FAS 10q24.1 Association with 
ganglioside Ab (Geleijns, 
Laman et al. 2005) 
 Rs9658702 0.363 1.019 
Fcgamma 
receptor IIa 
 
 
FCGR2A  Conflicting evidence 
(Vedeler, Raknes et al. 
2000, van Sorge, van der 
Pol et al. 2005, Sinha, 
Prasad et al. 2010) 
 Rs7529425 0.139 1.214 
Fcgamma 
receptor IIIb 
FCGR2B 1q23 Less severe disease 
(Vedeler, Raknes et al. 
2000) 
 Rs11799952 0.552 1.037 
Fcgammma 
receptor IIIa 
FCGR3A 1q23 Conflicting evidence 
(Vedeler, Raknes et al. 
2000, van Sorge, van der 
Pol et al. 2005, Sinha, 
Prasad et al. 2010) 
 Rs17411858 0.139 1.332 
FcR- like 3 
 
FCRL3 1q21 Association in Han Chinese 
(Sang, Chen et al. 2012) 
 Rs2282284 0.805 0.7972 
Glucocorticoid 
receptor 
NR3C1 5q31.3 No association, but linked to 
clinical course (Dekker, van 
den Akker et al. 2009) 
 Rs6190 0.777 0.898 
HLA-A HLA-B 6p21.3 No association (Ma,  Rs9404952 0.797  
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Nishimura et al. 1998) 
HLA-B HLA-B 6p21.3   Rs3819299 0.664 1.336 
HLA-C HLA-C 6p21.3   Rs7750641 0.209  
HLA-DQ HLA-DQ 6p21.3  Association (Mrad, 
Fekih-Mrissa et al. 
2013) 
Rs2854275 0.669 0.9692 
HLA-DR 
 
HLA-DR 6p21.3 Conflicting results 
(Gorodezky, Varela et al. 
1983, Magira, Papaioakim 
et al. 2003, Sinha, Prasad et 
al. 2010) 
Association (Mrad, 
Fekih-Mrissa et al. 
2013) 
Rs9286790 0.779  
Interleukin 10 IL10 1q31 Association (Myhr, Vagnes 
et al. 2003) 
 Rs3024492 0.09 0.8736 
MMP9 MMP9 20q11.2   Rs2250889 0.216 1.398 
Peripheral 
myelin protein 
22 
PMP22 17p12 Case reports (Odaka, Yuki 
et al. 2003) 
 
Case reports (Korn-
Lubetzki, Argov et 
al. 2002, Remiche, 
Abramowicz et al. 
2013) 
Rs16951239 0.262 1.022 
T cell specific 
adaptor protein 
SH2D2a 1q21  Association 
(Notturno, Pace et 
al. 2008) 
Rs21150906 0.1111 1.376 
TNF alpha 
 
TNF 6p21.3 Association with axonal 
GBS (Jiao, Wang et al. 
2012) 
 Rs3093662 0.437 0.5922 
Toll-like 
receptor 4 
TLR4 9q33.1 No association (Geleijns, 
Jacobs et al. 2004) 
 Rs1927906 0.22 0.805 
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6.4. Discussion 
We performed a genome-wide association study of a cohort of patients with a confirmed 
diagnosis of GBS and a control group of subjects available from an Australian (OATS, 
RAINE) and UK cohort (WTCCC).  
The patient characteristics of our case cohort were similar to previously described cohorts 
of Australian subjects with GBS (Hankey 1987, Storey, Cook et al. 1989, Blum, Reddel et al. 
2013). Our controls were derived from a previously collected cohort of individuals with 
Caucasian heritage from an Australian (OATS, RAINE) and UK background (WTCCC). 
Individuals with non-Caucasian heritage were excluded from analysis. 
Due to the small number of cases, it was anticipated that no genome-wide significance 
could be achieved in our study. The main aim, therefore, was to identify regions to enable 
more focused study in the future. 
We found 5 regions of interest. Of these, 2 regions were in the area of genes whose 
corresponding proteins had previously been studied and are thought important in GBS 
pathogenesis – IL15 and NFKBIB. Another region was associated with a transcription factor 
of importance in neuronal development – MYT1L. Finally, two other sites had less clear 
associations with known factors of GBS pathogenesis. We will subsequently review 
candidate genes identified by this method. 
6.4.1. IL-15 
rs7663689 is located in the promotor region of IL15, the gene encoding for the cytokine 
IL-15. It is structurally and functionally related to IL-2, and indeed the two proteins share 
subunits of their receptors (Di, Calarota et al. 2011, Steel, Waldmann et al. 2012). It has 
multiple functions in cell development, including both innate and adaptive lymphoid cells 
and neural cells (Lodolce, Burkett et al. 2002). IL-15 is widely expressed in the human body 
and expressed by both immune and non-immune cells (Fehniger and Caligiuri 2001) in 
development and adult individuals.  
IL-15 is an important cytokine in the innate and adaptive immune system (Lodolce, 
Burkett et al. 2002). IL-15 has important roles in immunity in both health and disease. It has 
been implicated in the pathogenesis of autoimmune diseases, i.e. celiac disease and type I 
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diabetes mellitus (Yokoyama, Watanabe et al. 2009, DePaolo, Abadie et al. 2011, Di, 
Calarota et al. 2011, Bobbala, Chen et al. 2012), but also in immune response to malignancies 
(Steel, Waldmann et al. 2012). 
IL-15 has its most important role in γ/δ+ lymphocytes and NK cells (de Rham, Ferrari-
Lacraz et al. 2007). It is critical in NK cell development, as evidenced by the absence of NK 
cells in IL-15 knockout-mice (Kennedy, Glaccum et al. 2000) and the defect of NK cell 
development out  of  CD34+ hematopoietic progenitor cells in the absence of IL-15 (Mrozek, 
Anderson et al. 1996). Moreover, IL-15 plays an important role in innate immune system 
cross-talk, with activated macrophages secreting IL-15 in a paracrine fashion, stimulating NK 
cells (Carson, Ross et al. 1995). IL-15 primes NK cell killing function, which has been 
implicated in human disease (Tang, Sally et al. 2013).  
 
Figure 6.19 - Human IL-15 mRNA and protein structure (Fehniger and Caligiuri 2001). 
Green colours represent the encoding gene of the mature protein, yellow parts of the pre-
proteins, purple are splice variants and red are parts of the mRNA not encoded into the 
precursor protein.  
It is of interest, that the SNP found (rs7663689) is not directly located in the IL15, but 
rather in the promotor region of this gene. Common functional polymorphisms in cytokine 
genes, which are widely distributed in the population, may affect gene transcription and 
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subsequently individual variations in cytokine levels. Polymorphisms in the promotor regions 
of IL-2, IL-4, IL-6, IL-10 and TNFα have been described (Kurzawski, Pawlik et al. 2005, 
Amirzargar, Khosravi et al. 2007). These genetic differences can result in variations of 
cytokine levels, leading to susceptibility to a range of different diseases (Ollier 2004). Also, a 
number of SNPs have been described in the IL15, and have been linked to smoking, juvenile 
idiopathic arthritis, allergies and left ventricular hypertrophy (Bierbaum, Sengler et al. 2006, 
Christensen, Haagerup et al. 2006, Arnett, Devereux et al. 2009, Fujisaki, Kakuda et al. 2009, 
Liu, Pei et al. 2009). Polymorphisms of IL-15 have also been described to be associated with 
resistance to certain infections (Kalani, Rasouli et al. 2011). 
A report by Van Rhijn et al. investigated the role of C. jejuni reactive T lymphocytes in 
patients with GBS. They found that γδ T cell proliferative responses were suppressed in 
patients with GBS due to Campylobacter infection, but could be restored by supplementing 
IL-2 or IL-15 (Van, Logtenberg et al. 2003). They suggested that host factors, rather than 
properties of the invading pathogen, are responsible for this aberrant response. Genetic 
changes in IL15 expression could therefore be a risk factor for developing GBS. 
6.4.2. NFKBIB 
Whilst other genes are in close vicinity to rs2302524, NFKBIB is the only gene in the 
region that can be easily associated with the immune system. NFKBIB is a member of the 
NF-κB inhibitor family IκB. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B 
cells) is a protein complex that controls transcription of DNA. NF-κB plays a key role in 
regulating the immune response to infection and other stressors (Gilmore 2006). The NF-κB 
complex is inhibited by  IκB proteins, which inactivate NF-κB by trapping it in the cytoplasm 
(Woronicz, Gao et al. 1997). Under the influence of cytokine-induced kinases, 
phosphorylation of serine residues on these proteins marks them for destruction via the 
ubiquitination pathway, thereby allowing activation of NF-kappa-B, which translocates to the 
nucleus to function as a transcription factor. NF-κB is thereby intimately involved in cell 
responses to stress, cytokines, free radicals and bacterial and viral antigens (Gilmore 2006). 
NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock and 
viral infections. 
In GBS and CIDP, NF-κB has been found to be increased in macrophages obtained from 
sural nerve biopsies, whereas IκB was upregulated in both macrophages and T cells 
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(Andorfer, Kieseier et al. 2001). In non-inflammatory neuropathies this upregulation of NF-
κB and IκB in immune cells was not found. Subsequently, it could be demonstrated that  
NF-κB translocates into the cell nucleus of inflammatory cells in both CIDP and GBS 
patients, but not in patients with other neuropathies (Mazzeo, Aguennouz et al. 2004). 
6.4.3. MYT1L 
Rs10519519 is located in an intron of MYT1L, with no other genes in close vicinity. The 
protein encoded by this gene is thought to be a pan-neural transcription factor associated with 
neuronal differentiation and is expressed in the developing brain (Kim, Armstrong et al. 
1997). Moreover, it has been found to be of paramount importance in the induction of 
neurons out of both human and mouse fibroblast cultures, together with other growth factors 
(Vierbuchen, Ostermeier et al. 2010, Ambasudhan, Talantova et al. 2011, Pang, Yang et al. 
2011, Yoo, Sun et al. 2011). MYT1L mutations and copy number variations (CNV) have been 
associated with a number of psychiatric disorders, including depression, autism and 
schizophrenia (Wang, Zeng et al. 2010, Lee, Mattai et al. 2012, Li, Wang et al. 2012, Meyer, 
Axelsen et al. 2012).  
The role of MYT1L in the peripheral nervous system has not been elucidated. However, 
this finding does raise the possibility of differences in neuronal development of the nervous 
system being a susceptibility factor for development of GBS. Target organ susceptibility has 
been raised as a factor in development of autoimmune diseases, but not studied in depth 
(Kuhr, Hala et al. 1994). 
6.4.4. rs17095496 and rs11151180 
The situation is unclear for these two SNPs. rs11151180 on chromosome 18 is in a 
genetic desert, with no previously identified genes. rs17095496 is in the vicinity of 4 genes 
(DACT1, DAAM1, C14orf135 and DHRS7), none of which has a known role which could be 
easily linked to GBS. Of some interest is the association of DACT1 with NF-κB in tumour 
cells (Wang, Kang et al. 2012), but the relevance of this gene in the immune system is 
unclear at present. 
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6.4.5. Relevant negatives 
We investigated SNPs on all previously studied genes in GBS. None of these was 
associated with a significant result in our cohort.  
 Of interest is the absence of any signal in the HLA region on chromosome 6. The HLA 
region is highly polymorphic and variations are strongly associated with virtually every 
autoimmune disease (Handunnetthi, Ramagopalan et al. 2010, Cho and Gregersen 2011, 
Thorsby 2011). Indeed, for many autoimmune diseases, the HLA locus hosts the strongest 
and most consistent susceptibility alleles (Rai and Wakeland 2011). In GBS, HLA has been 
extensively studied, with some conflicting results, but no clear and reproducible link has been 
established so far (Gorodezky, Varela et al. 1983, Winer, Briggs et al. 1988, Ma, Nishimura 
et al. 1998, Magira, Papaioakim et al. 2003, Geleijns, Schreuder et al. 2005). Whilst not 
conclusive, this argues against a dominant role of the adaptive immune system in GBS 
pathogenesis. Alternatively, this absence of signal could be a false-negative finding, given 
sample size. 
6.4.6. Summary 
In spite of the relatively small number of cases in our study, we were able to identify a 
number of loci of interest. Two of these (IL15 and NFKBIB) can easily be linked to proteins 
of importance in the immune system in general and GBS in particular. The role of IL-15 in 
NK cell development is of particular interest in the context of this thesis, seeing the 
previously mentioned role of NK cell activation proteins in GBS pathogenesis (see Chapters 
4 and 5). One locus (MYT1L) appears to be related to neuronal development; target organ 
susceptibility, rather than immune dysfunction, as cause for GBS is a novel idea and has not 
been studied so far. This is in contrast to the large GWAS performed in MS, where a number 
of immune genes have been identified, but no genes associated with neuronal function were 
detected (Beecham, Patsopoulos et al. 2013). For the two other loci no genes which could 
easily be related to GBS pathogenesis could be identified; one of these genes (DACT1) has 
been associated with NF-κB regulation in the context of gastric cancer. We found no 
indication that the HLA locus is in LD, which would make GBS very unusual compared with 
most other autoimmune diseases (Handunnetthi, Ramagopalan et al. 2010).  
In summary, our study provided several loci and genes of interest in a GWAS of subjects 
with GBS. It would be worthwhile to further study these sites, either using a replication 
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cohort or alternatively using the data as basis for a candidate gene approach as well as 
functional studies. 
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Chapter 7 Summary and conclusions 
This thesis studied the epidemiology of GBS in Australia and investigated a possible 
genetic basis of GBS pathogenesis in a cohort of Australian subjects with GBS. 
GBS is an inflammatory disease of the peripheral nervous system, which affects subjects 
of virtually any age, but is particularly common in the 5th and 6th decade of life. It is most 
frequently seen in as a post-infectious illness in individuals of otherwise good health. All 
functions of peripheral nervous system can be affected, with weakness, sensory disturbance, 
pain and autonomic dysfunction being common. Onset of the disease is subacute, with a 
frequently severe illness course, but usually good recovery. Nevertheless, the cost of 
treatment per patient is substantial (Frenzen 2008), mainly related to the need for lengthy and 
intensive supportive care. 
7.1. Characteristics of GBS in Australia 
GBS is a heterogeneous illness, and a range of subtypes have been characterized. These 
include AIDP, AMAN, AMSAN, MFS and several focal variants of GBS. These subtypes are 
defined predominantly on the basis of clinical and electrophysiological criteria, but have also 
pathogenetic differences. It was therefore of importance to study in detail the clinical 
characteristics of GBS in a contemporary Australian cohort (see Chapter 3). 
Using a retrospective chart review in seven hospitals along the East Coast of Australia, 
we identified a sizeable cohort of 335 subjects with a confirmed diagnosis of GBS. We found 
that incidence of GBS increased with age, peaking between the ages of 60 to 70 years, with a 
possible smaller peak in the early twenties. The predominant gender was male, with a ratio of 
M : F = 1.61 : 1. As expected with an inpatient based cohort, most patients were severely 
affected: 43% were bed- or wheelchair bound, and an additional 24% required ventilatory 
support. Mortality was low at 2%. Surprisingly, a comparison of our data with historical data 
collected before the wide-spread use of plasma exchange or IVIg showed that the illness peak 
severity and ICU admission rates have not been significantly altered by the use of these 
treatments (Hankey 1987, Storey, Cook et al. 1989). This highlights the need for more 
effective therapies of GBS. 
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Also of interest was the finding of the seasonal variation of GBS and its relationship to 
triggering factors. Based on historical data and the evidence for C. jejuni triggering axonal 
variants of GBS by molecular mimicry, diarrhea caused by this pathogen is still frequently 
thought to be the most common triggering factor. However, in our cohort the incidence of 
diarrhea as triggering factor was low (19%), compared with the finding that 45% of patients 
had preceding URTIs. This finding was congruent with the higher incidence of GBS during 
the Southern hemisphere winter months as compared to summer months. It could be 
speculated that changes in hygiene and wide-spread use of refrigeration has decreased the 
incidence of both C. jejuni and GBS triggered by this agent in recent decades, especially in 
developed countries (Baker, Kvalsvig et al. 2013). Axonal variants of GBS, possibly 
triggered by C. jejuni, still appear to be much more frequent in developing countries 
(McKhann, Cornblath et al. 1991, McKhann, Cornblath et al. 1993, Ye, Zhu et al. 2010, Ye, 
Wang et al. 2013). Diarrhea as trigger was significantly associated with AMAN in our cohort. 
We found that patients named a surprising variety of factors other than URTIs and 
diarrhea preceding GBS. These included trauma and surgery, herpes viridae infections, 
urinary tract infections and other traumatic events (myocardial infarction, delivery, status 
epilepticus) accounting for 11% of the total. In 25% of patients no trigger could be identified. 
This heterogeneity of triggering factors leading to a relatively stereotyped clinical picture and 
electrophysiology is difficult to explain solely on the basis of molecular mimicry (Ang, 
Jacobs et al. 2004). Whilst the evidence for molecular mimicry is reasonably strong for 
AMAN triggered by C. jejuni, the data is much less strong for AIDP. We propose that factors 
other than molecular mimicry could be important in GBS pathogenesis. 
7.2. A genetic basis of GBS pathogenesis? 
That genetics could play a role in GBS pathogenesis has been suggested by several 
reports of familial cases of GBS from different geographic areas (Wilmshurst, Pohl et al. 
1999, Geleijns, Brouwer et al. 2004, Aquil, Khan et al. 2011). Also, a link between GBS, 
CIDP and CMT disease has been suggested, based on reports of GBS and CIDP in the 
context of CMT (Dyck, Swanson et al. 1982, Odaka, Yuki et al. 2003). With the advent of 
large-scale GWAS it has also become clear that even diseases which do not show Mendelian 
inheritance patterns can have multiple genetic susceptibility markers scattered throughout the 
genome. 
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In the past, a number of genes have been studied in subjects with GBS, but genes 
reproducibly linked to GBS are scarce. Polymorphisms in HLA and CD1 have both been 
found in GBS cohorts, but these findings could not be confirmed in a larger sample 
(Gorodezky, Varela et al. 1983, Winer, Briggs et al. 1988, Wu, Zhou et al. 2012). A range of 
other genes, including IL-10, TNF-α, MMP9, Fc receptors and LPS receptors have been 
studied in single, un-replicated studies (see Chapter 2 and 6). 
Analysis of global gene expression of peripheral blood leukocytes in a Taiwanese cohort 
with GBS showed up- or downregulation of a range of genes (Chang, Chuang et al. 2012). 
Network analysis of these genes identified biological functions associated with inflammatory 
response, infectious disease, cell death, cellular development, haematological cell function 
and immune cell trafficking. These included MMP9 and ERK/MAPK signaling pathway 
genes, which are involved in the process of demyelination and cytokine production. This 
would be expected as it is generally accepted that macrophages and lymphocytes are 
activated and involved in the pathogenesis of GBS. 
Our approach to identify possible genetic factors for GBS pathogenesis was twofold: 
Firstly, we employed a candidate gene approach investigating KIRs and their HLA-
ligands in a cohort of GBS patients and also in patients with CIDP (see Chapters 2, 4 
and 5). Because of the complex interactions at the protein level, it is to be anticipated 
that these loci would not be identifiable on a GWAS. 
Secondly, we used a hypothesis-free approach by performing a GWAS on the 
same cohort of GBS patients, although the total number of subjects in the final 
analysis was reduced through quality control rejection of some samples (see Chapter 
6).  
7.2.1. KIRs and their HLA ligands in GBS and CIDP 
KIRs are important receptors on NK cells, controlling their activation. KIRs show 
considerable inter-individual polymorphism. We investigated the role of KIRs and their HLA 
ligands in cohorts of patients with GBS, CIDP and healthy controls.  
NK cells are important cells of the innate immune system and are of paramount 
importance in the early immune response against infection. Moreover, they are important in 
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linking the innate immune response to the adaptive immune system, predominantly by 
cytokine-mediated communication with T cells. NK cells could therefore have an important 
role in early GBS pathogenesis, but – rather surprisingly – have been only very incompletely 
studied. 
NK cell activation is regulated by a complex range of different receptors, the most 
important of which include the C-type lectin-like group CD94:NKG2 and the KIR group and 
their HLA ligands. Of these, KIRs constitute a large family of receptors with extensive 
polymorphisms and a large number of inhibitory and activating members. For a functional 
interaction both KIR and the specific HLA ligand needs to be present. In short, KIRs with a 
long cytoplasmic tail are inhibitory, whereas KIRs with a short tail are activating. KIRs are 
found on NK cells, but also on some subgroups of T lymphocytes, including γδ lymphocytes. 
Whilst no significant differences were found for the KIR gene frequencies themselves, we 
found significant difference when studying the HLA receptors of KIR and KIR/HLA 
functional pairs. We found that the inhibitory combinations KIR 3DL1/HLA-B Bw4-T and 
KIR 2DL1/HLA-C2 were significantly more frequently seen in GBS than in HC. Also, the 
activating combination 2DS2/HLA-C1 was less frequent in the GBS group, also producing a 
likely inhibitory effect on the NK cell population in GBS. The situation was reversed for 
2DL2/HLA-C1, where this inhibitory combination was less frequently seen in GBS patients. 
In CIDP patients, significant differences in KIR/HLA combinations were found for 
3DL1/HLA-B Bw4-I compared with healthy controls, but interestingly no such difference 
existed between the CIDP and GBS group for any of the KIR and HLA genes, nor their 
functional combinations. 
In summary, specific combinations of KIR and their HLA ligands can be either protective 
or risk factors for the development of GBS. We found some genetic evidence for NK cell 
involvement in the pathogenesis of GBS. Also of interest are the similarities in KIR/HLA 
gene frequencies found in GBS and CIDP groups, in contrast to healthy controls. 
7.2.2. A genome-wide association study of GBS 
Genome-wide association studies represent a hypothesis free method of studying genetic 
susceptibility of diseases. We performed a genetic analysis using the Omni-Express Bead 
Chip system, Illumina which tests for 650000 common polymorphisms. GWAS using SNP 
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data assume that common SNPs contribute to the risk of disease. Rare SNPs could also 
contribute to disease in the broad population. Because of the reliance on a large number of 
SNPs studied by this approach, successful GWASs need a large number of subjects and 
controls to give adequate statistical power. 
Our study used a relatively small sample of 230 patients, predominantly due to difficulties 
in identification and recruitment of subjects with this relatively rare disease. However, this 
was partially balanced by obtaining access to data from two large cohorts of controls 
(Australian OATS and RAINE, UK data from WTCCC). Likely due to the low number of 
cases we did not find any SNPs with genome-wide significance. However, we were able to 
identify 5 regions of interest with clusters of SNPs in linkage disequilibrium. All these 
regions showed SNPs with some evidence for LD in both control groups. The SNPs with 
highest significance in these regions were rs10519519, rs7663689, rs11151180, rs17095496 
and rs2302524. Some, but not all of these SNPs corresponded to known genes coding for 
proteins previously implicated in GBS pathogenesis. 
rs10519519 is located within the MYT1L gene, with no other closely linked genes. 
MYT1L is a pan-neuronal transcription factor, which has been linked to neuronal 
development in the CNS, but has not been studied so far in the PNS. Mutations and copy 
number variants in this gene have been seen in a range of psychiatric disorders.  
rs7663689 is in the promotor area of the IL15 gene, coding for the cytokine IL-15. This 
location raises the possibility of polymorphisms in the promotor region influencing 
expression of IL15 and therefore concentration of the final cytokine. IL-15 has structural and 
functional relationships with IL-2 and has multiple functions in cell development and in both 
the innate and adaptive immune system (Lodolce, Burkett et al. 2002).  
 rs2302524 is associated with a number of genes, including LGALS7 and LGALS4, ECH1, 
HNRPL, SIRT2, NFKBIB, SARS2, MRPS2 and FBXO17. Of particular interest in this region 
is NFKBIB, which is a member of the NF-κB inhibitor family IκB (Woronicz, Gao et al. 
1997). NF-κB is a key transcription factor in immune regulation and is under complex control 
by a range of different factors (Gilmore 2006).  
rs17095496 and rs11151180 are not linked to any genes known to have a role in the 
immune system. rs17095496 is in the vicinity of 4 genes (DACT1, DAAM1, C14orf135 and 
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DHRS7), whereas the gene most closely linked with rs11151180 is CDH7, a gene related to 
migration of malignant cells (Winklmeier, Contreras-Shannon et al. 2009). 
 Of interest were a number of relevant negative results: We found no SNPs in linkage 
disequilibrium in the HLA region, which has been found to be strongly associated with a 
range of other autoimmune diseases. Furthermore, we did not find associations with 
candidate genes which had been previously studied in GBS. The lack of HLA association is a 
clear difference between GBS and other autoimmune diseases. This opens the possibility of 
other pathogenic mechanisms to be explored. 
7.3. NK cells in the pathogenesis of GBS 
The absence of a specific linkage disequilibrium in the HLA region in our GWAS is of 
interest as this region is closely linked to genetic susceptibility in virtually every autoimmune 
disease studied so far. This raises the possibility of the innate immune system playing a 
substantial role in GBS pathogenesis. This has been incompletely studied so far. 
The finding of KIR/HLA ligand polymorphisms as well as IL15 as region of interest in 
the GWAS points towards a possible role of NK cells in the pathogenesis of GBS.  
NK cells as key factors in GBS would be consistent with the known role of NK in the 
early immune response to infection. NK cells are of paramount importance in linking an 
initial response to infections with subsequent adaptive immune system activation. We have 
suggested that the aberrant response of the adaptive immune system that causes GBS occurs 
early in the disease course, with rapid reconstitution of normal tolerance once this error has 
been “recognized” (see Appendix A).   
In spite of this theoretical link, the role of the innate immune system in GBS pathogenesis 
has not been studied in depth. Studies so far include the finding of macrophage infiltration of 
peripheral nerves mediating demyelination (Prineas 1981). Yoshii et al. found decreased NK 
cell activity early in the disease course, with recovery of normal function after plasma 
exchange (Yoshii and Shinohara 1998). The cytokine TNFα has been studied in both EAN 
animals and in human subjects with GBS. Zhu et al. found TNFα production to be 
upregulated in rats with EAN (Zhu, Mix et al. 2003, Zhu, Mix et al. 2004). Moreover, TNFα 
has been found to be upregulated in the acute phase of AMAN (Deng, Yang et al. 2008). 
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Finally, TNFα gene polymorphisms have been consistently found to be associated with GBS 
(Wu, Zhou et al. 2012), but could not be seen as a region of interest in our GWAS (see 
Chapter 6).  
Based on our findings, we propose that an aberrant response of NK cells is of paramount 
importance in the early development of GBS. Namely, we suggest that inhibition of normal 
NK cell response against infected cells (i.e. by KIR/HLA interaction, but likely also by other 
factors) leads to subsequent aberrant adaptive immune response to peripheral nervous system 
tissue in GBS (see Figure 7.1). There are well established links of NK cells to the adaptive 
immune system, namely T cells (Zingoni, Sornasse et al. 2005, Zingoni, Ardolino et al. 
2012). 
An interesting alternative explanation of the role of IL-15 in the pathogenesis of GBS – 
especially in the context of this thesis – is its link to the NF-κB pathway (Giron-Michel, 
Caignard et al. 2003). IL-15 has been shown to induce activation of NF-κB in lymphoid 
progenitor cells and other cell types. Also, macrophage mediated stimulation of CD4+ T 
lymphocytes has been described in rheumatoid arthritis (Ruckert, Brandt et al. 2009). This is 
speculative at present, but further work in this area could be of interest. 
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Figure 7.1 - Functional model of NK cell function in GBS pathogenesis (see Chapter 4) 
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7.4. Downstream mechanisms 
Pathological studies and functional evidence clearly point towards a role of the adaptive 
immune system in the active demyelination found in the acute phase of GBS (Prineas 1981, 
Scelsa, Ghali et al. 2004, Csurhes, Sullivan et al. 2005, Csurhes, Sullivan et al. 2005, Chi, 
Wang et al. 2007, Cencioni, Notturno et al. 2009). Indeed, we found genetic evidence of 
factors intricately involved in activation of the adaptive immune system, mainly in relation to 
genes regulating function of NF-κB in our GWAS.  
Rs2302524 is associated, amongst other genes, with NFKBIB, a gene coding for IκB. IκB 
is of paramount importance in cell activation, as it releases NF-κB upon cytokine-induced 
phosphorylation, allowing NF-κB to translocate into the nucleus (Mercurio, Zhu et al. 1997). 
Interestingly, DACT1, which is associated with rs17095496, has been associated with 
gastric cancer by inhibition of the NF-κB pathway (Wang, Kang et al. 2012). However, 
whilst expressed by immune cells, it has not been studied in the context of immune function. 
NF-κB has been found to be increased in macrophages in sural nerve biopsies, whereas 
IκB was upregulated in both macrophages and T cells (Andorfer, Kieseier et al. 2001). 
Moreover, translocation of NF-κB into the cell nucleus of inflammatory cells has been 
demonstrated in both CIDP and GBS, but was not seen in other neuropathies (Mazzeo, 
Aguennouz et al. 2004). 
We propose that once the dysregulated immune response to the peripheral nervous system 
has been triggered by the innate immune system, further protective safety mechanisms on the 
level of the adaptive immune system are usually put in place. To enable the specific attack 
against myelin protein, further lack of inhibition, most likely of T lymphocytes, needs to take 
place before GBS can develop. There have been reports of reduced regulatory T cells in GBS 
(Harness and McCombe 2008). This two-tiered dysfunctional response would explain the 
relative rarity of recurrent GBS (Kuitwaard, van Koningsveld et al. 2009, Olivier, Laribi et al. 
2010). 
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7.5. GBS - an autoimmune disease? 
GBS is thought to be immune mediated, but there must be some questions as to whether it 
represents a classical autoimmune disease. Evidence for an autoimmune process is 
predominantly based on the findings of an inflammatory pattern on nerve biopsies in patients 
with acute GBS and the finding of auto-antibodies in some subforms of GBS. Also, there is 
some evidence of activation of the immune system at disease onset. Finally, a disease with a 
range of clinical and pathological similarities to GBS - Experimental Autoimmune Neuritis 
(EAN) - can be induced in animals by vaccination with nerve proteins. Interestingly, an 
illness indistinguishable from GBS has been involuntarily induced in humans after 
vaccination with substances derived from animal brain tissue and vaccination against 
influenza virus (Hemachudha, Griffin et al. 1988, Salemi and D'Amelio 2010, Baxter, Lewis 
et al.). 
However, whilst having some similarities with autoimmune diseases like SLE or 
myasthenia gravis, GBS differs in a number of important aspects. These include the male 
predominance, self-limited monophasic course and being commonly triggered by infection. 
Also, GBS does not respond to treatment with steroids (Hughes, Newsom-Davis et al. 1978, 
Hughes, Swan et al. 2010). Finally, most autoimmune diseases show a clear genetic link to 
immune genes – most commonly HLA - which has not been consistently demonstrated in 
GBS (see Chapter 7.2).  
This has led to a number of alternative hypotheses for the pathogenesis of GBS: 
a) Steiner et al. proposed that GBS is caused by a transient immune deficiency induced 
by the pathogens involved in the triggering infection (Steiner, Rosenberg et al. 2010). 
His hypothesis would argue against an individual, genetically determined 
susceptibility for GBS.  
b) Hardy et al. argued that GBS is caused by the activation of pre-existing auto-reactive 
lymphocytes getting activated by potent danger signals and antigen presentation of 
APCs, thus causing an attack on peripheral nerve. This is followed by rapid 
reconstitution of normal immune tolerance subsequently, explaining why GBS rarely 
recurs (see Appendix A). 
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7.6. GBS – an autoinflammatory disease? 
An alternative approach to interpreting our data is to assess whether GBS could be an 
autoinflammatory disease, rather than an autoimmune disease.  
As discussed previously, GBS does not meet all criteria for autoimmune diseases (see 
Chapter 7.5). As discussed in Chapter 1, autoinflammatory diseases differ from autoimmune 
diseases in a number of important aspects, and several of these aspects could be linked to 
GBS in our study:  
- The inflammatory response is largely mediated by the innate immune system. We 
found two independent links of genetic determinants of NK cell function, the 
KIR/HLA system and IL-15, to be important in GBS. 
- NF-κB is an important factor in both autoimmunity and AIDs. We found 2 genes, 
NFKBIB and DACT1, within areas of interest in our GWAS, which are regulators of 
NF-κB function. 
On the other hand several facts argue against GBS being an autoinflammatory disease. 
These include the findings of anti-ganglioside antibodies in some subforms of GBS, the 
presence of T lymphocytes on biopsies in patients with GBS and the absence of raised 
inflammatory markers, like ESR and CRP, in the serum of patients with acute GBS. 
In summary, GBS does not neatly fit into either the group of autoimmune diseases or into 
autoinflammatory diseases, and might indeed be in a class of its own.  
7.7. Target organ susceptibility 
 The finding of MYT1L, a gene related to neuronal development, in this GWAS of GBS 
patients raises the possibility of target organ susceptibility being an important factor in GBS 
pathogenesis. Target organ susceptibility has been raised in the past as a possible factor in a 
range of autoimmune diseases, but has never been consistently proven. Indeed, the recent 
large GWAS of MS patients did not identify a single gene related to neuronal function or 
development (Beecham, Patsopoulos et al. 2013).  
However, both GBS and CIDP have been described in the context of disorders of 
peripheral nerve myelination, namely CMT. Inflammatory changes on nerve biopsy and 
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response to immune therapy have all been seen in proven CMT1A (Dyck, Swanson et al. 
1982, Vital, Vital et al. 2003, Ginsberg, Malik et al. 2004). Moreover, GBS has been 
described in several patients with both axonal and demyelinating forms of CMT and 
hereditary spastic paraparesis (Odaka, Yuki et al. 2003, Alhashel, Alshubaili et al. 2004, 
Münch, Epplen et al. 2008).  
Target organ susceptibility could be the final step in the development of GBS, possibly by 
exposure of antigens to activated immune cells, or by enabling penetration of immune cells 
through the blood-nerve barrier. 
 
7.8. Future directions 
There are several avenues for further research into the pathogenesis based on the findings 
presented in this study.  
The increased incidence of subjects with GBS with age is intriguing. It would be 
interesting to investigate the role of immunosenescence and its role in the innate and adaptive 
immune response to infection and its link to GBS (Solana, Tarazona et al. 2012, Ma and Fang 
2013). Furthermore, there are gender differences in immunosenescence which could account 
for the sex ratio of GBS.  
NK cell function in GBS could be further studied using functional assays of NK cell 
activity, including the role of cytokines (i.e. IL-2, IL-15, IL-18, IFNγ) as well as cytotoxicity. 
Parallel to this, polymorphisms in other genes related to NK cell function could be studied, 
including CD94:NKG2 receptors. 
Much work remains to be done following the GWAS of GBS. One would expect that with 
expansion of the sample size further genetic loci of interest could be identified, similar to the 
experience in the large GWASs in MS. The genetic loci identified will need to be reproduced 
in an independent cohort of subjects with GBS. Finally, functional studies of the proteins 
coded for by the identified genes could lead to a better understanding of GBS, and possibly 
could direct investigations into new therapies for this illness. 
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Appendix A – Guillain Barré Syndrome: Modern theories 
on Etiology 
 
 
 
This review was written in collaboration with Dr. Todd Hardy and Dr. Stephen Reddel 
from Concord Hospital, Sydney. It summarizes some of the theoretical groundwork for this 
thesis. 
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Appendix B - Genetics of Guillain Barré Syndrome (GBS) and 
Chronic Inflammatory Demyelinating 
Polyradiculoneuropathy (CIDP):  current knowledge and 
future directions 
 
 
Blum S and McCombe PA 
 
This review outlines the current knowledge of genetic factors in GBS pathogenesis. The 
manuscript has been accepted for publication in the Journal of the Peripheral Nervous System in 
April 2014. It was written in collaboration with Prof. Pamela McCombe.  
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Abstract 
Guillain Barre Syndrome (GBS) and chronic inflammatory demyelinating 
polyradicloneuropathy (CIDP) are thought to be autoimmune diseases, which are thought to arise 
after exposure to environmental triggers in genetically susceptible individuals.  The evidence that 
GBS has a genetic basis includes the finding of occasional families with GBS. In CIDP there is 
an overlap with hereditary neuropathy. There have been many attempts to find an HLA 
association with GBS and CIDP with little success. These studies are reviewed. There have been 
studies of other plausible genes in GBS and CIDP and the role of these genes in GBS and CIDP 
and the data from these genetic studies is reviewed. Some of the genes that have been studied are 
immune related and some others have nervous system effects. The studies are limited by small 
numbers. Some of the genes show association with disease severity rather than disease 
susceptibility. The need for more detailed molecular studies of the role of HLA molecules and 
the need for modern genetic approaches to GBS and CIDP is explained.  
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(1) Introduction  
 
Guillain Barré syndrome (GBS) is a severe acute polyradiculoneuropathy.  Several sub-groups  
of GBS have been described, with corresponding diagnostic criteria (Asbury and Cornblath, 
1990; Hadden et al., 1998). Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) 
is characterized pathologically by inflammation and demyelination (Asbury et al., 1969).  More 
recently, acute motor axonal neuropathy (AMAN), where there is primary axonal dysfunction 
has been described (McKhann et al., 1993). Another variant is acute motor and sensory axonal 
neuropathy (AMSAN) which may be a severe form of AIDP. There are other variants of GBS,  
such as  Miller Fisher Syndrome (MFS) (Winer, 2011), where the pathology is more focal.  
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic or relapsing 
motor and sensory neuropathy, with inflammation and demyelination of the peripheral nerve 
(McCombe et al., 1987).  GBS and CIDP  are  thought to be immune mediated (Hardy et al., 
2011) and abnormalities of T cells, antibodies and gene expression have been reported in the 
peripheral blood of subjects with GBS and CIDP (Chang et al., 2012).   
 
GBS and CIDP fulfil most of the criteria for autoimmune diseases (Rose and Bona, 1993), 
except for the lack of a clear HLA association, lack of a clear target antigen and male 
predominance.  Autoimmune diseases are considered to arise in genetically susceptible people 
after exposure to environmental triggers.  The environmental triggers for GBS and CIDP are 
commonly infections, but the genetic basis of GBS and CIDP is unknown. Genetic variation in 
immune related genes or in the peripheral nerves could contribute to the risk of acquiring disease 
and to severity of disease. In diseases, such as multiple sclerosis MS, where extensive genetic 
studies have been performed, there are associations with many genes that have a small risk  
(Sawcer et al., 2011; Beecham et al., 2013) .   In this review, GBS and CIDP are considered 
separately, although there is considerable overlap in the pathology and there are patients who 
develop CIDP after a first episode that is typical of GBS (Ruts et al., 2010). We review the 
evidence that there is a genetic basis to GBS and CIDP, the data obtained from studying 
candidate genes and discuss future options for investigation. The numbers of subjects in each 
study are listed in the tables. 
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(2) Evidence for genetic basis to susceptibility to GBS and CIDP: 
If there were a genetic basis to GBS and CIDP, it might be expected that disease would occur 
in families. There have been a number of reports of familial GBS  (Saunders and Rake, 1965; 
MacGregor, 1965; Wilmshurst et al., 1999; Naik et al., 2012; Senanayake et al., 2010; Barzegar 
et al., 2012) including one of siblings born to a consanguineous marriage (Aquil et al., 2011).  
There has also been a report of MFS occurring simultaneously in two siblings (Peeples, 2011).   
The largest report from The Netherlands described  12 families with GBS (Geleijns et al., 2004a) 
and found that among siblings of subjects with GBS, the observed incidence was 2.6-fold 
increased compared to the expected incidence (Geleijns et al., 2004a). These studies support a 
possible role for genetic factors in GBS. Studies investigating disease prevalence in twins can be 
used to evaluate the genetic predisposition, but there are no such studies in GBS or CIDP.   
 
There is one report of familial CIDP (Gabreels-Festen et al., 1986). However, there is 
considerable difficulty in making such a diagnosis because familial demyelinating neuropathy 
would very likely be diagnosed as a hereditary demyelinating neuropathy. There have been 
clinical studies that indicate an overlap between hereditary and inflammatory demyelinating  
neuropathy; some patients with  inherited neuropathy are responsive to treatment with 
corticosteroids, suggesting a super-imposed inflammatory component  (Dyck et al., 1982), some 
subjects with Charcot Marie Tooth disease (CMT) are found to have inflammatory changes on 
biopsy (Vital et al., 2003), including seven  subjects with CMT1A and one with CMTX 
(Ginsberg et al., 2004), there is a report of CIDP in a subject with CMT1A (Rajabally et al., 
2000) and children with CMT1A have been reported with superimposed inflammatory 
neuropathy (Desurkar et al., 2009).  In GBS, there are  reports of GBS in a subject with CMT1A, 
caused by PMP22 duplication (Munch et al., 2008), in subjects with hereditary neuropathy with 
pressure palsy, due to PMP22 gene deletion (Korn-Lubetzki et al., 2002; Remiche et al., 2013), 
and  axonal GBS in a patient with axonal Charcot Marie Tooth (CMT) disease (Odaka et al., 
2003).   Another degenerative neurological disease that has been associated with GBS is 
hereditary spastic paraparesis (Alhashel et al., 2004).  Hereditary amyloid neuropathy due to 
mutations of transthyretin has been found in subjects thought to have CIDP (Mathis et al., 2012).  
The finding of GBS in families supports a role for genetics in GBS. The finding of inflammatory 
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neuropathy in people with inherited neuropathies also could suggest that abnormalities in the 
peripheral nerve could make people more vulnerable to superimposed inflammation.  Twin 
studies and studies of the prevalence of disease in relatives can be used to evaluate the genetic 
predisposition.  There are no twin studies in GBS and CIDP.  The study of familial GBS found 
that among siblings of subjects with GBS, the observed incidence was 2.6-fold increased 
compared to the expected incidence (Geleijns et al., 2004a). 
 
Another genetic factor that is associated with GBS is gender. Being male, which requires 
carriage of at least one Y chromosome, is a substantial risk factor for GBS (Blum et al., 2013b). 
Male predominance is an unusual feature for an autoimmune disease, which generally are more 
prevalent in females (McCombe et al., 2009). The Y chromosome encodes at least 27 proteins, 
some of which are confined to the testes whilst others are more widely expressed (Skaletsky et 
al., 2003). The genetic risk of being male can be due to the effects of male gonadal hormones but 
also could be related to the Yaa gene cluster, which predisposes to autoimmunity in mice, and is 
a translocation of a cluster of X chromosome genes, including the Tlr7 gene (Subramanian et al., 
2006), which could also be linked to the increased incidence in males. 
 (3) Specific genes associated with GBS and CIDP 
In GBS and CIDP there have been studies of a number of candidate genes that could 
plausibly be involved in the pathogenesis of GBS and CIDP.  Below we describe studies that 
have examined the effects of genotype in the development of GBS and CIDP, on the severity of 
disease and on response to treatment, particularly IVIG. The HLA genes are listed in Tables 1 
and 2, and the other genes are summarized in Table 3. 
 
The MHC is a highly polymorphic region that contains many genes that are of importance to 
immunity (Trowsdale and Knight, 2013). HLA associations are common in autoimmune disease 
and the presence of an HLA association is one of the criteria for diagnosis of an autoimmune 
disease  (Rose and Bona, 1993).  Disease associations are reported with single genes, most 
commonly with the HLADRB1 gene, but often with extended haplotypes of linked genes. As 
shown in Tables 1 and 2 there was an expectation that there would be a HLA association with 
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GBS and CIDP and many studies have been undertaken.  Early studies (using serological 
methods) found no HLA associations with GBS (Stewart et al., 1978) (Latovitzki et al., 1979) 
(Hafez et al., 1985), except for one  from the USA of subjects with GBS found a slight reduction 
in the frequency of HLA A11   (Kaslow et al., 1984).    Studies from the UK found no 
association of HLA Class I or class II genes with GBS (Winer et al., 1988) and from Sweden 
found no association with MHC class II molecules (Hillert et al., 1991). One study in Mexico 
found that GBS was associated with carriage of HLA-DR3 (Gorodezky et al., 1983). A study 
from The Netherlands found no association of HLA DRB1 or HLA DQB1 with GBS (Geleijns et 
al., 2005b).  A study from North India reported no association of GBS with HLA DRB1, but 
increased HLA DQ1*06 in GBS and that HLA DRB1*0701 was increased in those with 
preceding infection (Sinha et al., 2010). A study from Japan showed no association with MHC 
class I or MHC class II genes (Ma et al., 1998b) and one from China showed no association with 
MHC class II molecules (Li et al., 2000). 
When GBS patients from China were classified as having AIDP or AMAN, it was found that 
certain DQB1 molecules are associated with AIDP but not axonal neuropathy (Magira et al., 
2003).  Another study from China showed that HLA DRB1*13 was increased in subjects with 
AIDP compared to AMAN (Monos et al., 1997) .   A study from Japan found a tendency for 
increased HLA DRB1*0803 in subjects with GBS associated with Campylobacter jejuni 
infection (Ma et al., 1998b) and a study from Greece reported  GBS associated with 
Campylobacter jejuni infection in a subject who was positive for HLA-B35 and HLA-DR8 
(Chatzipanagiotou et al., 2003).  A study from the United Kingdom found no association of 
MHC class II alleles with susceptibility to GBS or MFS, but increased HLA DQB1*03 in 
subjects with GBS or MFS with preceding Campylobacter jejuni infection (Rees et al., 1995).  
 
HLA C molecules can be assigned to two groups (C1 and C2) based on the presence of 
Asparagine or Lysine at position 80. Patients with GBS are significantly more likely to carry 
HLA-C2 than controls (Blum et al., 2013a). This is important because this polymorphism 
determines interaction with Killer immunoglobulin-like receptor (KIR) molecules, which are 
crucial for NK cell activation.. HLA Bw4 can be classified according to the presence of 
Threonine or Isoleucine at position 80. Patients with GBS are significantly more likely to carry 
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Isoleucine at this position than controls (Blum et al., 2013a) and again this is important in KIR 
binding.  
 
In CIDP, one early study found increased frequency of carriage of the HLA-Aw30, HLA B8 
and HLA Dw3 (Stewart et al., 1978) and a similar finding was reported from another two small 
studies (Adams et al., 1979;Vaughan et al., 1990).  A later study found increased HLA DR2 
(Feeney et al., 1990).  A study from The Netherlands found no HLA associations with CIDP  
(van Doorn et al., 1991). We found a significant association of CIDP with HLA DR2, which is 
stronger in women than men (Greer et al., 2004) .  In Tunisia there is a report of an association of 
CIDP with HLA DRB1*13 allele (Mrad et al., 2013).  
 
The T cell receptor recognizes antigen presented by HLA molecules, and genetic variation in 
the T cell receptor can influence immune reactivity. There is evidence of T cell involvement in 
the pathogenesis of GBS and CIDP, with T cell infiltration into the peripheral nerves CIDP 
(Schmidt et al., 1996; Zweiman et al., 1983) and reports of T cell reactivity to peripheral nerve 
antigens (Csurhes et al., 2005b; Csurhes et al., 2005a).  In CIDP, there are studies that indicate 
that the T cell repertoire is altered in CIDP, mostly in the CD8 population (Schneider-Hohendorf 
et al., 2012;Mausberg et al., 2013).  Another study found no association of T cell receptor genes 
with GBS, although there was a trend to an influence on the severity of disease (Ma et al., 
1998b).   There are no studies of T cell receptor genes in CIDP.  
 
Glycolipid antigens, such as gangliosides, are the target of antibodies found in some forms of 
GBS and CIDP. Production of antibodies usually requires T cell help. In addition, in GBS there 
are reports of T cells which are reactive with GM1 (McCombe and Csurhes, 2010). Gangliosides 
are presented to T cells in association with CD1 (Porcelli et al., 1998;Ulrichs and Porcelli, 2000) 
and so it would seem likely that CD1-restricted pathways would be important in disease 
pathogenesis. There are five closely related CD1 genes (CD1A-CD1E), and there is allelic 
variation in CD1A, CD1D and CD1E (Porcelli et al., 1998;Han et al., 1999). In GBS, one small 
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study found an association of susceptibility of GBS with CD1 polymorphisms (Caporale et al., 
2006), but another study of did not confirm this (Kuijf et al., 2008).  A meta-analysis of data 
from 1590 cases of GBS found no significant association with CD1A or CD1E polymorphisms 
(Wu et al., 2012). In CIDP, one small study found no association with CD1 polymorphisms (De 
Angelis et al., 2007).   
 
Killer immunoglobulin-like receptors (KIRs) constitute the largest family of human NK 
receptors, with multiple inhibitory and activating members showing extensive 
polymorphisms(Middleton and Gonzelez, 2010). Generally, KIR with a long cytoplasmic tail 
(i.e. KIR 2DL1) are inhibitory, whereas KIR with a short tail are activating (i.e. KIR 2DS1). 
KIRs are found on NK cells, but also on subgroups of CD4+ and CD8+ T lymphocytes (van et 
al., 2004). For a functional interaction both KIR and its specific Class 1 HLA-ligand need to be 
present. The importance of these interactions has been shown in a number of diseases, e.g. in 
multiple sclerosis, where the KIR 2DS1 / HLA-C2 pair appears to be a risk factor (Fusco et al., 
2010). KIR and their HLA ligands have also been found to have a role in susceptibility to a range 
of viruses, but have not been studied for the infective agents more commonly associated with 
GBS (Kulkarni et al., 2008). The intricacies of the KIR/HLA interaction have been reviewed 
elsewhere (Rajalingam, 2012;Boyton and Altmann, 2007).   We recently reported that the 
frequency of KIR genes did not differ between GBS patients and controls. However, KIR 
molecules need HLA ligands for signaling, and we found that GBS patients lacked inhibitory 
HLA ligands for their KIR ligands (Blum et al., 2013a).  We have found similar results in CIDP 
(unpublished data). The importance of an alteration in KIR/HLA combinations in GBS and CIDP 
is that it suggests a role for innate immunity.  
 
Interleukin 10 (IL10) is a cytokine that has a role in the regulation of innate immunity (Ng et 
al., 2013) and is thought to be anti-inflammatory. IL10 has numerous polymorphisms that have 
been implicated in disease susceptibility (Wang et al., 2013). One experimental study found that 
transgenic mice with over-expression of IL10 develop a macrophage mediated neuropathy that 
resembles CIDP (Dace et al., 2009). Polymorphisms in the promoter regions of IL10 were 
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associated with susceptibility to GBS, but not with disease severity (Myhr et al., 2003). There are 
no studies of IL10 polymorphisms in CIDP. Thus although IL10 is an attractive candidate gene 
for autoimmune disease, there is little evidence as yet to support a role in GBS and CIDP. 
 
Tumor necrosis factor (TNF) is a cytokine produced mainly by macrophages and monocytes. 
It interacts with the TNF receptor to influence immunity and inflammation (Chen and Goeddel, 
2002). Circulating levels of TNF are increased in GBS (Radhakrishnan et al., 2003).  Episodes of 
GBS have occurred after the use of anti-TNF therapy in rheumatology (Shin et al., 2006). One 
study found that polymorphisms of TNF were not associated with the development of GBS but 
were associated with disease severity (Geleijns et al., 2007). A study from China showed that 
TNF polymorphisms were associated with the AMAN and AMSAN forms of GBS (Jiao et al., 
2012;Zhang et al., 2007). One study from Japan found that TNF polymorphisms were linked to 
GBS (Ma et al., 1998a), while another  showed an association  of TNF polymorphisms with 
axonal forms of GBS and higher levels of circulating TNF (Prasad et al., 2010) . A meta-analysis 
of 1590 cases of GBS found that polymorphisms of TNFA 308G/A were significantly associated 
with risk of GBS (Wu et al., 2012). There are no studies of TNF in CIDP. Thus there is 
considerable evidence that polymorphisms of TNF can influence susceptibility to GBS. 
 
Matrix metalloproteinases (MMP) can play a role in inflammation, and possibly can be 
involved in opening the blood nerve barrier. MMP9 is expressed in the peripheral nerve in GBS 
(Kieseier et al., 1998) and in CIDP (Leppert et al., 1999). MMP9 gene expression is upregulated 
in peripheral blood leukocytes in GBS (Chang et al., 2012) and elevated levels of MMP9 are 
found in GBS (Nyati et al., 2010a). A study of polymorphisms of MMP9 found that these were 
not associated with the development of GBS but were associated with disease severity (Geleijns 
et al., 2007). There are no studies of MMP9 polymorphisms in CIDP.  
Fc receptors bind immunoglobulin molecules in immune complexesThere are 
polymorphisms of these receptors and these have been correlated with autoimmune and 
infectious disease such as systemic lupus erythematosus (SLE) (Zidan et al., 2013) and Graves 
disease (Yesmin et al., 2010).  In CIDP there is impaired expression of the inhibitory receptor 
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FcIIB (Tackenberg et al., 2009a) and this is restored by treatment with IVIG (Creange et al., 
2003).  A study from North India found that FcgammaR IIA and Fcgamma IIIA, but not 
FCgamma RIIIB were associated with GBS (Sinha et al., 2010).  In a study  from Norway found  
no association of  FcgammaR IIA, Fcgamma IIIA or FCgamma RIIIB  with GBS, but 
polymorphisms of the FCgamma RIIIB  were found to influence the severity of GBS (Vedeler et 
al., 2000). The FcgammaRIIIa gene was associated with severity of GBS in studies from United 
Kingdom and The Netherlands (van Sorge et al., 2005). However, a meta-analysis of data from 
1590 cases of GBS found no significant association with FcgammaR IIA, Fcgamma IIIA or 
FCgamma RIIIB (Wu et al., 2012).  The rare -386C/-120A FcgammaRIIB promoter 
polymorphism resulting in reduced promoter activity previously associated with autoimmune 
phenotypes was overrepresented in CIDP (Tackenberg et al., 2009a).  
 
FcR-like molecules (also known as FcR homologues) are structurally similar to Fc receptors 
but do not bind immunoglobulin. These molecules are expressed on B cells and appear to have 
an immunoregulatory function (Davis, 2007). FcR like 3 is expressed on marginal zone B cells 
(Won et al., 2006). Mutations of FcR-like 3 have been associated with autoimmune diseases  
(Yang et al., 2013).  Polymorphisms of the FcRL3 gene gave been linked with incidence of GBS 
in study of Han Chinese subjects   (Sang et al., 2012).  There are no studies of FcRL3 genes in 
CIDP.   
 
Fas  cell surface death receptor (CD95) is involved in apoptosis (Wajant, 2002) and plays a 
role in killing of target cells and lymphocyte homeostasis (Strasser et al., 2009).  Fas mediated 
apoptosis is impaired in subjects with CIDP compared to controls (Comi et al., 2006)  and is 
impaired in CIDP compared to GBS subjects (Comi et al., 2009). In a study from the 
Netherlands, Fas polymorphisms were not associated with the development of GBS but were 
associated with the  development of antiganglioside antibodies (Geleijns et al., 2005a). There are 
no studies in CIDP.  
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Toll-like receptors (TLR) detect molecules released by pathogens. Activation of these 
receptors leads to intracellular signaling of cells of the innate immune system (Lester and Li, 
2013). TLR4 is a toll-like receptor that responds to lipopolysaccharide. Polymorphisms of TLR4 
have been implicated in susceptibility to various diseases including cancer (Zhang et al., 2013). 
Since GBS and CIDP frequently occur after infections, it is expected that signaling through the 
innate immune system would be involved in the pathogenesis.  A Dutch found that 
polymorphisms of TLR 4 were not associated with GBS (Geleijns et al., 2004b). However, a 
study from North India found that TLR4 polymorphisms were associated with risk of GBS 
(Nyati et al., 2010b).  There are no studies in CIDP.   
 
CD14 is a glycosylphosphatidylinositol (GPI)-anchored receptor known to serve as a co-
receptor for several Toll-like Receptors (TLRs) both at the cell surface and in the endosomal 
compartment (Zanoni and Granucci, 2013). CD14 is involved in the response to LPS  (Ziegler-
Heitbrock and Ulevitch, 1993). Given the frequent occurrence of GBS and relapses of CIDP after 
infection, a role molecules involved in the innate immune response seems possible. A Dutch 
study found that polymorphisms of CD14 were not associated with GBS (Geleijns et al., 2004b). 
There are no studies of CD14 in CIDP. 
 
Glucocorticoid receptors (GR) act directly in the nucleus to regulate gene transcription, or  
interact with other transcription factors  (Ratman et al., 2013). GR are involved in the immune 
response (Pandolfi et al., 2013).  There are polymorphisms of the GR genes that influence the 
sensitivity of the GR and susceptibility to rheumatoid arthritis (van Oosten et al., 2010).  In GBS, 
one study found that polymorphisms of the GR are not linked to susceptibility but are related to 
the clinical course (Dekker et al., 2009). There are no studies in CIDP.   
 
T cell specific adaptor proteins function in signal transduction in T cells (Lapinski et al., 
2009) and play a role  in the regulation of autoimmune disease (Marti et al., 2005). This gene has 
been associated with MS (Dai et al., 2001;Lorentzen et al., 2008) . One study showed that a 
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polymorphism of the SH2D2A T cell adaptor protein was associated with CIDP in a study of 48 
patients and healthy controls (Notturno et al., 2008).  There are no studies of this gene in GBS.  
 
Alpha-1 antitrypsin (SERPIN1A) is a serine protease inhibitor.  It also has anti-inflammatory 
properties (Bergin et al., 2012). In an old study, using protein electrophoresis distinguish alpha1 
antitrypsin alleles, one study found an association of with GBS  and CIDP (McCombe et al., 
1985) . Since alpha-1 antitrypsin plays a role in protease inhibition and in immunology, it would 
be worth further investigation with modern genetic approaches. 
 
Transient axonal glycoprotein-1 (TAG-1) (contactin 2) is a membrane-linked glycoprotein 
that functions as a cell adhesion molecule. It is found in the juxtanodal region, which is a key 
region of pathology in inflammatory neuropathy (Pollard and Armati, 2011). It also has a role in 
endocytosis (Dang et al., 2012).  There are no studies of TAG-1 in GBS. In CIDP, 
polymorphisms of TAG1 are correlated with responsiveness to IVIG in Japanese subjects with 
CIDP (Iijima et al., 2011).  There was no association with CIDP in a small series of Chinese 
subjects with CIDP (Pang et al., 2012).  
 
IgG heavy chain allotype (Gm markers) are markers of variability of the heavy chains of IgG.  
Molecular studies have subsequently shown these to be due to polymorphisms of the heavy chain 
of immunoglobulin genes (Grubb, 1995; Lefranc and Lefranc, 2012).  Allelic variation of these 
genes leads to differences in immune function and disease associations (Oxelius and Pandey, 
2013). In GBS and CIDP, there has been one study showing an association of Gm allotypes with 
CIDP but not with GBS  (Feeney et al., 1989) while and another  showed no association  (Pandey 
et al., 2005).  Immunoglobulin kappa light chain allotypes (KM markers) are similar to Gm 
markers and are due to polymorphisms of the Kappa light chain of immunoglobulin molecules. 
One study showed that KM allotypes are associated with autoantibodies to GD1a in GBS, but not 
with susceptibility to disease (Pandey et al., 2005). 
T  
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Apoliprotein E (Apo E) is involved in cholesterol transport and is important in neuronal 
biology (Holtzman et al., 2012).  Apo E has three major alleles e2, e3, and e4 (Seripa et al., 
2011). It is well known to be a risk factor for Alzheimer's disease (Kline, 2012). Recently ApoE 
has been found to have an immunomodulatory role in GBS and EAE (Zhang et al., 2010).  One 
study found that ApoE genotype did not influence the outcome after GBS (Pritchard et al., 2003).  
There are no studies in CIDP.   
 
CD59 (MAC-inhibitory protein) is a molecule that prevents the activation of complement and 
the formation of the membrane attack complex (Tandon et al., 1992). CD59 has a number of 
polymorphisms.  There is evidence of complement deposition in nerves in GBS  (Hays et al., 
1988)  and of activation of the  membrane attack complex in GBS  (Koski et al., 1987).  CD59 is 
upregulated in peripheral nerves in GBS, possibly as a compensatory response to complement 
activation (Wanschitz et al., 2003).  Eculizumab, a monoclonal antibody that block formation of 
the membrane attack complex, is effective in treating experimental autoimmune neuritis, the 
animal model of GBS (Halstead et al., 2008).  There are no disease association studies of GBS or 
CIDP with CD59. However, there is a report that a patient with CD59 deficiency had associated 
CIDP (Nevo et al., 2013). This is intriguing and suggests that a genetic study would be of 
interest. 
 
In summary, a number of plausible candidate genes have been investigated in GBS and 
CIDP. Some of these have been replicated but in general these are only single studies of small 
numbers of subjects. The genes that have shown an association with GBS and CIDP have been 
implicated in the pathology of the disease.  Many of the candidate genes have been implicated in 
other autoimmune diseases. In autoimmunity there is considerable evidence of genetic 
susceptibility to specific autoimmune disease. These are also reports of a familial susceptibility 
to autoimmunity in general (McCombe et al., 1990a).  However, GBS and CIDP have some 
features that are atypical for autoimmune disease and it is possible that GBS and CIDP will have 
a different genetic background. The strong relationship of GBS and CIDP to infection suggests 
that genes of the innate immune response could be important.  
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(4) Future directions 
GBS and CIDP are important diseases that cause significant morbidity and use of resources, 
so there is a need to understand more about the cause of these diseases and especially the genes 
that predispose to disease, because this could suggest possible therapies. The numbers of subjects 
that have been studied are small, so there would be benefit in repeating the studies mentioned 
above.  There appear to be genes that make subjects susceptible to the development of disease 
and genes that regulate the severity of disease. Such genes are promising candidates for further 
study because knowledge of the biological pathways that modify the severity of disease could 
suggest treatments for disease.  
 
There could also be further studies of the differences between GBS and CIDP. GBS and 
CIDP have similar pathological features but differ in the course of disease. Of the candidate 
genes, many show similar results in GBS and CIDP.  However, it would seem very likely that 
subjects with GBS would differ from subjects with CIDP in their ability to regulate immune 
attack on peripheral nerve, with GBS being an acute self-limited disease and CIDP an ongoing 
disease. In experimental autoimmune neuritis, acute disease can be converted to a chronic 
relapsing form of disease with low dose immunosuppression (McCombe et al., 1990b), 
suggesting that relapses are prevented by immune mechanisms. It is possible that GBS and CIDP 
will differ in genes that regulate the immune response, while showing similarity in genes that are 
directly involved in the pathogenesis of disease. Therefore more studies comparing GBS and 
CIDP would be of interest.  
 
There is no clear HLA association in GBS or CIDP. The lack of strong HLA class II 
association with inflammatory neuropathy could suggest that MHC restricted antigen 
presentation is not of prime importance in susceptibility to GBS and CIDP. However, there are 
some instances where the fine specificity of HLA molecules has been shown to be important.  
The first example is the finding that alleles that encode HLA proteins that have an RLD motif at 
residues 55-57 (RLD55-57) and an ED70-71 motif in the DQ chain and a E9V11H13 motif in the 
DR chain(Magira et al., 2003) were associated with the development of AIDP, but not AMAN, 
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in patients from Northern China. These motifs occur primarily in DRB1*04 and DQB1*06 and 
*04 alleles, with these DR and DQ alleles not being in linkage-disequilibrium. The other 
examples are our findings that patients with GBS are significantly more likely to carry Lysine 
than Arginine at position 80 of HLA C molecules and that patients with GBS are significantly 
more likely than controls to carry Isoleucine at position 80 of Bw4 than controls  (Blum et al., 
2013a). Therefore, the very fine specificity of HLA molecules could be worth further 
exploration, looking at the detailed molecular interactions that occur with different 
polymorphisms of genes in the HLA region, looking for causative genes rather than for disease 
associations.  
 
Genotyping with Single nucleotide polymorphisms (SNPs) or whole exome sequencing 
(WES) has now become standard. Full sequencing of the entire genome has also become more 
common.  As yet there are no published GWAS studies in GBS and CIDP. It will be important 
that GWAS studies indicate whether subjects have AIDP or AMAN, and whether the subjects 
have any family history of neuropathy. GWAS studies are able to look at the effects of relatively 
common polymorphisms that are selected for inclusion, but will not distinguish less common 
alleles.   Future studies with whole exome sequencing (WES) will be able to look for rare alleles 
that predispose to disease (Casals et al., 2012).  More detailed sequencing of the non-transcribed 
regions of the chromosome is likely to be needed to account for all the genetic basis of disease. 
Analysis of SNP studies requires making allowance for the many comparisons by requiring a 
very low probability that differences between disease and control groups occurred by chance. 
This is done in an attempt to avoid false positive results (Type I error) but has the risk of leading 
to false negative results (Type II error). To look for evidence that disease is hereditable, a new 
approach to this is to consider all SNPs at the same time, to see if there are overall differences 
between groups when using all the data (Yang et al., 2010; Lee et al., 2011) .  
Taken together it seems likely that there is a genetic element in predisposition to GBS and 
CIDP, that at least some of the genes will be involved in immunity and that there may well be 
genes that modify the severity of disease. In the future large cohorts of subjects and modern 
techniques will be required to test this.  
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Table 1   Studies of  HLA  associations  in GBS  
Gene No of subjects  Country/Date Method Result Reference 
 
MHC Class I   HLA A 
HLA-A 59 GBS/561 controls United 
Kingdom/1977 
Serological No association with GBS (Adams et al., 
1977) 
 
HLA-A 22 GBS, 322 controls Australia/1978 Serological No association with GBS (Stewart et al., 
1978) 
HLA-A 
 
18 GBS, 103 controls USA/1979 Serological No association with GBS (Latovitzki et al., 
1979) 
HLA-A 
 
92 GBS, 100 controls USA/1984 Serological Slight reduction in HLA A11 in GBS (Kaslow et al., 
1984) 
HLA-A 32 GBS, 234 controls Egypt/1985 Serological No association with GBS (Hafez et al., 
1985) 
HLA-A 
 
89 GBS,  unknown 
controls 
United 
Kingdom/1988 
Serological No association with GBS (Winer et al., 
1988) 
HLA-A 81 GBS, 87 controls Japan/1998 Serological No association with GBS (Ma et al., 1998b) 
HLA-A 
 
195 GBS,  225 
controls 
Australia/2013 PCR-SSP 
 
No increase in HLA A Bw4 alleles (Blum et al., 
2013a) 
 
MHC Class I   HLA B 
HLA-B 22 GBS, 322 controls Australia/1978 Serological No association with GBS (Stewart et al., 
1978) 
HLA-B 
 
18 GBS, 103 controls USA/1979 Serological No association with GBS (Latovitzki et al., 
1979) 
HLA-B 
 
92 GBS, 100 controls USA/1984 Serological No association with GBS (Kaslow et al., 
1984) 
HLA-B 32 GBS, 234 controls Egypt/1985 Serological No association with GBS (Hafez et al., 
1985) 
HLA-B 89 GBS,  unknown United Serological No association with GBS (Winer et al., 
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 controls Kingdom/1988 1988) 
HLA-B 81 GBS, 87 controls Japan/1998 Serological No association with GBS (Ma et al., 1998b) 
HLA-B 195 GBS,  225 
controls 
Australia/2013 PCR-SSP Increased carriage of isoleucine at 
position 80 of Bw4 alleles 
(Blum et al., 
2013a) 
 
MHC Class I   HLA C 
HLA-C 92 GBS, 100 controls USA/1984 Serological No association with GBS (Kaslow et al., 
1984) 
HLA-C 81GBS, 87 controls Japan/1998 Serological No association with GBS (Ma et al., 1998b) 
HLA-C 195 GBS,  225 
controls 
Australia/2013 PCR-SSP 
 
Increased carriage of alleles with lysine 
at position 80. 
(Blum et al., 
2013a) 
       
MHC Class II HLA-DPB1 
HLA-DPB1 49 GBS, 100 controls Sweden/1991 RFLP No association with GBS (Hillert et al., 
1991) 
HLA- DPB1 47 AMAN, 25 AIDP, 
97 controls 
China/2003 PCR/sequencing No association with AIDP or AMAN (Magira et al., 
2003) 
 
MHC Class II HLA-DQA1 
HLA DQA1 47 GBS, 50 controls China/2000 PCR-SSP No association with GBS, increased 
DQA1*03 with GM1 antibodies. 
(Li et al., 2000) 
HLA DQA1 74 GBS, 158 controls Australia/2006 Serological/PCR-SSP No association with GBS (McCombe et al., 
2006) 
 
MHC Class I I  HLA-DQB1 
HLA-DQB1 90 GBS, 7MFS, 100 
controls 
United 
Kingdom/1995 
PCR No association with susceptibility to 
GBS, increased HLA DQB1*03 with C 
jejuni infection 
(Rees et al., 1995) 
HLA-DQB1 49 GBS, 100 controls Sweden/1991 RFLP No association with GBS (Hillert et al., 
1991) 
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HLA-DQB1 31 AMAN, 12 AIDP, 
34 controls 
China/1997 PCR No association with GBS (Monos et al., 
1997) 
HLA-DQB1 81 GBS, 87 controls Japan/1998 PCR 2 digit typing No association with GBS (Ma et al., 1998b) 
 
HLA DQB1 47 GBS, 50 controls China/2000 PCR-SSP No association with GBS (Li et al., 2000) 
HLA-DQB1 47 AMAN, 25 AIDP, 
97 controls 
China/2003 PCR/sequencing DQ epitopes associated with AIDP but 
not AMAN 
(Magira et al., 
2003) 
HLA-DQB1 167 GBS, 207 
controls 
The 
Netherlands/2005 
PCR with SSPs No association with GBS (Geleijns et al., 
2005b) 
HLA-DQB1 
 
74 GBS, 158 controls Australia/2006 Serological/PCR-SSP No association with GBS (McCombe et al., 
2006) 
HLA-DQB1 54 GBS, 202 controls North India/2010 
 
PCR with SSPs Increased DQ*06 in GBS (Sinha et al., 
2010) 
 
MHC Class I   HLA- DRB1 
HLA-DRB1 
 
 
18 GBS, 103 controls USA/1979 Serological No association with GBS (Latovitzki et al., 
1979) 
HLA-DRB1 38 GBS, 100 healthy 
controls 
Mexico/1983 
 
Serotyping Increased DR3 in GBS (Gorodezky et al., 
1983) 
HLA-DRB1 
 
 
79 GBS patients United 
Kingdom/1988 
Serological No association with GBS (Winer et al., 
1988) 
HLA-DRB1 49 GBS, 100 controls Sweden/1991 RFLP No association with GBS (Hillert et al., 
1991) 
HLA-DRB1 90 GBS, 7MFS, 100 
controls 
United 
Kingdom/1995 
PCR No association with susceptibility to 
GBS 
(Rees et al., 1995) 
HLA- DRB1 31 AMAN, 12 AIDP, 
34 controls 
China/1997 PCR Increased DRB1*13 in AIDP (Monos et al., 
1997) 
HLA-DRB1 81 GBS, 87 controls Japan/1998 PCR 2 digit typing No association with GBS (Ma et al., 1998b) 
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HLA DRB1 47 GBS, 50 controls China/2000 PCR-SSP No association with GBS (Li et al., 2000) 
HLA-DRB1 47 AMAN, 25 AIDP, 
97 controls 
China/2003 PCR/sequencing DRB1 epitopes associated with AIDP, no 
association with AMAN 
(Magira et al., 
2003) 
HLA-DRB1 167 GBS, 207 
controls 
The 
Netherlands/2005 
PCR-SSP No association with GBS (Geleijns et al., 
2005b) 
HLA-DRB1 
 
74 GBS, 158 controls Australia/2006 Serological/PCR-SSP No association with GBS (McCombe et al., 
2006) 
HLA-DRB1 54 GBS, 202 controls North India/2010 
 
PCR with SSPs No association with GBS, but increased 
DRB1*0701 in patients with preceding 
infection 
 
(Sinha et al., 
2010) 
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Table 2  Studies of  HLA  associations  in CIDP 
 
Gene No of 
subjects 
 Country Method Result Reference 
 
MHC Class I  HLA- A 
HLA-A 16 CIDP, 
322 
controls 
Australia/1978 Serological Increased HLA A Aw30 in CIDP (Stewart et 
al., 1978) 
HLA-A 
 
 
14 CIDP,  
351 
controls 
United 
Kingdom/1979 
Serological  No association with CIDP (Adams et 
al., 1979) 
HLA-A 31 CIDP,  
unknown 
controls 
United 
Kingdom/1990 
RFLP No association with CIDP (Vaughan et 
al., 1990) 
HLA-A 
 
 
52 CIDP, 
504 
controls 
The 
Netherlands/1991 
Serological No association with CIDP (van Doorn 
et al., 1991) 
HLA-A 71 CIDP, 
2516 
controls 
Australia/1990 Serological Increased HLA A3 (Feeney et 
al., 1990) 
 
MHC Class 1 HLA-B 
 
HLA-B 16 CIDP, 
322 
controls 
Australia/1978 Serological Increased HLA B8 in CIDP (Stewart et 
al., 1978) 
HLA-B 
 
 
14 CIDP,  
351 
controls 
United 
Kingdom/1979 
Serological  Increased HLA B8 (Adams et 
al., 1979) 
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HLA-B 31 CIDP,  
unknown 
controls 
United 
Kingdom/1990 
RFLP Increased HLA-B7 (Vaughan et 
al., 1990) 
HLA-B 
 
 
52 CIDP, 
504 
controls 
The 
Netherlands/1991 
Serological No association with CIDP (van Doorn 
et al., 1991) 
 
MHC Class I  HLA-C 
HLA-C 31 CIDP,  
unknown 
controls 
United 
Kingdom/1990 
RFLP Increased HLA-Cw7 (Vaughan et 
al., 1990) 
HLA-C 
 
 
52 CIDP, 
504 
controls 
The 
Netherlands/1991 
Serological No association with CIDP (van Doorn 
et al., 1991) 
 
MHC Class II HLA- DPB1 
HLA-DPB1 31 CIDP,  
unknown 
controls 
United 
Kingdom/1990 
RFLP No association with CIDP (Vaughan et 
al., 1990) 
 
MHC Class II HLA-DQA1 
HLA-DQA1 104 CIDP, 
296 
controls 
Australia/2006 Serological No association with CIDP (McCombe 
et al., 2006) 
 
MHC Class II  HLA-DQB1 
HLA-DQB1 31 CIDP,  
unknown 
controls 
United 
Kingdom/1990 
RFLP No association with CIDP (Vaughan et 
al., 1990) 
HLA-DQB1 
 
52 CIDP, 
504 
controls 
The 
Netherlands/1991 
Serological No association with CIDP (van Doorn 
et al., 1991) 
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HLA-DQB1 102 CIDP,  
300 
control 
 
Australia/2006 Serological No association with CIDP (McCombe 
et al., 2006) 
HLA-DQB1 36 CIDP, 
100 
controls 
Tunisia/2013 PCR-SSP No association with CIDP (Mrad et al., 
2013) 
 
MHC Class II  HLA-DRB1 
HLA-DRB1 16 CIDP, 
322 
controls 
Australia/1978 Serological Increased HLA Dw3 in CIDP (Stewart et 
al., 1978) 
HLA-DRB1 
 
 
14 CIDP,  
351 
controls 
United 
Kingdom/1979 
Serological  Increased HLA Dw3 (Adams et 
al., 1979) 
HLA-DRB1 31 CIDP,  
unknown 
controls 
United 
Kingdom/1990 
RFLP No association with CIDP (Vaughan et 
al., 1990) 
HLA-DRB1 
 
 
52 CIDP, 
504 
controls 
The 
Netherlands/1991 
Serological No association with CIDP (van Doorn 
et al., 1991) 
HLA-DRB1 102 CIDP,  
300 
control 
 
 
Australia/2006 Serological No association with CIDP in total 
group, but increased HLA DR2 in 
females 
(McCombe 
et al., 2006) 
HLA-DRB1 36 CIDP, 
100 
controls 
Tunisia/2013 PCR-SSP Increased HLA DRB1*13 (Mrad et al., 
2013) 
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Table 3    Non-HLA genes investigated in GBS and CIDP 
 
Protein Gene Chromosome 
location 
Link to GBS Link to CIDP 
Alpha1 
antitrypsin 
 
SERPINA1 14q32.1 Yes (McCombe et 
al., 1985) 
Yes (McCombe 
et al., 1985) 
Apolipoprotein  
E 
 
APOE 19q13.2 No influence on 
outcome 
(Pritchard et al., 
2003). 
Not studied in 
CIDP 
CD1a 
 
 
CD1A 1q22-23 Yes (Caporale et 
al., 2006) 
No(Kuijf et al., 
2008) (Wu et al., 
2012) 
No(De Angelis 
et al., 2007) 
CD1d 
 
 
CD1d 1q22-23 No (Caporale et 
al., 2006) 
 
Not studied in 
CIDP 
CD1e 
 
 
CD1E 1q22-23 Yes(Caporale et 
al., 2006) 
No(Kuijf et al., 
2008) (Wu et al., 
2012) 
No (De Angelis 
et al., 2007) 
CD14 
 
 
CD14 5q31.1 No (Geleijns et al., 
2004b). 
Not  studied in 
CIDP  
CD59 
 
 
CD59 11p13 Not studied One subject 
with CD59 
deficiency had 
CIDP  (Nevo et 
al., 2013) 
Contactin 2 
(Transient 
axonal 
glycoprotein-1) 
CNTN2 1q32.1 Not studied Yes – response 
to IVIG (Iijima 
et al., 2011) 
 
No (Pang et al., 
2012)  
 
Fas (CD95) 
 
 
FAS 10q24.1 Linked to 
production of 
ganglioside 
antibodies  
(Geleijns et al., 
2005a) 
 
Not studied in 
CIDP 
Fcgamma 
receptor IIa 
FCGR2A 1q23 Yes(Sinha et al., 
2010)   
Not studied in 
CIDP 
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No (Vedeler et al., 
2000)   
 
Fcgamma 
receptor IIb 
 
 
FCGR2B  Not studied Associated with 
CIDP 
(Tackenberg et 
al., 2009b) 
Fcgamma 
receptor IIIa 
 
 
FCGR3A 1q23 Yes(Sinha et al., 
2010) 
No(Vedeler et al., 
2000)  
No effect in 
incidence but 
effect on severity 
(van Sorge et al., 
2005) 
 
 
Not studied in 
CIDP 
Fcgammma 
receptor IIIb 
 
 
FCGR3B 1q23 No(Sinha et al., 
2010)   
No effect in 
incidence but 
effect on 
severity(Vedeler et 
al., 2000) (van 
Sorge et al., 2005) 
Not studied in 
CIDP 
FcR- like 3 
 
 
FCRL3 1q21 Yes  (Sang et al., 
2012) 
Not  studied in 
CIDP 
Glucocorticoid 
receptor 
 
 
NRC31 5q31.3 Related to clinical 
course (Dekker et 
al., 2009) 
Not studied in 
CIDP 
G1M marker 
 
 
IGHG1 14q32.33 Yes(Feeney et al., 
1989)    
No(Pandey et al., 
2005) 
No(Feeney et 
al., 1989)  
G2M marker IGHG2 
 
14q32.33 Yes(Feeney et al., 
1989) 
No(Pandey et al., 
2005) 
No(Feeney et 
al., 1989) 
G3M marker IGHG3 
 
14q32.33 Yes(Feeney et al., 
1989) 
No(Pandey et al., 
2005) 
No(Feeney et 
al., 1989)  
Interleukin 10 
 
 
IL 10 1q31 Linked to disease 
susceptibility 
(Myhr et al., 2003) 
Not studied in 
CIDP  
 
Killer KIR2DL1, 19q13.4 No(Blum et al., No studied in 
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immunoglobulin-
like receptors 
(KIR) 
 
KIR2DL2,KIR2DL3, 
KIR2DL4, 
KIR2DL5A, 
KIR2DL5B, 
KIR2DS1, 
KIR2DS2, 
KIR2DS3, 
KIR2DS4, 
KIR3DL1, 
KIR3DL2, 
KIR3DL3, KIR3DS1 
2013a)  CIDP  
KM marker 
 
 
IGKC 2p12 Linked to antibody 
production(Pandey 
et al., 2005) 
Not studied in 
CIDP  
MMP9 
 
MMP9 20q11.2 No effect on 
susceptibility, but 
link with severity 
(Geleijns et al., 
2007) 
Not studied in 
CIDP 
T cell specific 
adaptor protein 
 
SH2D2a 1q21 No studies  Linked to CIDP 
(Notturno et al., 
2008). 
TNF alpha 
 
TNF 6p21.3 Yes (Ma et al., 
1998a;Wu et al., 
2012) 
Linked to severity 
(Geleijns et al., 
2007)  
Associated with 
AMAN (Jiao et 
al., 2012;Zhang et 
al., 2007;Prasad et 
al., 2010) 
Not  studied in 
CIDP 
Toll-like 
receptor 4 
 
TLR4 9q33.1 No (Geleijns et al., 
2004b) 
Yes  (Nyati et al., 
2010b) 
Not  studied in 
CIDP 
Peripheral 
myelin protein 
22*** 
 
PMP22 17p12 Reports of subject 
with GBS and 
CMT1A (Munch 
et al., 2008) 
Reports of 
subjects with 
CIDP and 
CMT1A 
(Rajabally et 
al., 
2000;Desurkar 
et al., 2009) 
 
****  This gene is included because of  the reports of GBS and CIDP in subjects with CMT. 
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